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Nottingham, Nottingham, UK
3Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
4South Tyneside District Hospital, South Tyneside NHS Foundation Trust, South Shields, UK
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6School of Pharmacy and Medical Sciences, Institute of Cancer Therapeutics, University of Bradford,
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7Department of Oncology & Metabolism, Human Nutrition Unit, The Medical School, University of
Sheffield, Sheffield, UK
*Corresponding author M.A.Hull@leeds.ac.uk
Background: The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) and aspirin both have
proof of concept for colorectal cancer (CRC) chemoprevention, aligned with an excellent safety profile.
Objectives: The objectives were to determine whether or not EPA prevents colorectal adenomas, either
alone or in combination with aspirin, and to assess the safety/tolerability of EPA, in the free fatty acid (FFA)
form or as the triglyceride (TG), and aspirin.
Design: This was a randomised, blinded, placebo-controlled, 2 × 2 factorial trial.
Setting: The NHS Bowel Cancer Screening Programme (BCSP).
Participants: Patients (aged 55–73 years) identified as ‘high risk’ (i.e. those who have five or more
colorectal adenomas of < 10 mm in size or three or more colorectal adenomas if one is ≥ 10 mm in size) at
screening colonoscopy.
Interventions: The interventions were capsules containing 2000 mg of 99% EPA–FFA or 2780 mg of 90%
EPA–TG (equivalent to 2000 mg of FFA) taken daily, or identical placebo capsules; and 300mg of aspirin
taken daily, or an identical placebo, enteric-coated tablet. Both were taken for ≈1 year until surveillance
colonoscopy. All participants and staff were unaware of treatment allocation.
Main outcome measures: The primary outcome was the number of participants with one or more
colorectal adenomas [adenoma detection rate (ADRa)] at surveillance colonoscopy. Outcomes were
analysed for all participants with observable follow-up data by an ‘at-the-margins’ approach, adjusted for
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BCSP site and by the need for repeat baseline endoscopy. Secondary outcome measures – these included
the number of colorectal adenomas per patient [mean adenomas per patient (MAP)], ‘advanced’ ADRa
and colorectal adenoma location (right/left) and type (conventional/serrated).
Results: Between November 2011 and June 2016, 709 participants were randomised, with 707 providing
data (80% male, mean age 65 years). The four treatment groups (EPA + aspirin, n = 177; EPA, n = 179;
aspirin, n = 177; placebo, n = 176) were well matched for baseline characteristics. Tissue EPA levels and
tolerability were similar for FFA and TG users. There was no evidence of any difference in ADRa between
EPA users (62%) and non-users (61%) [risk difference –0.9%, 95% confidence interval (CI) –8.8% to 6.9%]
or for aspirin users (61%) versus non-users (62%) (risk difference –0.6%, 95% CI –8.5% to 7.2%). There
was no evidence of an interaction between EPA and aspirin for ADRa. There was no evidence of any effect
on advanced ADRa of either EPA (risk difference –0.6%, 95% CI –4.4% to 3.1%) or aspirin (risk difference
–0.3%, 95% CI –4.1% to 3.5%). Aspirin use was associated with a reduction in MAP [incidence rate ratio
(IRR) 0.78, 95% CI 0.68 to 0.90), with preventative efficacy against conventional (IRR 0.82, 95% CI 0.71 to
0.94), serrated (IRR 0.46, 95% CI 0.25 to 0.87) and right-sided (IRR 0.73, 95% CI 0.61 to 0.88) lesions,
but not left-sided (IRR 0.85, 95% CI 0.69 to 1.06) adenomas. There was evidence of chemopreventive
efficacy of EPA on conventional (IRR 0.86, 95% CI 0.74 to 0.99) and left-sided (IRR 0.75, 95% CI 0.60 to
0.94) adenomas, but not on total MAP (IRR 0.91, 95% CI 0.79 to 1.05) or serrated (IRR 1.44, 95% CI 0.79
to 2.60) or right-sided (IRR 1.02, 95% CI 0.85 to 1.22) adenomas. EPA and aspirin treatment were well
tolerated, with excess mild/moderate gastrointestinal (GI) adverse events (AEs) in the EPA alone group.
There were six GI bleeding AEs.
Conclusion: EPA and aspirin treatment were not associated with a reduction in ADRa. However, both
agents displayed evidence of chemopreventive efficacy, based on adenoma number reduction, which was
specific to adenoma type and location, and is compatible with known anti-CRC activity of aspirin.
Limitations: Limitations of the trial included the failure to recruit to the target sample size of 853, and an
unexpected switch of EPA formulation mid-trial.
Future work: A future objective should be to understand the mechanism(s) of action of EPA and aspirin
using the trial biobank. Established trial infrastructure will enable future trials in the BCSP.
Trial registration: Current Controlled Trials ISRCTN05926847.
Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a MRC
and NIHR partnership.
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Plain English summary
Bowel cancer kills > 15,000 people every year in England and Wales. Most bowel cancers develop froma polyp, also known as an adenoma, which is a fleshy growth on the bowel wall. Polyps are found and
removed at colonoscopy, which is a large-bowel camera test, but colonoscopy does not prevent further
polyps. Use of drugs or dietary supplements (called chemoprevention) may be able to reduce polyp growth
and the possibility of developing bowel cancer.
The Systematic Evaluation of Aspirin and Fish Oil (seAFOod) trial tested the effects of naturally occurring
omega-3 eicosapentaenoic acid (EPA) (a dose roughly equivalent to two oily fish portions every day) and
aspirin on bowel polyp growth. Patients took EPA on its own, aspirin on its own, EPA and aspirin together
or placebo (dummy) medication.
The trial recruited 709 participants who had three or more adenomas found and removed at a NHS Bowel
Cancer Screening Programme colonoscopy and needed a check-up colonoscopy 1 year later. Allocation to
one of the four treatment options before the check-up was by chance and ‘blinded’, so that all participants
and trial staff did not know what treatment was taken.
The results showed that there was no reduction in the number of patients who had at least one adenoma
at check-up (≈60%) in either EPA or aspirin users. However, EPA and aspirin were found to reduce the
number of certain types of adenoma in different parts of the bowel by 10–20%. Both EPA treatment
and aspirin treatment were safe for patients, with no increased bleeding risk, but EPA caused 10% more
symptoms of mild stomach upset, including diarrhoea.
It is concluded that both EPA and aspirin have chemoprevention benefits, which are limited to certain
bowel polyp types. The results also suggest that aspirin (possibly with EPA) could be used to help prevent
bowel cancers that occur despite colonoscopy.
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Scientific summary
Background
Chemoprevention (the use of drugs or nutritional agents) is one strategy for the prevention of colorectal
cancer (CRC), the development of which occurs predominantly via a benign colorectal lesion termed an
adenoma (also known as a polyp). The molecular pathogenesis of the early stages of colorectal carcinogenesis
is complex, and is reflected by two main histological types of precursor lesion [(1) conventional (i.e. tubular,
tubulo-villous, villous) adenoma and (2) serrated adenoma (now termed polyp, recognising that no dysplasia
is present in most serrated lesions)], which map onto different molecular characteristics, such as chromosomal
instability or deoxyribonucleic acid (DNA) hypermethylation, and are both believed to progress to CRC.
The omega-3 (ω-3) polyunsaturated fatty acid (PUFA) eicosapentaenoic acid (EPA) and aspirin are candidate
CRC chemoprevention agents: both have proof of concept in humans, aligned with an excellent safety and
toxicity profile. Therefore, a randomised, Phase III, polyp-prevention trial was performed to investigate the
chemoprevention efficacy of both agents in individuals at risk of ‘sporadic’ colorectal adenoma recurrence
within a colonoscopy screening and surveillance programme.
Different ‘nutraceutical’ formulations of EPA exist, including EPA in the free fatty acid (FFA) form, as a
triglyceride (TG) conjugate, or as ethyl ester. All three forms of EPA have anti-CRC activity in pre-clinical
studies. A direct comparison between EPA bioavailability and tolerability of different formulations in a
randomised trial has not been reported previously.
Objectives
Primary objective
The primary objective was to determine whether or not EPA prevents colorectal adenomas, either alone or
in combination with aspirin.
The following primary hypotheses were tested:
l 2 g of EPA-FFA or 2780 g of EPA-TG (equivalent to a 2-g FFA dose) daily is more effective than placebo
for reduction in colorectal adenoma recurrence.
l 300 mg of aspirin daily is more effective than placebo for reduction in colorectal adenoma recurrence.
Secondary objectives
The secondary objectives were to assess the tolerability and safety of EPA, as the FFA or as the TG, alone
and in combination with aspirin.
Methods
Trial design
This was a randomised, blinded, placebo-controlled 2 × 2 factorial trial, which was integrated into the
screening and surveillance phases of the NHS Bowel Cancer Screening Programme (BCSP) so that
participation did not alter routine clinical practice.
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Eligibility
Recruitment was restricted to BCSP patients aged 55–73 years who were identified as ‘high risk’ [five or
more small (< 10 mm in size) colorectal adenomas or three or more colorectal adenomas, with at least
one being ≥ 10 mm, based on endoscopic findings and confirmed later by the histopathology report] at a
complete screening colonoscopy. This included patients who were identified as ‘high risk’ at colonoscopy
after faecal occult blood test (FOBt) screening, or who were deemed ‘high risk’ after a bowel scope flexible
sigmoidoscopy (FS) and subsequent screening colonoscopy.
Interventions
l Four gastro-resistant capsules of 99% EPA-FFA or five soft gelatin capsules of 90% EPA-TG (both
equivalent to 2 g of FFA daily), or identical placebos (both containing capric and capryllic acid medium-
chain TGs). The capsule investigational medicinal product (IMP) switch was necessitated by cessation of
supply of EPA-FFA and its placebo during the trial. Each participant received either the FFA or the TG
formulation (or respective placebo), but not both.
l One enteric-coated aspirin tablet (300 mg) or identical placebo.
Both IMPs were provided from randomisation until the day before surveillance colonoscopy, 12 months
after the screening procedure.
Randomisation and blinding
After written informed consent was obtained, the participant was randomised according to a 2 × 2
factorial design (Table a).
Internet-based treatment assignment was determined by a computer-generated pseudorandom code using
random permuted blocks of randomly varying size (4–12). Trial participants were allocated with equal
probability to each treatment group. Stratification was by BCSP site. The sequence of treatment allocations
was concealed until recruitment, data collection and all other trial-related assessments had been
completed. Allocation was not divulged to researchers or participants.
The seAFOod trial biobank
Blood [for red blood cells (RBCs), plasma and leucocytes (DNA)], urine and rectal mucosa samples were
obtained at baseline and at 6 and 12 months (rectal mucosa samples were obtained at 12 months only).
One or more biological samples were received from 95% of participants, with 73% providing a full sample
set.
Outcomes
Primary outcome
The primary outcome was the number of participants with one or more colorectal adenomas detected at
the first BCSP surveillance colonoscopy 12 months after the screening examination [the adenoma detection
rate (ADRa)].
TABLE a The Systematic Evaluation of Aspirin and Fish Oil (seAFOod) trial 2 × 2 factorial design
l 2 g of EPA-FFA, or equivalent FFA dose of EPA-TG
l 300mg of aspirin
l 2 g of EPA-FFA, or equivalent FFA dose of EPA-TG
l Placebo aspirin
l Placebo EPA
l 300mg of aspirin
l Placebo EPA
l Placebo aspirin
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Secondary outcomes
The secondary outcomes were as follows:
l Total number of colorectal adenomas per participant at BCSP surveillance colonoscopy [total mean
adenomas per participant (MAP)].
l Detection of one or more ‘advanced’ (i.e. ≥ 10 mm in diameter, high-grade dysplasia or villous
histology) colorectal adenomas at the 12-month BCSP surveillance colonoscopy (advanced ADRa).
l Number of ‘advanced’ colorectal adenomas per participant at the 12-month BCSP surveillance
colonoscopy (advanced MAP).
l Detection of one or more conventional adenomas (conventional adenoma end points were defined
after database lock) at the first BCSP surveillance colonoscopy (conventional ADRa).
l Number of conventional adenomas (conventional adenoma end points were defined after database
lock) per participant at the first BCSP surveillance colonoscopy (conventional MAP).
l Detection of one or more serrated adenomas at the first BCSP surveillance colonoscopy (serrated ADRa).
l Number of serrated adenomas per participant at the first BCSP surveillance colonoscopy (serrated MAP).
l The region of the colorectum (right colon: any part of the colon proximal to the splenic flexure; left
colon: the rectum and the colon at/distal to the splenic flexure) in which adenomas are detected at the
first BCSP surveillance colonoscopy.
l Reclassification from ‘high risk’ to ‘intermediate risk’ after the first BCSP surveillance colonoscopy (BCSP
risk stratification at the first surveillance colonoscopy states that any individual who does not continue
to fulfil ‘high-risk’ criteria is classified as ‘intermediate risk’ for further colonoscopic surveillance at
3 years).
l Detection of CRC prior to, or at, the first BCSP surveillance colonoscopy.
l Dietary fish and other seafood intake at baseline and at the end of the trial.
l Red blood cell EPA and rectal EPA levels at baseline and at 6 months (RBC only) and 12 months
from randomisation.
l Absolute RBC fatty acid [docosahexaenoic acid (DHA), arachidonic acid (AA), EPA-to-AA ratio] levels
and difference from baseline at 6 and 12 months.
l Rectal mucosal fatty acid (DHA, AA, EPA-to-AA ratio) levels at surveillance colonoscopy.
l Adverse events, including clinically significant bleeding episodes [haemorrhagic stroke or gastrointestinal
(GI) bleeding requiring hospital admission or investigation].
Exploratory outcomes
l Colorectal adenoma size.
l Association between change of RBC EPA level at 12 months and individual number of total colorectal
adenomas.
l Association between rectal and RBC EPA levels at 12 months.
Sample size
It was planned to randomise 853 individuals to detect an 18% relative reduction in ADRa in each two-group
comparison, assuming a 10% drop-out rate.
Statistical methods
The primary analysis was performed on an intention-to-treat basis, without imputation of missing data.
The primary end point was analysed ‘at the margins’, as there was no evidence of an interaction between
EPA and aspirin. The log relative risk was estimated using a mixed-effects log-binomial regression model,
with site included as a random effect. Both interventions were fitted simultaneously and the analysis was
adjusted for repeat colorectal endoscopic procedure within 3 months. Other outcomes were analysed
using appropriate regression models depending on outcome type.
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Results
Recruitment
A total of 3911 ‘high-risk’ individuals were screened for eligibility, of whom 709 (18%) were randomised.
Of those individuals not randomised (n = 3202), 2179 (68%) met one or more exclusion criteria [regular
aspirin/non-steroidal anti-inflammatory drug use, n = 594 (19%); need for more than one repeat endoscopy,
n = 328 (10%); bleeding diathesis or anticoagulant/antiplatelet therapy, n = 313 (10%)]. The other 1023
individuals either did not wish to participate or were not randomised for unknown reasons.
Randomisation
A total of 177 participants were randomised to receive EPA + aspirin, 179 were randomised to receive
EPA + placebo aspirin, 177 were randomised to receive placebo EPA + aspirin and 176 were randomised to
receive placebo EPA + placebo aspirin. Two participants withdrew immediately after randomisation. A total
of 422 (60%) participants were randomised to active or placebo EPA-FFA and 287 (40%) participants were
randomised to active or placebo EPA-TG. Of those randomised, 641 (90%) participants underwent
surveillance colonoscopy; endoscopic data were available for 640 of these participants.
Baseline characteristics
Baseline characteristics were well balanced across all four treatment groups with respect to demographic
data, medical history, prevalent GI symptoms and total and oily fish intake, as well as baseline colorectal
adenoma characteristics. The mean age was 65 years; the male-to-female ratio was 4 : 1. Thirty-eight per
cent of participants were obese. Approximately half of the participants were on regularly prescribed drugs
at trial entry, which was balanced (including metformin and statin use) between the treatment groups.
Compliance with trial medication was uniformly excellent (> 95%). The median time between randomisation
and the 12-month surveillance colonoscopy was between 344 and 348 days in the four treatment groups.
Red blood cell and rectal mucosal polyunsaturated fatty acid levels
Individuals in the active EPA groups had higher RBC EPA levels than placebo EPA users at both time points
after the start of the intervention. RBC EPA levels were similar between participants who received either
active EPA-FFA or EPA-TG at 6 and 12 months. The increase in RBC EPA level from baseline to the 6- and
12-month time points for all participants was similar across the two EPA formulations. Rectal mucosal EPA
levels at the end of the intervention period were higher in those who received EPA-TG than in those who
received EPA-FFA, but with substantial overlap between the two groups and no difference in the rectal
mucosal EPA-to-AA ratio. As there was no clear difference in RBC or rectal mucosal EPA incorporation
between those allocated EPA-FFA and those allocated EPA-TG, it was deemed appropriate to combine
the primary and secondary outcome data from those who received either of the capsule investigational
medicinal products.
Primary outcome (adenoma detection rate)
In the EPA + aspirin group, 98 out of 161 (61%) participants had at least one colorectal adenoma at
surveillance colonoscopy; in the EPA + placebo aspirin group, 97 out of 153 (63%) had at least one colorectal
adenoma at surveillance colonoscopy. The ADRa was 61% (100/163) in the placebo EPA + aspirin group
and 61% (100/163) in the placebo EPA + placebo aspirin group. When summarised at factorial margins,
the ADRa was similar across interventions, with an ADRa of 62% for those who received active EPA versus
61% for those who did not receive EPA, and an ADRa of 61% for aspirin users versus 62% for those who
did not receive aspirin (62%). The risk difference for EPA versus no EPA was –0.9% [95% confidence interval
(CI) –8.8% to 6.9%] and for aspirin versus no aspirin was –0.6% (95% CI –8.4% to 7.2%). There was no
interaction between EPA and aspirin for the ADRa (p = 0.85). Sensitivity analyses were supportive of the
primary analysis.
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Secondary colorectal adenoma outcomes
Aspirin use was associated with a reduction in the total MAP [incidence rate ratio (IRR) 0.78, 95% CI 0.68
to 0.90], with preventative efficacy against conventional (IRR 0.82, 95% CI 0.71 to 0.94), serrated (IRR 0.46,
95% CI 0.25 to 0.87) and right-sided (IRR 0.73, 95% CI 0.61 to 0.88) lesions, but not left-sided (IRR 0.85,
95% CI 0.69 to 1.06) adenomas. There was evidence of chemopreventive efficacy of EPA on conventional
(IRR 0.86, 95% CI 0.74 to 0.99) and left-sided (0.75, 95% CI 0.60 to 0.94) adenomas, but not on the
total MAP (IRR 0.91, 95% CI 0.79 to 1.05) or on the total number of serrated (IRR 1.44, 95% CI 0.79
to 2.60) or right-sided (IRR 1.02, 95% CI 0.85 to 1.22]) adenomas. Overall, colorectal adenoma number
was reduced in the EPA + aspirin group (166 adenomas) compared with the other groups (238 in the
EPA + placebo group, 209 in the placebo + aspirin group and 231 in the placebo + placebo group),
with 794 (94%) of the recurrent lesions being conventional colorectal adenomas.
Safety and tolerability of eicosapentaenoic acid and aspirin
Dietary fish intake did not change during the trial. There were no safety concerns about either EPA or
aspirin. A similar proportion of participants reported at least one adverse event (AE) or adverse drug
reaction in all treatment groups (45% in the EPA + aspirin group, 46% in the EPA + placebo group, 39%
in the placebo + aspirin group and 44% in the placebo + placebo group). The most commonly reported
AEs were GI symptoms, with an excess of mild to moderate GI AEs (i.e. diarrhoea, nausea, abdominal pain)
in the EPA + placebo aspirin group. There was no difference in tolerability between EPA-FFA and EPA-TG
users. Six significant GI bleeding events were distributed across the treatment groups. No CRCs were
detected.
Conclusions
The Systematic Evaluation of Aspirin and Fish Oil (seAFOod) polyp-prevention trial has found no evidence
of an effect of either EPA or aspirin on the primary end point of the proportion of individuals with one or
more colorectal adenomas at the 12-month surveillance colonoscopy (the ADRa) in patients deemed ‘high
risk’ in the English BCSP.
However, secondary analyses of the effects of EPA and aspirin on colorectal adenoma number provided
evidence of chemopreventive activity of both agents. Aspirin was effective at reducing the total number of
colorectal adenomas per participant, but the reduction in the total MAP associated with EPA treatment
was not statistically significant. Other secondary analyses suggested that there are colorectal adenoma
subtype- and site-selective effects of EPA and aspirin. Participants randomised to EPA had a reduced
number (MAP) and ADRa of conventional dysplastic colorectal adenomas in the left colon and rectum
compared with those randomised to placebo. Participants randomised to aspirin had a reduced number
of adenomas in the right colon, particularly for serrated adenomas, and also reduced risk of conventional
colorectal adenomas. Although multiple analyses were undertaken with potential for spuriously significant
results, reduction in colorectal adenoma number by aspirin is consistent with published polyp-prevention
trial data and the ‘right sidedness’ of the aspirin effect is in keeping with observational data on CRC risk
and mortality. Moreover, the ‘left sidedness’ of EPA is consistent with efficacy in the familial adenomatous
polyposis (FAP) trial of EPA-FFA against conventional rectal adenomas (West NJ, Clark SK, Phillips RK,
Hutchinson JM, Leicester RJ, Belluzzi A, Hull MA. Eicosapentaenoic acid reduces rectal polyp number and
size in familial adenomatous polyposis. Gut 2010;59:918–25).
Historically, the ADRa has been used as the primary end point in polyp-prevention trials. However, its use
may be confounded by its widespread use as a quality assurance measure of colonoscopist performance.
By contrast, colorectal adenoma number has always been used as an end point in Phase II FAP trials.
Improved colonoscopy lesion reporting in routine practice now allows MAP to be considered as a more
sensitive primary end point in ‘sporadic’ Phase III trials, with the clinical meaningfulness of an approximate
20% reduction in MAP being supported by the CRC risk reduction from aspirin demonstrated in long-term
observational studies.
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Safety and tolerability of both EPA and aspirin were excellent. Mild GI symptoms are recognised with ω-3
PUFA use. The excess of GI AEs in the EPA-alone group compared with combined treatment with aspirin
should be investigated further. This is the first demonstration that two dose-equivalent formulations of EPA
have similar bioavailability and tolerability during long-term (12-month) dosing.
The seAFOod trial should create a paradigm shift in CRC chemoprevention research, whereby:
l Colorectal adenoma number will be introduced and further validated as a primary end point in polyp-
prevention trials.
l A stratified approach will be employed for use of the colorectal adenoma as an end point, based on
histological type and location.
A key objective should be to identify a predictive biomarker(s) for the type and site of colorectal adenoma
recurrence, allowing a precision-medicine approach to the provision of optimal chemoprevention at an
individual level. The observation that combination EPA and aspirin treatment was associated with the
largest reduction in colorectal adenoma number requires investigation in an appropriately powered study.
The trial biobank will be used to support mechanistic studies into the adenoma selectivity of EPA and
aspirin, as well as to explore use of ω-3 PUFA levels as a predictor of conventional colorectal adenoma risk.
Trial registration
This trial is registered as ISRCTN05926847.
Funding
This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research
Council and National Institute for Health Research partnership.
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Chapter 1 Introduction
Parts of this chapter have been reproduced from Hull et al.1 © 2018 The Author(s). Published by Elsevier Ltd.
This is an Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Background
The health burden of colorectal cancer
Colorectal cancer (CRC) continues to represent a huge health burden in the UK. There were approximately
41,300 new cases of CRC (also known as bowel cancer) in the UK in 2014, making it the fourth most
common cancer.2 In the UK, 1 in 14 men and 1 in 19 women will be diagnosed with CRC during their
lifetime. CRC is the second most common cause of cancer death in the UK, causing 16,000 deaths in
2014. Worldwide, it has been estimated that nearly 1.4 million cases were diagnosed in 2012.2 Despite
significant advances in the diagnosis and treatment of CRC, overall 5-year survival is currently only 59%
(survival figure is for England and Wales for 2010 and 2011).2
Prevention of colorectal cancer
One strategy to reduce CRC incidence and mortality is prevention. The scientific and clinical rationale for
prevention of CRC is well established and is based on the following:
l Knowledge of several environmental and behavioural factors that increase CRC risk, including dietary
factors (e.g. red and processed meat intake), excess body weight (i.e. obesity), lack of physical activity,
tobacco smoking and excess alcohol consumption. The World Cancer Research Fund has estimated that
approximately 45% of CRCs are preventable based on modification of these lifestyle factors.3
l The long natural history of colorectal carcinogenesis, during which a benign, precursor lesion termed a
colorectal adenoma (or polyp) develops and transforms into a malignant neoplasm over a period of
years (estimated to be approximately 5–10 years).4,5
l Improved outcomes for CRC treatment after diagnosis at earlier stages of CRC (98% 1-year overall
survival for stage I CRC compared with 40% for stage IV disease; 95% 5-year survival for stage I
compared with 7% for stage IV disease).6,7
Colorectal cancer prevention strategies that are currently used, or are under evaluation, include:
l population screening –
¢ early CRC diagnosis by a guaiac faecal occult blood test (FOBt) or a faecal immunochemical test
(FIT), conferring secondary benefit from colorectal adenoma identification and removal at
colonoscopy
¢ detection and removal (by polypectomy) of colorectal adenomas by primary screening endoscopy
[colonoscopy or flexible sigmoidoscopy (FS)]
l endoscopic surveillance of high-risk groups, for example individuals with long-standing colitis or
previous colorectal adenoma(s)
l chemoprevention (a term first coined in 1976 to describe the use of drugs, vitamins or other nutritional
agents to try to reduce the risk of, or delay the development or recurrence of, cancer)
l health education, leading to beneficial lifestyle modification and screening uptake
l promotion of awareness and earlier diagnosis of CRC by education aimed at the public and health-care
professionals.
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Chemoprevention of colorectal cancer
Despite the undoubted clinical effectiveness of endoscopic polypectomy,8,9 CRC remains a significant
problem in screened populations and high-risk surveillance cohorts because of a combination of factors
that include suboptimal screening uptake, poor acceptability of endoscopic procedures and ‘interval’ CRC
(i.e. those cancers that are diagnosed despite FOBt/FIT and/or endoscopy).10–13 In a Dutch biennial FIT-based
CRC screening programme,14 23% of individuals developed a FIT-interval CRC. The corresponding interval
CRC rate for guaiac FOBt programmes is approximately 50%.15 Moreover, 18 years’ follow-up of the
Minnesota guaiac FOBt trial (in which the colonoscopy rate was nearly 40%) found only a 20% reduction
in CRC incidence.13 The UK once-only FS trial10 demonstrated only a 23% reduction in CRC incidence in the
intervention group compared with the control group at 10 years. It is also clear that CRC occurs even in
patients under close colonoscopic surveillance (1.7 CRCs per 1000 person-years),16 with an estimated post-
colonoscopy CRC (PCCRC) rate of between 2% and 9%.17 Overall, only 10% of CRCs in the UK in 2013
were diagnosed within the UK screening programmes.18 Therefore, there is still an unmet clinical need for
safe and effective primary CRC chemoprevention in combination with existing screening and surveillance
programmes.
The natural history and molecular pathogenesis of colorectal carcinogenesis
The molecular pathogenesis of CRC (histopathological term: colorectal adenocarcinoma) has been the subject
of several recent reviews.4,19 In recent years, the original multistage model of cumulative genetic mutations,
proceeding through a benign adenoma stage (the so-called adenoma–carcinoma sequence), based on loss of
function of the ‘gatekeeper’ tumour suppressor gene adenomatous polyposis coli (APC), which was proposed
by Fearon and Vogelstein,20 has been superseded by widespread acceptance that ‘sporadic’ (i.e. not occurring
on a background of a distinct genetic predisposition syndrome or inflammatory bowel disease) CRC is not
‘one disease’, but occurs via several pathogenic pathways, which are not mutually exclusive.21,22
The chromosomal instability (CIN) pathway is characterised by chromosomal abnormalities, including
aneuploidy, usually associated with loss-of-function APC mutation and later-stage gain-of-function KRAS
mutation.23 It is exemplified by the rare genetic predisposition syndrome familial adenomatous polyposis
(FAP), an autosomal dominant condition that occurs in carriers of a heterozygous germline APC mutation.24
The microsatellite instability (MSI) pathway is driven by defective deoxyribonucleic acid (DNA) mismatch
repair (MMR), leading to accumulation of further somatic mutations (termed MSI-high) including BRAF.23 It
is exemplified by Lynch syndrome, in which carriers of mutations in MMR genes (most commonly MLH1 and
PMS2) exhibit increased cancer (including colorectal) risk.25 Furthermore, a CpG island methylator phenotype
(CIMP) pathway is recognised in colorectal adenomas and adenocarcinomas, by which epigenetic changes
in DNA methylation lead to altered gene function, in particular silencing of the MMR gene MLH1 leading to
defective MMR, which is associated strongly with BRAF mutation.23 Epigenetic silencing of MLH1 explains
the substantial overlap between MSI and CIMP pathways.4
There are limited data on how early during colorectal carcinogenesis the above phenotypes manifest
themselves.4 There are some data to suggest that CIN features are present in adenomas.4,26 The CIMP
pathway is linked strongly to benign serrated lesions (see below).
Colorectal adenoma
The importance of the benign precursor lesion, which exhibits epithelial cell dysplasia but not invasion of
the epithelial basement membrane (termed the adenoma, or adenomatous polyp), as a risk stratification
biomarker of future CRC risk but also as a clinically significant lesion (the removal of which is associated
with reduced CRC incidence and mortality), has been reviewed in detail.5
In parallel with more nuanced understanding of the diverse molecular pathogenesis of CRC, the
histopathological classification and terminology of the colorectal adenoma has been revised.5 In particular,
hyperplastic-serrated pathway lesions are now acknowledged as separate entities from the more common
(conventional) dysplastic adenoma (which can be tubular, villous or mixed tubulo-villous in morphology).
Serrated lesions are recognised to have malignant potential per se and may account for 20–30% of CRCs.27
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The World Health Organization’s (WHO’s) WHO Classification of Tumours of the Digestive System28 in 2010
included the term sessile (a term used to recognise that the vast majority of these lesions are ‘flat’ and not
polypoid when viewed endoscopically) serrated adenoma. However, the term sessile serrated polyp is now
preferred on the basis that the majority of sessile serrated lesions do not display any dysplasia, which is a
prerequisite for pathological classification as an adenoma.5 The traditional serrated adenoma is a separate,
rare, fully dysplastic lesion with classical serrated appearances.27 For the purposes of this report, the term
serrated adenoma will continue to be used as the terminology employed continuously throughout the
Systematic Evaluation of Aspirin and Fish Oil (seAFOod) trial from 2009 onwards.
Sessile serrated adenomas are more prevalent in the proximal (also known as right) colon (most commonly
defined as proximal to the splenic flexure) than the distal (also known as left) colon.4 Conventional tubular/
tubulo-villous adenomas are more uniformly distributed throughout the right and left colon.4 Molecular
features also distinguish between conventional adenomas and serrated adenomas, with a high prevalence
of CIN features in conventional adenomas and serrated adenomas commonly displaying a CIMP-high,
BRAF mutation-positive, MSI-high phenotype.4,21,27 Results from a study29 of CRCs suggest that, in reality,
there is likely to be a continuous positive gradient of CIMP-high, MSI-high and BRAF mutation frequency
in tumours along the distal to proximal colon, rather than an anatomical dichotomy in the distal transverse
colon. There is conflicting evidence that a given tumour genotype/phenotype predicts that of synchronous/
metachronous lesions, but the majority of data pertain to CRC, not to colorectal adenomas.4
As direct precursor lesions of CRC, the removal of which is unequivocally associated with decreased future
CRC risk,8,9 the colorectal adenoma is a clinically important lesion in its own right.5 It has been estimated
(based on cohort prevalence studies) that approximately 1 in 10–20 colorectal adenomas may eventually
acquire a malignant phenotype.5 The features associated with malignant progression are size, grade of
dysplasia and ‘villousness’, namely the degree of villous histological architecture in an individual lesion.5 On
the other hand, the colorectal adenoma can also be considered a biomarker of future CRC risk, regardless
of its individual malignant potential.5 Both colorectal adenoma number and colorectal adenoma size are
widely used as the basis for future CRC risk stratification for surveillance after colonoscopy in the UK and
elsewhere in the world.30–33 A common feature of guidelines is the definition of the ‘advanced’ colorectal
adenoma based on size (≥ 10 mm), with or without additional histological (e.g. grade of dysplasia,
‘villousness’) features.30,31,33
Colorectal adenoma measures
Based on widespread acceptance of the number and size of colorectal adenomas as a CRC risk biomarker,
the colorectal adenoma has been used as a surrogate colonoscopic end point of reduced CRC risk in
chemoprevention trials following polyp clearance at an index procedure (the ‘polyp-prevention trial’).
Historically, the presence or absence of any colorectal adenoma [the so-called adenoma detection rate
(ADRa)] has been employed as the primary end point in chemoprevention trials, with reliance on this binary
end point reflecting the varying quality of colonoscopy between different endoscopists and susceptibility of
colorectal adenoma detection to observer variation.5,34–36 However, this percentage value does not take into
account any change in colorectal adenoma number (or size), unlike pre-clinical rodent studies and proof-of-
concept clinical studies in FAP patients, in which lesion number and size are routinely measured.37 More
recently, driven by the dramatic improvement in colonoscopy quality and quality assurance (QA) reporting,38
colorectal adenoma number has begun to be reported as a primary outcome in ‘sporadic’ polyp-prevention
trials as the mean adenomas per participant (MAP).39 Population-based studies have consistently demonstrated
that colorectal adenoma multiplicity predicts future CRC incidence and mortality.40–42
Candidate colorectal cancer chemoprevention agents
The existing literature on several potential CRC chemoprevention agents, including non-steroidal anti-
inflammatory drugs (NSAIDs), hormone replacement therapy and micronutrients (e.g. folic acid, vitamin D),
is well summarised in published reviews.34,36 The largest body of evidence supports the use of the NSAID
aspirin for CRC chemoprevention.43,44
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Aspirin
Observational and randomised controlled trial (RCT) data44,45 suggest primary prevention efficacy of low-dose
(usually defined as < 325 mg daily) aspirin; these data are summarised in comprehensive reviews. In brief,
observational follow-up studies of historical RCTs of aspirin (variable dose: 75–1000 mg daily) for
antithrombotic indications have reported that aspirin reduces the risk of CRC incidence [hazard ratio (HR)
0.75, 95% confidence interval (CI) 0.56 to 0.97] and mortality, with a lag period of approximately 8 years,
compatible with the long natural history of ‘sporadic’ colorectal carcinogenesis.46,47 A similar phenomenon
was also observed in the Women’s Health Study,48 which is the only placebo-controlled RCT of aspirin
(i.e. 100 mg of aspirin taken on alternate days) with a primary CRC prevention end point. Original 10-year
follow-up did not reveal any effect on CRC incidence, but reduced CRC incidence (HR 0.80, 95% CI 0.67 to
0.97) emerged after longer follow-up.48 A consistent finding from these RCTs has been the differential
effect of aspirin on proximal, as opposed to distal, CRC, with the risk reduction associated with aspirin
being primarily for proximal CRC.47,48
Consistent with its role as an established biomarker of CRC risk, a random-effects meta-analysis49 of four
previous polyp-prevention RCTs of aspirin (using daily doses varying from 81 mg to 325 mg), using ADRa
as the primary outcome measure, reported a pooled risk ratio for ‘advanced’ colorectal neoplasm or any
size of colorectal adenoma in aspirin users of 0.72 (95% CI 0.57 to 0.90) and 0.83 (95% CI 0.72 to 0.96),
respectively, an effect that was already apparent at colonoscopy in the first year of follow-up in these
studies (risk ratio 0.62, 95% CI 0.48 to 0.81). Three of these aspirin RCTs reported MAP data as a secondary
outcome, and all demonstrated a consistent reduction in the MAP value associated with aspirin use.49
Aspirin (900 mg) has also been shown to reduce CRC (and other cancer) risk in Lynch syndrome.50
Chemopreventive efficacy of aspirin in Lynch syndrome was not associated with reduced colorectal
adenoma risk during routine surveillance colonoscopy follow-up in a non-screening programme setting.51
However, despite the strength of the evidence that regular, long-term aspirin use prevents CRC, aspirin
has not yet been widely adopted for primary or secondary CRC chemoprevention because of continuing
uncertainty about the optimal daily dose [different trials have reported efficacy of either high- (> 300mg)
or low-dose (< 100mg) aspirin49] and the absence of a clearly defined at-risk population in whom benefit
would outweigh the small risk of gastrointestinal (GI) and intracerebral bleeding associated with aspirin.44,52,53
Nevertheless, the US Preventive Services Task Force52 has recommended low-dose aspirin use for the primary
prevention of cardiovascular disease (CVD) and CRC in some adults aged 50–59 years who have a 10-year
CVD risk of ≥ 10%.
Selective cyclooxygenase-2 inhibitors
Consistent with the role of cyclooxygenase (COX)-2-dependent prostaglandin (PG) E2 in the early stages
of colorectal carcinogenesis,54 selective COX-2 inhibitors (i.e. celecoxib and rofecoxib) displayed significant
chemopreventive efficacy in RCTs in FAP patients (20–30% reduction in polyp number and size)55 and in
individuals with previous ‘sporadic’ colorectal adenoma (risk reduction of approximately 20%).34 However,
the unexpected CVD toxicity associated with prolonged selective COX-2 inhibition, which became apparent
in the polyp-prevention trials, precludes a role for selective COX-2 inhibitors in primary ‘sporadic’ CRC
chemoprevention.56
Omega-3 polyunsaturated fatty acids
Polyunsaturated fatty acids (PUFAs) are important components of a normal diet. Two classes of PUFAs, ω-6
and ω-3, are classified as essential in that they cannot be readily synthesised in the human body and so must
be obtained from dietary sources.57 The principal bioactive ω-3 PUFAs are C20:5ω-3 [in CX:Yω-Z, X denotes
the number of carbon atoms; Y denotes the number of carbon–carbon double bonds and Z denotes the
carbon atom from which the first double bond starts from the ω (methyl) end], eicosapentaenoic acid (EPA)
and C22:6ω-3 docosahexaenoic acid (DHA), which are found predominantly in oily, cold-water fish such as
mackerel, having entered the food chain following synthesis by plankton and algae.57 In addition, C18:3ω-3
alpha-linolenic acid (ALA) is found in vegetables, but can be converted to EPA and then DHA (by a series of
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elongases and desaturases58) only very inefficiently (approximately 5%) in humans.59 In ‘Western’ diets, ω-6
PUFAs dominate, including C20:4ω-6 arachidonic acid (AA), which is the predominant substrate for the COX
enzymes in humans.57
Anticolorectal cancer activity of eicosapentaenoic acid
Eicosapentaenoic acid is an attractive candidate as a ‘natural’ CRC chemoprevention agent based on several
strands of evidence.60 There is strong pre-clinical evidence that ω-3 PUFAs have anti-CRC activity.61 However,
a systematic review of epidemiological studies has not demonstrated unequivocal benefit from dietary ω-3
PUFA intake on CRC risk.62 This may be related to the methodological difficulties of measuring ω-3 PUFA or
fish intake retrospectively. Alternatively, ω-3 PUFA exposure may not be sufficient for consistent anti-CRC
activity in individuals consuming moderate amounts of fish (a portion of oily fish two or three times per week
provides only the equivalent of approximately 500 mg per day of EPA and DHA combined). Omega-3 PUFA
intake can be increased by ‘over-the-counter’ fish oil supplements, which contain a complex mix of ω-3
and ω-6 PUFAs.63 However, many of these supplements are associated with a range of minor, troublesome
side effects [e.g. eructation (burping), halitosis]. In the prospective VITAL (VITamin And Lifestyle) cohort
study, which has uniquely collected data on fish oil supplement use, as well as dietary fish intake, fish oil
supplement users were shown to have a 49% reduced CRC risk compared with non-users, an effect
primarily observed in men.64
Purified and concentrated EPA is available in several forms and pharmaceutical formulations.65,66 EPA alone
(without DHA) is available as the free fatty acid (FFA), as a triglyceride (TG) conjugate (the predominant
natural form of EPA) or as an ethyl ester (EE) conjugate.65 Dietary EPA-TG is converted to EPA-FFA in the small
intestine by the action of pancreatic lipase, which is released in response to (particularly fatty) food intake.
It is unclear which form of EPA is absorbed best from the small intestine and has maximal bioavailability,
especially during prolonged use.65,66 Administration of EPA with food maximises absorption of all forms of
EPA.65 A 500-mg gastroresistant capsule formulation of 99% pure EPA as the FFA has been produced (SLA
Pharma AG, Liestal, Switzerland). This formulation was used for the administration of 2 g of EPA-FFA daily
as four capsules in the RCT in FAP patients described below.67 Alternative formulations of purified EPA exist,
including a 574-mg formulation of 90% EPA-TG (equivalent to 400 mg of EPA-FFA) in a soft gelatin capsule
(Igennus Healthcare Nutrition, Cambridge, UK) that can be used to provide the equivalent 2-g daily dose of
EPA-FFA in five capsules.
Eicosapentaenoic acid in all three forms (i.e. FFA, TG and EE) has been demonstrated to have
chemopreventive activity in several rodent models of colorectal carcinogenesis, including azoxymethane-
induced intestinal tumorigenesis and the ApcMin/+ mouse model of FAP.61,68,69 Preliminary evidence that EPA
has chemopreventive efficacy in humans was provided by two separate Phase II studies of 2 g of EPA-FFA
daily in patients with previous colorectal adenoma(s), which demonstrated a significant reduction in rectal
epithelial cell mitosis frequency (not observed with a 1-g daily dose), which was associated with a fivefold
increase in rectal mucosal EPA content.70,71 These studies led to a Phase III RCT of the effect of 2 g of
EPA-FFA daily for 6 months on rectal polyposis in patients with FAP (n = 58).67 This RCT provided the first
definitive evidence of chemopreventive efficacy of EPA in humans, with a net decrease in rectal adenoma
number and cumulative rectal adenoma size of 22.4% and 29.8%, respectively, between the EPA and
placebo groups.67 The percentage reduction in adenomatous polyp burden was similar to that observed
in FAP patients treated with celecoxib,55 a drug that was subsequently demonstrated to prevent ‘sporadic’
colorectal adenomas.34 In 2012, high dietary intake of marine-derived ω-3 PUFAs was associated with
reduced colorectal adenoma risk.72 The protocol for a RCT of 2.7 g of EPA daily for prevention of rectal
aberrant crypt foci was published in 2012 (UMIN000008172), but the trial has yet to report results.73
Mechanisms of the antineoplastic activity of eicosapentaenoic acid and aspirin
The precise mechanism(s) by which aspirin and EPA have anti-CRC activity is not fully understood.43,45,61
However, it is currently accepted that, even though these agents are likely to act via multiple COX-dependent
and COX-independent mechanisms, modulation of COX activity plays an important role in their antineoplastic
effects. EPA and, particularly, aspirin are both potent inhibitors of COX-1, but they alter COX-2 activity in
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different ways, leading to the production of different bioactive lipid mediators, including PGE3 (EPA) and
15R-HETE (hydroxyeicosatetraenoic acid) (aspirin).57 There is some evidence that PGE3 (unlike pro-tumorigenic
PGE2) has antitumorigenic activity74 and it is known that aspirin-triggered lipoxins derived from 15R-HETE
have antiangiogenic properties.75
Aspirin irreversibly acetylates the COX enzymes.75 When EPA acts as a substrate for aspirin-acetylated
COX-2, it leads to synthesis of 18R-hydroxyeicosapentaenoic acid (18R-HEPE), which can be converted in
a 5-lipoxygenase-dependent manner to resolvin (Rv) E1.75,76 RvE1 has potent anti-inflammatory activity,76
but it is currently not known whether or not RvE1 has direct antineoplastic activity.77 Specialised pro-resolving
(lipid) mediators, such as resolvins and lipoxins, including RvE1, are technically difficult to measure in biological
samples and are likely to exert any biological activity at trace concentrations;77 therefore, it remains unclear
whether or not sufficient quantities are generated in humans to have meaningful antineoplastic activity.78
Although RvE1 synthesis provides a hypothesis for a potential interaction between EPA and aspirin, the
available clinical evidence suggests that the antiplatelet (COX-1-dependent) effects of EPA and aspirin are
simply additive based on the accumulated evidence of extensive use of dual therapy in cardiology patients79
and the effects of the two agents in ex vivo human platelet aggregation studies.80,81 Colorectal carcinogenesis
and atherosclerosis share common pathophysiological mechanisms and clinical risk factors, including
obesity.82 As a consequence, ischaemic heart disease and stroke are common in elderly populations with
colorectal neoplasia.82 Therefore, an attractive feature of CRC chemoprevention using EPA and/or aspirin is
the potential for additional vascular benefit in elderly colorectal adenoma ‘formers’ at simultaneous risk of
occlusive vascular events.43,79
A precision-medicine approach to colorectal cancer chemoprevention
A precision or stratified medicine approach to chemoprevention, whereby the need for chemoprevention
and the use of a specific agent is determined based on an individual benefit–risk assessment, has yet to be
realised.
The preliminary finding of the APACC polyp-prevention trial,83 that the pattern of COX-2 expression in an
index colorectal adenoma predicted the preventative efficacy of aspirin, suggests that baseline colorectal
adenoma characteristics have potential as predictive biomarkers of individual chemoprevention efficacy.
Red blood cell (RBC) membrane ω-3 PUFA levels (as a validated surrogate biomarker of ω-3 PUFA tissue
exposure84,85) have been long established as a biomarker of dietary ω-3 PUFA exposure in cancer
epidemiological studies.86 Between 2014 and 2016, ω-3 PUFA levels were used in RCTs of ω-3 PUFAs as a
biomarker of target tissue ω-3 PUFA exposure (termed ‘bioavailability’ here), but also as a possible indicator
of compliance and/or placebo group ‘contamination’ by over-the-counter (OTC) ω-3 PUFA use.67,87,88
In a RCT of EPA-FFA in patients with CRC liver metastasis, tumour EPA content predicted exploratory
survival outcomes.88 However, there was no relationship between the individual rectal mucosal EPA
content and the reduction in rectal polyp number in the small RCT of EPA in FAP patients.67 Therefore,
there is a need for further evaluation of RBC and colorectal mucosal ω-3 PUFA levels, as well as novel
biomarkers based on the mechanism of action of EPA, as predictors of individual therapeutic response.
There are no validated biomarkers of aspirin anti-CRC activity. However, all the COX-dependent lipid
mediators described earlier are measurable by liquid chromatography–mass spectrometry (LC-MS)77,89 and
may find utility as therapeutic biomarkers.77
Safety and tolerability of eicosapentaenoic acid and aspirin
Aspirin and ω-3 PUFAs are already used widely in patient populations, that are relevant to ‘sporadic’ CRC
prevention, for prophylaxis following myocardial infarction (aspirin and ω-3 PUFAs), hypertriglyceridaemia
(ω-3 PUFAs) and stroke (aspirin).79
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The safety and tolerability of aspirin (≤ 325 mg daily) in previous polyp-prevention trials has been
excellent.34,49 Aspirin use is associated with a dose- and age-dependent increased risk of upper GI and
intracranial bleeding.45,90 Cuzick et al.53 have put forward the case for a favourable benefit–risk profile for
aspirin dosing of ≤ 325 mg daily for 10 years for primary CRC (and other adenocarcinoma) prevention in
average-risk individuals aged 50–65 years.
There is little doubt about the safety and tolerability of ‘nutraceutical’ forms of EPA, confirmed by vast
experience of intake in healthy human populations.91–93 Gastroresistant EPA-FFA of 2 g daily has been
compared with placebo for up to 6 months in four RCTs, in which tolerability has been excellent.67,70,71,87
In the RCT involving FAP patients, there was no significant excess of adverse events (AEs) in the EPA-FFA
group compared with the placebo group, with only one patient withdrawing from the EPA-FFA group as
a result of nausea and epigastric pain.67 In two Phase II studies of colorectal adenoma patients, there was
a slight excess of mild to moderate AEs in the EPA-FFA group compared with the no-treatment70 and
placebo groups.71 In the latter study,71 the GI AEs observed in the EPA-FFA 2-g daily group were not
apparent in those taking 1 g of EPA-FFA daily.71 EPA-TG may be associated with fewer GI AEs, particularly
diarrhoea, than EPA-FFA.66 However, a formal comparison of tolerability between different EPA
formulations in a RCT has not yet been undertaken.
Although aspirin and ω-3 PUFAs share antiplatelet activity and both agents prolong bleeding time, excess
bleeding episodes with their combined use have not been observed in cardiological practice, in which they
are widely used together following myocardial infarction.79,94 However, clinically significant bleeding events
associated with treatment with EPA either alone or in combination with aspirin have, to date, not been
monitored in a RCT.
The NHS Bowel Cancer Screening Programme
The NHS Bowel Cancer Screening Programme (BCSP) in England began in 2006. It is currently based on
a biennial guaiac FOBt targeted at all individuals aged 60–74 years who are covered by NHS registration
data in England (the uptake, based on a returned FOBt kit, is approximately 50–60%).95 Individuals with
an abnormal FOBt (≈2%) are invited for colonoscopy via a specialist screening practitioner (SSPr)-run clinic.
All colonoscopy is undertaken by screening-accredited colonoscopists working within a continuous QA
framework based on multiple measures, including individual caecal intubation rate, withdrawal time and
ADRa.38,95 Recording of endoscopic findings and subsequent histopathological assessment is also directed
by BCSP guidelines and a QA reporting system.96,97 Any abnormality detected is discussed with the patient
at a SSPr follow-up clinic. Detection of a CRC (≈10%, but variable dependent on the number of prevalent
vs. incident screening investigations) prompts further management by the local multidisciplinary team
(MDT) for CRC. Detection of one or more colorectal adenomas prompts surveillance colonoscopy within
the BCSP, as per British Society of Gastroenterology guidelines.30 Individuals classified as being at ‘low risk’
(i.e. those having one or two subcentimetre colorectal adenomas) are not offered colonoscopy, but remain
in the biennial guaiac FOBt programme. Those individuals with three or four small colorectal adenomas
(i.e. < 10 mm in size) or one colorectal adenoma of ≥ 10 mm in diameter are classified as being at
‘intermediate risk’ and are offered another colonoscopy at 3 years from the index procedure. Individuals
with five or more subcentimetre colorectal adenomas, or three colorectal adenomas with at least one
colorectal adenoma of ≥ 10 mm in diameter (i.e. 12% of men and 6.2% of women who undergo
screening colonoscopy), are recommended to undergo surveillance colonoscopy 12 months from the
screening colonoscopy.98
Since 2013, the bowel scope programme has been rolled out across England, whereby, in addition to the
biennial guaiac FOBt invitation, a single FS is offered to all individuals aged 55 years.99 The presence of a
colorectal adenoma of ≥ 10 mm in diameter, three or more small (i.e. < 10 mm) colorectal adenomas or
any adenoma with ‘advanced’ features prompts an invitation for full colonoscopic evaluation, with the
combined colorectal adenoma findings from the FS and colonoscopy directing the subsequent surveillance
strategy within the BCSP, as described above.95
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The seAFOod polyp-prevention trial
Based on strong proof of concept for primary CRC chemoprevention activity of EPA67 and aspirin,49 the
National Institute for Health Research (NIHR)/Medical Research Council (MRC) Efficacy and Mechanism
Evaluation (EME) programme funded a 2 × 2 factorial RCT of 2 g of EPA-FFA daily and/or 300 mg of aspirin
in ‘high-risk’ individuals identified in the English BCSP. The trial was termed the seAFOod polyp-prevention
trial.100
Main research question
Does the ω-3 PUFA EPA prevent colorectal adenomas, either alone or in combination with aspirin?
Objectives
Primary objective
The primary objective was to determine whether or not EPA prevents colorectal adenomas, either alone or
in combination with aspirin. This was addressed by testing the following hypotheses:
l 2 g of EPA-FFA daily is more effective than placebo for reduction in colorectal adenoma recurrence.
l 300 mg of aspirin daily is more effective than placebo for reduction in colorectal adenoma recurrence.
Secondary objectives
The secondary objectives were to assess the tolerability and safety of EPA-FFA and EPA-TG alone and in
combination with aspirin.
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Chapter 2 Methods
Parts of this chapter have been reproduced from Hull et al.1 © 2018 The Author(s). Published by Elsevier Ltd.
This is an Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
The trial protocol has been published in open-access form.100
Trial design
The seAFOod polyp-prevention trial was a randomised, blinded, placebo-controlled 2 × 2 factorial trial.
The trial was designed to integrate fully into the screening and surveillance phases of the BCSP in England
so that participation would not alter routine clinical practice.
Participants were randomised to one of four groups to receive EPA-FFA or EPA-TG (both 2 g of FFA
equivalent daily) daily with food, or identical placebo, AND 300 mg of enteric-coated aspirin daily taken
with food, or identical placebo, until the day before surveillance colonoscopy (at 12 months). The primary
outcome was the number of individuals with one or more colorectal adenomas at the surveillance
colonoscopy (the ADRa). Secondary outcomes included the total number of colorectal adenomas per
participant, subtype (advanced, conventional, serrated, left and right) of adenomas (ADRa and number),
the number of participants reclassified as being at intermediate risk for future surveillance, EPA and other
PUFA levels in RBCs and rectal mucosa, dietary fish intake and assessment of the tolerability and safety of
EPA (both FFA and TG formulations) alone and in combination with aspirin.
Trial setting and participants
NHS Bowel Cancer Screening Programme recruiting sites
The English BCSP is organised into local centres of a variable number (usually 1–3) of individual BCSP sites
(hospitals undertaking endoscopy), which receive referrals for screening colonoscopy after guaiac FOBt
analysis at five regional hubs. Participants identified as ‘high risk’ at participating sites were randomised
and followed to surveillance colonoscopy at 12 months. The trial was integrated into the BCSP to utilise
routine clinical pathways in order to collect quality-assured data from screening and surveillance
colonoscopies.
During the trial, 61 BCSP sites were opened. The date of the first participant, first visit (FPFV) was
11 November 2011; the last participant in was 10 June 2016; and the last participant, last visit (LPLV)
was 8 June 2017. Despite approval from the BCSP Research Advisory Committee, widespread engagement
from SSPrs and Clinical Research Network (CRN)-funded research nurses (RNs) and a trial extension
in 2014, the trial did not recruit to target, recruiting 709 participants against a revised target of 755.
The sample size calculation remained at 853, based on the predicted effect size of the interventions,
giving 80% power. However, recruitment figures achieved prior to the 2014 extension, the limited
recruitment period mandated by the funder and the limitations set by the expiry date on the capsule
(EPA-TG) investigational medicinal product (IMP) suggested that recruitment of 755 individuals would be
feasible in the extended intervention period (see Statistical methods).
The original strategy was to open 15 recruiting sites from two BCSP hubs (North-East and Eastern). This
was based on data from the national BCSP database that suggested that each BCSP centre could identify
approximately 50 high-risk patients per year. Trial screening data supported this assumption; however,
the eligibility rate was much lower than expected, primarily because of a higher than expected number
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of screened high-risk individuals who were excluded because of the need for repeat colonoscopy or FS to
check for adenoma excision within a 3-month window. Analysis of up-to-date BCSP data in early 2012
revealed that the number of cases requiring repeat endoscopy as part of routine BCSP care had increased
nationally during the grant application and set-up phases of the trial. It was determined that a second
colonoscopy or FS did not significantly alter the overall ADRa at the 12-month surveillance colonoscopy
(see Changes to the protocol). Therefore, the protocol was amended (version 4.0, dated 24 May 2012)100
to include these patients, without loss of statistical power.
A trial site expansion strategy was also implemented in 2012, increasing the number of recruiting sites across
England, from Cornwall to Cumbria, to 60 (representing ≈50–60% of English BCSP centres). In late 2015,
a decision was made to add one further site that had expressed a strong interest to be involved in the trial.
Delays were experienced in gaining NHS trust research and innovation (R&I) approvals as a result of a
general lack of Good Clinical Practice accreditation and research training for BCSP staff, many of whom
had not previously contributed to a Clinical Trial of an Investigational Medicinal Product (CTIMP). Sites
were supported by the Nottingham Clinical Trials Unit (NCTU) and local CRNs to access training. The
median time to gain R&I approval at trial sites was 11.5 (range 4–19) weeks. In addition to a site initiation
visit, supplementary training was provided to sites by the co-ordinating centre for participating local
investigators, RNs and SSPrs via an instructional video.
In February 2014, recruitment was disrupted significantly when the manufacturer of the original capsule IMP
(EPA-FFA) was no longer able to provide stock for the trial. Until an alternative capsule IMP could be identified,
approved, manufactured and distributed, sites continued to recruit until local stock was exhausted, at which
point that site temporarily suspended recruitment. To maximise recruitment during this period, the top eight
most active sites were prioritised for allocation of remaining central stock of capsule IMP. Stock management
also ensured that all participants completed the intervention phase of the trial using the same EPA formulation
(FFA or TG). This strategy enabled the trial to continue recruiting between February and October 2014, after
which a new capsule IMP became available. Partly because of this delay, a 36-month extension was approved
(in October 2014) by the NIHR EME board in order to complete trial recruitment.
Identification of participants
Individuals identified as ‘high risk’ at screening colonoscopy on the basis of colorectal adenoma number
and (endoscopic) size, and confirmed later by the histopathology report, were screened for the trial and
approached by a member of the site research team to determine whether or not they were interested in
trial participation. For those participants who had a bowel scope FS, summated colorectal adenoma
findings were used to define individuals as ‘high risk’.
All ‘high-risk’ participants were given written trial information on discharge by a BCSP SSPr or RN. They
were provided with a patient information leaflet (PIL), given a verbal explanation of the trial and given the
opportunity to ask questions.
Participants were able to discuss the trial with their family, friends and/or health-care professionals before
they attended a routine BCSP outpatient follow-up visit 7–14 days after screening colonoscopy. All
participants provided written informed consent.
Eligibility criteria
Patients were eligible for inclusion if they were aged 55–73 years and were a BCSP participant identified as
‘high risk’ (i.e. they had five or more small colorectal adenomas or three or more colorectal adenomas with at
least one being ≥ 10mm in diameter) at the first complete screening colonoscopy. This included participants
who were identified as ‘high risk’ at colonoscopy after FOBt screening, or who were deemed ‘high risk’
on the basis of the combined findings from a bowel scope FS and subsequent full colonoscopy. If the first
screening colonoscopy was defined as complete, the participant was immediately stratified as ‘high risk’.
If the first colonoscopy was incomplete, that individual was required to have a second colonoscopy to complete
METHODS
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the initial examination, after which both procedures were added together as the screening colonoscopy
result for the purposes of BCSP surveillance and trial eligibility.
Patients were excluded from the trial if:
l They had a requirement for more than one repeat colonoscopy or FS within the BCSP 3-month
screening window (see Changes to the protocol).
l They had a malignant change in a colorectal adenoma requiring management by a CRC MDT.
l They were regularly (i.e. more than three doses per week) taking prescribed or OTC aspirin or regularly
(i.e. more than three doses per week) taking prescribed or OTC non-aspirin NSAIDs. This was not an
exclusion criterion if the drug was self-prescribed and not recommended by a doctor and if the
individual was willing to stop taking it for the duration of the trial.
l They had aspirin intolerance or hypersensitivity, including aspirin-sensitive asthma.
l They had had active peptic ulcer disease within 3 months or previous peptic ulcer (and were not on
proton pump inhibitor prophylaxis).
l They had a fish or seafood allergy.
l They used or were planning to regularly use (i.e. more than three doses per week) fish oil supplements.
This was not an exclusion criterion if the supplements were self-prescribed and not recommended by a
doctor and if the individual was willing to stop taking them for the duration of the trial.
l They had a known clinical diagnosis or were a gene carrier of a hereditary CRC predisposition (e.g. FAP).
l They had Lynch syndrome, also known as hereditary non-polyposis colon cancer (HNPCC).
l They had a previous or planned colorectal resection.
l They had known bleeding diathesis or concomitant warfarin therapy or use of any other anticoagulant
or antiplatelet agent.
l They had severe liver impairment.
l They had severe renal failure (i.e. creatinine clearance of < 10 ml/minute).
l They currently used methotrexate at a weekly dose of ≥ 15 mg.
l They were not able to comply with trial procedures and IMP use.
l They had a serious medical illness interfering with trial participation.
l They were taking part in another interventional clinical trial.
l They failed to give written informed consent.
Responsibilities for checking eligibility and obtaining informed consent could be delegated to the SSPr or
RN according to site approvals, but eligibility was confirmed by the local principal investigator (PI) for all
participants.
Changes to the protocol
Soon after FPFV on 11 November 2011, it became apparent from screening log activity at individual BCSP
sites that the eligibility rate was ≈15–20%, rather than the 60% that had been predicted in the original
recruitment projection. A contributing factor was the higher than expected use of other non-aspirin
antiplatelet agents, such as clopidogrel, which was later added as an exclusion criterion in January 2012
(protocol version 3.1, dated 12 January 2012). Another major contributing factor was the larger than
expected number of ‘high-risk’ individuals (≈25%) who required a repeat endoscopy after randomisation.
Repeat endoscopy was originally an exclusion criterion because the primary end point might be confounded
by colorectal adenoma detection and removal at an extra endoscopic procedure between the screening
(index) and 1-year surveillance colonoscopies. However, subsequent analysis in April 2012 of 1189 ‘high-
risk’ patients who underwent 1-year surveillance colonoscopy in 2010 in 26 BCSP centres did not support
this notion. The overall ADRa at surveillance colonoscopy [including those who underwent repeat partial
colonoscopy or FS (ADRa 54%), repeat full colonoscopy (ADRa 67%) or no repeat procedure (ADRa 63%)]
was 62%, which was consistent with the value (60%) used in the original sample size calculation. Therefore,
the protocol was amended to allow recruitment of those individuals who required no more than one repeat
endoscopic procedure [either colonoscopy (full or partial) or FS] within a 3-month screening episode window
(version 4.0, dated 24 May 2012).100 A number of other changes to details contained within the protocol are
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documented in the statistical analysis plan (SAP) (version 1.1, dated 24 August 2017). These are listed in
Statistical methods.
During trial recruitment, the trial was included as part of a larger MRC-funded programme of research
[Systematic Techniques for Assisting Recruitment to Trials (START)] to assess web-based recruitment
strategies. A separate protocol was approved for the cluster randomised (by site) substudy of a web-based
information tool and the PIL was updated accordingly. Details of this study and the seAFOod trial
contribution will be reported separately by the MRC-START study team.
Trial procedures
Trial procedures were performed as shown in Figure 1.
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FIGURE 1 The seAFOod trial participant pathway. (a) Participants whose visit 6 date was scheduled from the
first complete colonoscopy; and (b) participants whose visit 6 date was scheduled from a repeat full colonoscopy.
FFQ, Food Frequency Questionnaire.
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Baseline visit
Individuals attending a routine outpatient follow-up BCSP appointment to obtain results of the screening
colonoscopy were approached. Individuals who were eligible and willing to take part in the trial were
asked to provide written informed consent. Demographic information and details of participants’ medical
histories were collected and participants were randomised. It was preferred that participants were
randomised within 4 weeks of the first complete BCSP screening colonoscopy. However, to maximise
recruitment, randomisation was allowed outside this time window as long as it was recorded on the
protocol deviation log. A prescription was issued for the supply of IMP for 6 months. The local hospital
pharmacy dispensed the trial treatment. A second prescription for a further 6 months of IMP was provided
at visit 4.
Biological samples were taken, comprising a blood sample [2 × 6-ml K2EDTA (ethylenediaminetetraacetic
acid) Vacutainer® tubes; Becton, Dickinson and Company (BD), Franklin Lakes, NJ, USA] and a urine
specimen of 5–10 ml. Samples were taken only if the participant provided separate, specific consent for
collection of blood and urine.
In addition, participants were asked to complete a pre-treatment Food Frequency Questionnaire (FFQ)
so that any change in dietary ω-3 PUFA intake during trial involvement could be determined.
Repeat endoscopy
Participants were informed whether or not a repeat colorectal endoscopic examination was required at
the baseline visit. This was one of the following: a second full colonoscopy, a partial colonoscopy (planned
incomplete views of the colorectum) or a FS. Participants undergoing one repeat endoscopy within 3 months
of the screening colonoscopy remained eligible for the trial. The results of the colonoscopy were collected
at visit 3. These participants were in the intervention period of the trial for a maximum of 15 months,
rather than 12 months, so an additional 3-month trial prescription was dispensed to cover this period. If a
participant who had already undergone a repeat endoscopy had a further repeat procedure scheduled by the
local BCSP team, this made him or her ineligible for the trial.
All participants were asked to commence the IMP immediately following consent at the baseline visit (visit 1).
Those participants who were due to undergo a repeat endoscopy procedure temporarily stopped IMP
10 days prior to the endoscopic procedure and restarted IMP 4 days after the endoscopy. Participants who
underwent a partial colonoscopy or FS had a surveillance colonoscopy 12 months after the first complete
screening colonoscopy, as per BCSP guidelines. Participants who underwent a second full colonoscopy had a
surveillance colonoscopy date booked as per BCSP team preference, but preferably dated 12 months after
the first screening colonoscopy.
Visits 2 and 3: telephone calls at 2 and 12 weeks
Participants were contacted by the SSPr/RN by telephone at 2 and 12 weeks after starting trial treatment.
Participants were asked about any symptoms or new medical problems since the last contact and were
reminded to take the IMP as directed.
Participants who were due to undergo a repeat colorectal endoscopic procedure between visits 2 and 3
were reminded to discontinue IMP temporarily. Colonoscopic findings at the repeat procedure were
collected and recorded in the same way as for the baseline visit.
Visit 4: outpatient visit
At 6 months, participants were invited to attend the BCSP site, at which time mid-treatment blood and
urine specimens were collected from those who had provided consent. Participants were asked about any
symptoms or new medical problems since the last contact. Any unused trial treatment from the first
prescription was collected and counted. Each participant then received a new prescription for trial
treatment for a further 6 months.
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Visit 5: telephone call
A third telephone contact was conducted with participants at 38 weeks after starting the trial treatment.
The SSPr/RN asked about any symptoms or new medical problems since the last contact and reminded the
participant to take trial treatment as directed.
Visit 5a: telephone call
An extra telephone contact was conducted for participants who had a repeat full colonoscopy between
visits 2 and 3 after starting the trial treatment. The SSPr/RN asked about any symptoms or new medical
problems since the last contact and reminded the participant to take his/her trial treatment as directed. The
SSPr/RN liaised with the hospital pharmacy about delivery of a third dispensing of IMP to these participants.
The relevant participants then received a new prescription for trial treatment for a further 3 months.
Visit 6: surveillance colonoscopy
Participants attended for routine surveillance colonoscopy at 12 months from the date of the screening
colonoscopy. Participants took the final dose of trial treatment on the day before surveillance colonoscopy.
Blood and urine specimens were obtained, as well as four random biopsies of macroscopically normal
rectal mucosa (at least 2 cm from any polyp) at the end of the surveillance colonoscopy.
Colorectal adenoma outcomes at the 12-month surveillance colonoscopy were collected as per usual BCSP
practice, including the number, size (maximum dimension in mm from the histopathology report, or the
endoscopic size if the adenoma was not retrieved or was removed by hot biopsy), site [proximal to the
splenic flexure (right) or at/distal to the splenic flexure (left)], histological type (tubular/tubulo-villous, villous,
serrated) and presence of high-grade dysplasia of all colorectal adenomas.
Visit 7: routine post-colonoscopy visit
Participants were seen after surveillance colonoscopy as part of routine BCSP follow-up, during which a
second FFQ was completed. Participants had the option to complete the FFQ at visit 6 or over the
telephone if they decided to receive colonoscopy results by telephone.
Randomisation
Participants were registered in the trial using a secure web-based randomisation system. Randomisation was
based on a computer-generated, internet-based treatment assignment determined by a pseudo-random
code using random permuted blocks of randomly varying size, created by NCTU. Participants in the trial
were allocated with equal probability to either treatment group. It was planned to stratify by BCSP centre.
However, after database lock, it was discovered that BCSP site had been used, rather than BCSP centre.
As sites could be associated only with an individual BCSP centre, this still ensured balance between centres.
Participants were randomised to a simple 2 × 2 factorial design (Table 1) to:
l 2 g of EPA-FFA, or an equivalent FFA dose of 90% EPA-TG (2780 mg), daily by mouth, or their identical
placebos (capric and capryllic acid medium-chain TGs for both formulations)
in addition to:
l 300 mg of enteric-coated aspirin daily by mouth (as one 300-mg tablet taken with food) or
identical placebo.
The sequence of treatment allocations was concealed until interventions had all been assigned and
recruitment, data collection and all other trial-related assessments were completed. The actual allocation
was not divulged to either the staff at the BCSP site or the participant. The trial prescription produced by
the randomisation system referenced specific trial treatment containers. The trial drug prescription was
signed by the local PI or a co-investigator, as defined by the site delegation log.
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Interventions
The IMPs used in this trial were gastroresistant capsules of 99% pure EPA in the FFA form (EPA-FFA), 90%
EPA as the TG conjugate (EPA-TG) in soft gelatin capsules, enteric-coated aspirin tablets and their identical
placebos.
In February 2014, the supplier of the EPA-FFA IMP (SLA Pharma AG) disclosed that it could no longer
provide further capsule IMP to the trial. The Trial Management Group (TMG), NIHR EME programme and the
Trial Steering Committee (TSC) made the decision to continue the trial using an alternative EPA formulation
and identical (medium-chain TG) placebo. Close consultation with the Medicines and Healthcare products
Regulatory Agency (MHRA) and the Research Ethics Committee (REC) was also undertaken. A substantial
amendment (number 14) was approved by the REC on 26 August 2014 and the trial received a Clinical
Trials Authorisation (CTA) from the MHRA on 29 August 2014 for a new capsule IMP (EPA-TG). The new
formulation maintained FFA equivalence (2000 mg daily) with the previous EPA-FFA formulation by using
5 × 574-mg 90% EPA-TG capsules per day (a total of 2870 mg), taking into account the percentage weight
per weight (w/w) content of EPA and the presence of the glycerol backbone in the re-esterified TG.
The CTA required a specific simplified IMP dossier for the 90% EPA-TG, detailing its multistep manufacture,
and also a cover document for the existing investigator brochure, which compared the chemical structure,
GI absorption, bioavailability and tolerability profiles of the FFA and TG forms of EPA.
Although the 90% EPA-TG capsules that were proposed as a new IMP were publicly available for purchase
as a nutritional supplement (from Igennus Healthcare Nutrition), the MHRA requested a programme of
stability testing to meet manufacturing QA requirements for a CTIMP (see Appendix 1). A programme of
accelerated (30 °C, 65% relative humidity) and standard (25 °C, 60% relative humidity) stability testing
of capsules began in July 2014 (performed by ALS Food & Pharmaceutical, Carlisle, UK) and was performed
once every 3 months. The core data set comprised the peroxide value (POV), para-anisidine value (pAV) and
derived total oxidation (TOTOX) value, as well as a full PUFA analysis, to determine the EPA content. Data
from initial accelerated testing at 3 months gave a minimum 12-month shelf life under standard conditions
for the trial to continue with the new capsule IMP. Rolling stability testing provided a continuous extension
of shelf life until 12 June 2016, when capsule IMP use ceased, as per the maximum approved shelf life
(3 years) of the capsule IMP approved by MHRA.
The commercially available 90% EPA-TG capsule was also encapsulated with a differently coloured soft
gelatin coat (olive green) to be able to produce an identical placebo because of the difference in
appearance of EPA and medium-chain TG oils.
Participants took only one formulation of the EPA, which was either FFA or TG, or its matching placebo.
Stocks of the IMP were managed during the transition period from the FFA formulation to the TG formulation
to ensure that sites had sufficient stock of EPA-FFA and placebo capsules to manage existing and new
participants throughout each individual intervention period.
The trial treatment was taken daily from the date of randomisation to the day before the 12-month
surveillance colonoscopy.
TABLE 1 The seAFOod trial 2 × 2 factorial design
l 2 g of EPA-FFA, or equivalent FFA dose of EPA-TG
l 300mg of aspirin
l 2 g of EPA-FFA, or equivalent FFA dose of EPA-TG
l Placebo aspirin
l Placebo EPA
l 300mg of aspirin
l Placebo EPA
l Placebo aspirin
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Suppliers
SLA Pharma AG supplied EPA-FFA capsules and an identical placebo free of charge. Igennus Healthcare
Nutrition supplied the 90% EPA-TG capsules and an identical placebo at cost price. Aspirin and its identical
placebo were supplied by Bayer AG (Leverkusen, Germany) free of charge.
Eicosapentaenoic acid-free fatty acid dose
Participants took two 500-mg gastroresistant capsules of 99% pure EPA-FFA (or placebo) twice daily with
food, giving a total daily dose of 2 g of EPA-FFA. Previous experience suggested that 2 g of EPA-FFA daily
is well tolerated; principal side effects are diarrhoea, abdominal pain, nausea and vomiting, which are
generally mild in severity and minimised or avoided by dosing with food or dose reduction to 1 g daily.
A dose-reduction algorithm was used for participants experiencing side effects and managed by the local
RN or SSPr.
Eicosapentaenoic acid-triglyceride dose
Alternatively, five soft gelatin 574-mg capsules of 90% EPA-TG (or placebo), equivalent to 2780 mg,
were taken orally with food each day. It was preferred that three of the EPA-TG capsules were taken with
the largest meal of the day and two capsules were taken with a smaller meal. Each capsule contained
approximately 516 mg of EPA-TG, which is equivalent to 398mg of EPA-FFA. Other PUFAs in the formulation
included 3.9% (w/w) AA. The 90% EPA-TG did not have pharmaceutical marketing approval [see the project
web page: www.journalslibrary.nihr.ac.uk/programmes/eme/0910025/#/ (accessed 25 April 2019)]. Clinical
studies have indicated that EPA-TG (usually in a fish oil mixture with other PUFAs) is well tolerated at doses
exceeding 2 g per day over periods of up to 6 months. The principal known side effects are the same as
indicated for EPA-FFA.101–105
Aspirin
Participants were randomised to one 300-mg enteric-coated aspirin tablet (or placebo), taken orally once a
day with food. Aspirin (acetylsalicylic acid) was supplied as 300-mg enteric-coated tablets in accordance
with the Summary of Product Characteristics for aspirin (see Appendix 2). These tablets had marketing
approval in the European Union.
Placebos
The EPA-FFA and EPA-TG placebos consisted of identical capsules of capric and capryllic acid medium-chain
TGs that had previously been used in placebo-controlled trials of EPA.67
The placebo for aspirin consisted of the same excipients as the active formulation of the drug minus the
active ingredient.
Discontinuation of treatment
In the event of an adverse drug reaction (ADR), either serious or non-serious, the local PI or attending
physician was to take direct and appropriate action to provide care for the participant and to decide
whether or not the trial treatment should be discontinued. However, unless there was a clear
contraindication, trial treatment was continued, or stopped temporarily.
In all cases, the reasons for discontinuation of trial treatment were recorded in the clinical record file and if
the investigator had recorded more than one reason, he or she was to indicate the main reason.
Treatment was discontinued permanently if the participant needed treatment with a contraindicated drug:
≥ 15 mg of methotrexate weekly, any dose of warfarin or any other anticoagulant therapy, any other
antiplatelet agent such as clopidogrel, or prescription of aspirin for any other indication. These participants
were still followed up for the remainder of the trial.
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Prescriptions and accountability
The local PI or delegated pharmacy trial staff member was responsible for ensuring trial treatment
accountability, including reconciliation of trial treatment and maintenance of trial treatment records,
throughout the course of the trial, in accordance with UK regulatory requirements. On receipt of a delivery
of trial treatment, details were checked for accuracy and receipt was acknowledged by signing and dating
the documentation provided. In addition, receipt was acknowledged in the web-based system by the local
pharmacy team, which had access to the web-based stock control system. Stock did not become available
for allocation until it was accepted in the stock control system.
The local hospital pharmacy completed the dispensing process by addition of a participant’s name, subject
number, date of dispensing and visit number to each allocated container. This process was repeated again
at visits 4 and 5a if required.
Blinding
Participants, SSPr/RNs, local investigators and those assessing the outcomes were all blinded to treatment
allocation. The statistical analysis for the trial was also blinded until data were locked, except for
independent Data Monitoring Committee (DMC) reports.
Trial treatment
The trial treatment was packaged and labelled in accordance with UK regulatory requirements. The containers
were clearly marked and had a unique identification number.
Bulk supplies of EPA-FFA, EPA-TG, aspirin and placebo capsules and tablets were delivered to Stockport
Pharmaceuticals (Stockport, UK) for packaging and labelling to allow preparation of blinded supplies.
Blinded supplies were then stored at Stockport Pharmaceuticals for distribution to participating sites under
a web-based stock control system reviewed regularly by the NCTU pharmacist.
Unblinding
Access to the sequence of treatment allocations was confined to the NCTU data manager and a central
pharmacy, in case of out-of-hours unblinding. In the event of the need to break the code, the date and
reason were recorded on the web-based unblinding system. The local hospital pharmacy had access to the
web-based unblinding system in normal office hours and out-of-hours access was provided via the sponsor
at St James’s University Hospital. The requirement for unblinding was considered low. All participants were
given a trial identification card, containing details of the IMPs, which participants were encouraged to show
when seeking advice or management from any health professional. Unblinding did not occur during the trial.
End of the trial
Participants left the trial when they completed their routine post-surveillance colonoscopy visit (visit 7).
Cases of failure to receive allocated treatment and withdrawal from follow-up were reported, and the
reason(s) for withdrawal (if given) were documented. If a participant did not receive allocated treatment
but agreed to remain in the trial, outcome data collection continued in accordance with the protocol.
Participants were informed at the start of the trial that data collected up to the point of withdrawal would
be retained and used in the final analysis.
Trial withdrawal
Participants could withdraw from the intervention or the trial at any time without giving a reason and
without compromising future management. Data collected up to the point of withdrawal were retained
for the purposes of the intention-to-treat (ITT) analysis. Participants could withdraw from the intervention
only but continue in the trial, thereby completing outcome measures. To maximise primary outcome data
collection, BCSP surveillance colonoscopy data were also collected from participants who withdrew from
the trial, as per the informed consent.
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Outcome measures
Primary outcome
The primary outcome was the number of participants with one or more colorectal adenomas detected at
the first BCSP surveillance colonoscopy 12 months after the screening examination (ADRa).
Secondary outcomes
The secondary outcomes were as follows:
l Total number of colorectal adenomas per participant at BCSP surveillance colonoscopy (total MAP).
l Detection of one or more ‘advanced’ (i.e. ≥ 10 mm in diameter, high-grade dysplasia or villous
histology) colorectal adenomas at the 12-month BCSP surveillance colonoscopy (advanced ADRa).
l Number of ‘advanced’ colorectal adenomas per participant at the 12-month BCSP surveillance
colonoscopy (advanced MAP).
l Detection of one or more conventional adenomas (conventional adenoma end points were defined
after database lock) at the first BCSP surveillance colonoscopy (conventional ADRa).
l Number of conventional adenomas (conventional adenoma end points were defined after database
lock) per participant at the first BCSP surveillance colonoscopy (conventional MAP).
l Detection of one or more serrated adenomas at the first BCSP surveillance colonoscopy (serrated ADRa).
l Number of serrated adenomas per participant at the first BCSP surveillance colonoscopy (serrated MAP).
l The region of the colorectum (right colon: any part of the colon proximal to the splenic flexure; left
colon: the rectum and the colon at/distal to the splenic flexure) in which adenomas are detected at the
first BCSP surveillance colonoscopy.
l Reclassification from ‘high risk’ to ‘intermediate risk’ after the first BCSP surveillance colonoscopy (BCSP
risk stratification at the first surveillance colonoscopy states that any individual who does not continue
to fulfil ‘high-risk’ criteria is classified as ‘intermediate risk’ for further colonoscopic surveillance at
3 years).
l Detection of CRC prior to, or at, the first BCSP surveillance colonoscopy.
l Dietary fish and other seafood intake at baseline and at the end of the trial.
l Red blood cell EPA and rectal EPA levels at baseline, 6 months (RBC only) and 12 months
from randomisation.
l Absolute RBC fatty acid (i.e. DHA, AA, EPA-to-AA ratio) levels and difference from baseline at 6 months
and 12 months.
l Rectal mucosal fatty acid (i.e. DHA, AA, EPA-to-AA ratio) levels at surveillance colonoscopy.
l Adverse events, including clinically significant bleeding episodes (i.e. haemorrhagic stroke or GI bleeding
requiring hospital admission or investigation).
Exploratory outcomes
l Colorectal adenoma size.
l Association between change of RBC EPA level at 12 months and individual number of total colorectal
adenomas.
l Association between rectal and RBC EPA levels at 12 months.
Research governance
The trial was conducted in accordance with (1) the recommendations adopted by the 18th World Medical
Assembly, Helsinki 1964, amended at the 48th General Assembly, Somerset West, Republic of South Africa,
October 1996 (www.wma.net/wp-content/uploads/2018/07/DoH-Oct1996.pdf); (2) the principles of the
International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use – Good Clinical Practice (ICH-GCP) guidelines (https://ichgcp.net); and (3) the Medicines for
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Human Use (Clinical Trials) Regulations 2004106 (UK Statutory Instrument 2004/1031) and any subsequent
amendments of the Clinical Trial Regulations.
The National Research Ethics Service (NRES) Trent – Trent REC (reference number 10/H0405/90) gave ethics
approval for the trial for NHS participants. First, MHRA CTA approval was obtained on 16 March 2011.
The trial was approved by the BCSP Research Committee on 13 October 2009.
This project was funded by the EME programme, a MRC and NIHR partnership (project number 09/100/25).
The trial was registered (as ISRCTN05926847) in a publicly available database prior to FPFV.
The final, approved protocol was version 6.0, approved on 11 August 2014. There were a number of
administrative and procedural changes made to the protocol during the trial, which are outlined in
Appendix 3.
Protocol deviations
The protocol defined a protocol violation as:
l > 50% of trial medication returned in total
l inadvertent use of OTC medication containing aspirin, NSAIDs or fish oil for > 2 weeks in total
l surveillance colonoscopy occurring outside the allowed time windows (48–52 weeks after the last
complete screening BCSP colonoscopy, or 60–64 weeks for participants undergoing a repeat full
colonoscopy within 3 months of initial screening).
The protocol deviation log collected the above violations and any additional protocol deviations (i.e. any
deviation from the protocol that occurred during a participant’s time in the trial, whether deliberate or
non-deliberate).
Trial oversight
Oversight committees were assembled to ensure the proper management and conduct of the trial, and to
uphold the safety and well-being of participants. The general purpose, responsibilities and structures of the
committees were described in the protocol.
Trial Management Group
The TMG comprised the chief investigator, members of the NCTU and other visiting members of the wider
trial team, including the University of Bradford biobank and lipid analysis team and an expert in human
nutrition, as required. This group met regularly, with supplementary meetings as required, to oversee the
day-to-day operational aspects of the trial, reviewing progress and resolving issues that arose.
Trial Steering Committee
The TSC was led by an independent chairperson and consisted of members with professional expertise in
delivering RCTs, CRC diagnosis and management, primary care gastroenterology and the BCSP. The TSC
also had a patient and public involvement (PPI) representative (an individual who had undergone BCSP
colonoscopy) during the course of the trial. The TSC monitored, reviewed and supervised the progress
of the trial, particularly advising on recruitment and retention, as well as ensuring adherence to the trial
protocol. It also monitored blinded data to consider safety and effectiveness indications. The TSC considered
reports from the DMC when making recommendations. The chief investigator, trial manager and at least
one co-investigator were also in attendance as non-independent members to provide information to the
committee. The trial sponsor (University of Leeds) and IMP providers were invited to attend as observers.
The TSC met independently prior to the start of the trial and agreed terms of reference in a charter.
The committee met approximately every 6 months thereafter, convening supplementary meetings as
required (e.g. related to the capsule IMP switch).
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Data Monitoring Committee
An independent DMC, which met approximately every 6–12 months, was established with access to
unblinded data to provide independent review and recommendations in the light of potential treatment
effect and harm, as well as to assist and advise the TSC and the TMG. The DMC consisted of a chairperson
and members with expertise in colorectal surgery and prevention, early detection and treatment of CRC,
and statistics. The DMC met prior to the start of the trial and agreed terms of reference in a charter. Only
the DMC had access to unblinded data until the final end-point assessment was completed.
Risk assessment and safety monitoring
A risk assessment was conducted as part of protocol development and was monitored regularly throughout
the trial for new risks. The main risks to the trial were reliance on the BCSP to recruit to a large multicentre
RCT, as the BCSP had not previously hosted CTIMP research and staff were not experienced in recruiting
participants. Compliance with trial medication and drug accountability was reliant on participants returning
medication and patient reports, as well as staff maintaining detailed records of medication logs.
Recruitment sites were supported by the NCTU, which initially provided training through a site initiation
visit, as well as supplementary training, as required. Investigators had access to a research area of the trial
website (www.seafood-trial.co.uk) and access to the NCTU trial team for day-to-day queries. To obtain
high-quality data, regular central monitoring checks were performed according to the monitoring plan,
including review of recruitment, retention and data collection rates by the TMG, TSC and DMC.
Data on AEs and serious adverse events (SAEs) were collected. As agreed by the sponsor, REC, DMC and
TSC, the DMC was provided with a listing of all AEs and SAEs, including any deaths (if applicable), at each
DMC meeting.
As part of the switch from the EPA-FFA formulation to the EPA-TG formulation, a review was undertaken
of the Reference Safety Information (RSI) for the trial. Evidence was provided in a supplement, including
MHRA-stipulated RSI for the EPA formulations, version 2.0, dated 22 August 2016 (approved by the MHRA
on 3 October 2016) to the investigator brochure version 6, dated 10 January 2014, that the FFA and TG
formulations were likely to have a similar pharmacological and risk/AE profile, as well as similar anti-CRC
efficacy, in the seAFOod trial population [see the project web page: www.journalslibrary.nihr.ac.uk/
programmes/eme/0910025/#/ (accessed 25 April 2019)].
Monitoring
Following an internal assessment of the trial by the quality assurance manager at the NCTU, the trial was
assessed as a medium-risk trial requiring low-intensity monitoring. Based on this risk category and the specific
risks identified, the monitoring strategy consisted of on-site routine and triggered monitoring visits, central
monitoring and review of regular reports by trial oversight committees, as well as assessment and oversight
of third-party vendors. On-site visits were conducted by either the trial manager or a trial monitor. Central
monitoring was conducted by the NCTU and reviewed regularly by the TMG, the TSC and the DMC. On-site
and central monitoring revealed no major common concerns during the trial. Sites that received an on-site
monitoring visit at some point during the trial accounted for 68% of randomised participants.
Patient and public involvement
There was PPI throughout the trial. One PPI member was integral to trial design, grant application and
production of participant-facing trial materials. He then took no further part in the trial. Subsequent PPI
input on the TSC was provided by a different PPI member. Both PPI representatives brought personal
experience of the BCSP pathway to their roles. Two PPI representatives from Independent Cancer Patients’
Voice contributed to the production of site and participant results summaries and to the development of
the dissemination plan for the trial findings.
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Payments to participants
Participants were not paid to participate in the trial. Visits 1, 6 and 7 were planned to co-ordinate with
routine BCSP appointments. However, an additional visit at 6 months (visit 4) was required; therefore,
participants were offered a reimbursement of travel expenses up to a maximum of £10.
The seAFOod polyp-prevention trial biobank
Blood, urine and rectal mucosa sample collection in the seAFOod polyp-prevention trial is described in
detail in an appendix of the trial protocol, which has been published.100
In brief, a blood sample and a urine specimen were obtained at visits 1, 4 and 6. Blood was immediately
separated into plasma, leucocytes and RBCs. Rectal biopsies were obtained only at the surveillance
colonoscopy at visit 6.
Sample cryovials were stored in either a Liebherr Underbench –20 °C freezer (Liebherr Group, Bulle,
Switzerland) supplied by the seAFOod trial or the existing trust freezer facility at –20 °C or colder, in
PathoSeal bags (DGP Intelsius Ltd, York, UK). Storage temperature was monitored using a Hanna HI-141
CH Datalogger (Hanna Instruments Ltd, Leighton Buzzard, UK), or a similar system provided by the trust
site, and recorded on sample worksheets.
University of Bradford staff, in close collaboration with the NCTU, organised the collection of samples from
each BCSP site approximately every 6 months by a specialist courier (CitySprint Health, London, UK). The
original proposal was to transfer samples to the central biobank facility every 3 months. However, the
expansion of participating trial sites in 2012–13 meant that the collection strategy was revised. BCSP sites
were grouped into 10 individual routes by CitySprint Health so that collection from these sites could be
scheduled for the same day. Sites were asked to confirm whether or not they required a collection, and the
number of PathoSeal bags at that site, to allow CitySprint Health to supply the correct thermal box size.
If sites were unable to accommodate a collection on their scheduled route day, individual collections were
arranged. The day before collection, CitySprint Health arranged for pre-addressed thermal boxes, which
contained dry ice, to be sent to appropriate BCSP sites. The lid of the thermal box was removed only when
necessary for adding samples. All sealed PathoSeal bags collected since the last courier sample collection
were placed in the thermal box and dry ice was spread around the bags to ensure that they were completely
covered. The thermal boxes were delivered to the University of Bradford on the same day or, in the case of
routes involving longer distances, the following morning. No units were received with low dry ice levels and
all samples were received frozen.
Each BSCP site completed a shipment form that documented the samples being transported. A carbon copy
of the shipment form was kept in the site file with the carbon copy of the completed sample worksheets.
The original shipment form and the original completed sample worksheets were sent with the samples.
On receipt of each shipment of transportation units at Bradford, a sample tracking form was completed.
Contents were then checked against the sample worksheet. Cryovials were transferred into sample boxes
(10 × 10 cell cryoboxes, manufactured by Sarstedt, Nümbrecht, Germany) specific to each sample type, and
cryoboxes were kept on ice at all times when removed from the freezer. All details were entered onto a
separate sample tracking form for each thermal box. Samples were stored in type-specific cryoboxes and
racks, minimising disruption when samples were removed for analysis.
All samples were stored in a dedicated –80 °C freezer (New Brunswick™ U570 –80 °C; Eppendorf, Hamburg,
Germany), which was connected to the emergency power supply at the Institute of Cancer Therapeutics,
University of Bradford, and supported with a CO2 back-up system (New Brunswick) and Centroller AD11+
(Centroller, Staines, UK) telephone alarm system. Freezer temperature was monitored daily.
The details from the sample tracking form and the sample worksheets were entered into the seAFOod trial
biobank sample database. The database allocated a unique Clinical Trials Pharmacology Laboratory (CTPL)
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tracking identification (ID) to each participant-specific set of samples in a PathoSeal bag (i.e. if a participant
had samples taken on three visits, they received three CTPL IDs). The CTPL ID was marked on the sample
worksheet and the sample tracking form. The database was stored on the University of Bradford server,
in the ‘Secure’ section, accessible only by nominated CTPL staff, and backed up regularly, as described in
the University of Bradford’s computer policy. The database was the primary source for sample tracking;
however, paper documents were available as a secondary source if necessary, stored in participant and
shipment folders in the secure Human Tissue Act-approved laboratory.107
Samples were obtained at BSCP sites between FPFV (i.e. 11 November 2011) and LPLV (i.e. 8 June 2017).
The first samples received at Bradford were delivered on 18 July 2012 and the last sample shipment took
place on 27 July 2017. In the intervening time, 332 collections were made from BCSP sites, with 1775
individual PathoSeal bags received.
Samples were stored at BSCP sites for between 1 and 696 days (mean 124 ± 92 days, median 115 days).
There were 1378 (78%) sample sets stored at BSCP sites for < 6 months. Thirty (2%) sample sets were
stored at BSCP sites for > 12 months.
The majority of sample sets (n = 1021; 58%) were stored in BCSP sites at –20 °C (range –16 to –24 °C), with
230 (13%) sample sets stored at –40 °C (range –25 to –69 °C) and 524 (30%) sets stored at or below –70 °C.
One or more biological samples were received from 677 of 709 (95%) randomised seAFOod trial participants.
Of the 709 participants, 73% (519) of participants provided full sample sets of blood, urine and rectal mucosa
from all three visits. There were 76 participants who provided samples at two visits (visits 1 and 4, n = 49;
visits 4 and 6, n = 15; visits 1 and 6, n = 12). Eighty-two participants provided samples at only a single visit
(visit 1, n = 75; visit 4, n = 2; visit 6, n = 5).
Overall, a total of 7322 biological samples were received (16,258 sample aliquots):
l 1715 plasma samples (6746 aliquots)
l 1714 leucocyte samples (1714 aliquots)
l 1707 RBC samples (3421 aliquots)
l 1664 urine samples (3309 aliquots)
l 522 rectal biopsies (1068 aliquots).
Compliance with biological sample collection [defined as the proportion of sample sets expected (n = 2127)
that were received with at least one sample aliquot] was 80% (blood), 78% (urine) and 74% (rectal mucosa).
Laboratory protocol deviations were monitored carefully by sample worksheets:
l 80% of blood samples were obtained per protocol (centrifugation within 30 minutes and transfer to
the freezer within 60 minutes).
l 2% of sample sets were received without worksheets.
l 1% of samples sets were received with insufficient data to assess timing.
l 8% of blood was separated after 30 minutes, but frozen within 1 hour of collection.
l 9% of blood samples took > 1 hour to separate (often related to split hospital sites for endoscopy and
sample handling).
A small number of other protocol deviations were noted, including:
l 1% of sample sets that suffered a temperature deviation (but no thaw).
l 1% of sample sets that defrosted at some point.
l 0.5% of sample sets suffered ‘other’ deviations (including wrong anticoagulant blood tube used and
biopsies placed in formalin).
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
Fatty acid measurement and analysis
The methods used are described in detail by Volpato et al.89 In brief, fatty acids were extracted from washed
RBC membranes, or rectal mucosal homogenates, using an isopropanol/chloroform method with acid
hydrolysis, in order to measure the total membrane/tissue fatty acid pool.89 Liquid chromatography, in
combination with electrospray ionisation triple quadrupole tandem mass spectrometry (ESI-MS), was performed
with a Waters Alliance™ 2695 High Pressure LC module (Waters, Milford, MA, USA) in combination with a
Waters Micromass™ Quattro Ultima triple quadrupole mass spectrometer on derivatised samples, in the
presence of internal standard (deuterated ALA), as described by Volpato et al.89 Data are expressed as the
percentage of each fatty acid relative to the total fatty acid peak chromatographic area for the ω-3 PUFAs
C18:3 (ALA), C20:5 EPA, C22:5 docosapentaenoic acid (DPA) and C22:6 DHA; the ω-6 PUFAs C18:2 linoleic
acid (LA) and C20:4 AA; and the monounsaturated C18:1ω-9 oleic acid and saturated fatty acids C18:0 stearic
acid and C16:0 palmitic acid.89
Measurement of dietary fish intake
Participants were asked to complete a FFQ at baseline (visit 1) and at the end of the intervention (visit
6 or 7). The validated European Prospective Investigation of Cancer (EPIC) short FFQ was used, which is a
semiquantitative, paper-based FFQ that includes 130 food items and supplementary questions about use
of fat, milk, cooking methods, salt and supplement use.108 The FFQ measures an individual’s habitual food
intake over the preceding 12 months. The primary purpose of the FFQ was to determine if there was any
change in dietary marine ω-3 PUFA intake during trial participation. As fish is the primary source of
bioactive ω-3 PUFAs EPA and DHA, the reported consumption of fish was analysed before and after
intervention with IMP.
Total fish consumption and consumption of oily fish were considered separately. Six FFQ food item variables
were used for the analysis of total fish (i.e. fried fish, fish fingers, white fish, oily fish, shellfish, roe).
Consumption of oily fish was based on a single food item variable (oily fish). Participants indicated the
frequency of food consumption, ranging from ‘never or less than once per month’ to ‘six times per day’.
This was recoded into frequency per day (Table 2). The consumption of total fish per day was calculated by
summing the reported fish consumption for each of the six fish variables.
The data were used to recode participants into four categories (i.e. never, low, middle or high), based on
their weekly consumption of total fish and oily fish (Table 3). Categorisation of weekly fish consumption
was based on the Scientific Advisory Committee on Nutrition recommendation to consume two portions of
fish per week, one of which should be oily.109
Further analysis of the dietary PUFA intake data is planned and will include full nutrient and food group analysis
using FETA (FFQ EPIC Tool for Analysis) software (www.srl.cam.ac.uk/epic/epicffq/; accessed April 2018).
TABLE 2 The FFQ categories
FFQ category Frequency per day
Never or less than once per month 0
1–3 times per month 0.07
Once per week 0.14
2–4 times per week 0.43
5 or 6 times per week 0.79
Once per day 1
2 or 3 times per day 2.5
4 or 5 times per day 4.5
≥ 6 times per day 6
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Planned laboratory studies
The nested laboratory studies originally planned for the EME-funded seAFOod trial project are described
in the trial protocol version 6.0, dated 11 August 2014 [see the project web page: www.journalslibrary.nihr.
ac.uk/programmes/eme/0910025/#/ (accessed 25 April 2019)]. The switch in capsule IMP that occurred in
2014 required a more detailed PUFA analysis than was originally planned to test equivalence of the
bioavailability of FFA and TG formulations measured by RBC and rectal mucosal EPA content. Therefore,
funding for much of the planned biomarker work was diverted to a more extensive PUFA analysis.
Statistical methods
Changes from the protocol to the statistical analysis plan
A number of changes to details contained within the protocol are documented in the SAP (version 1.1,
dated 24 August 2017) [see the project web page: www.journalslibrary.nihr.ac.uk/programmes/eme/
0910025/#/ (accessed 25 April 2019)]. These are listed in Table 4.
In addition, the changes documented in Table 5 were made after database lock and release of the
treatment codes.
TABLE 3 Frequency of fish consumption according to the FFQ
Category Reported frequency of consumption
Total fish
Never 0
Low < 1 portion per week (0.01–0.13 per day)
Middle 1–2.99 portions per week (0.14–0.429 per day)
High ≥ 3 portions per week (0.43–highest per day)
Oily fish
Never 0
Low < 1 portion per week (0.07 per day)
Middle 1–2.99 portion per week (0.14 per day)
High ≥ 3 portions per week (0.43–highest per day)
TABLE 4 Summary of changes to the SAP from the protocol
Protocol SAP Justification
The protocol does not include a
comparison between the two
formulations of EPA used in the trial,
EPA-FFA and EPA-TG, as a secondary
end point
The SAP includes the prespecified
secondary end point ‘Red Blood Cell
(RBC) EPA and rectal EPA levels at
baseline, 6 months (RBC only) and
12 months from randomisation’ in
section 2.9.2 (Secondary end points).
The corresponding statistical analysis
is specified in section 6.3 (Secondary
analyses)
The formulation of EPA changed during
the trial (details in section 2.4). The daily
doses of FFA and TG formulations were
calculated to be FFA dose equivalent, but
there are no available data to determine
bioavailability equivalence during clinical
use over 6–12 months. Although it is
assumed that the two formulations
would be approximately bioequivalent,
it was deemed important to summarise
the EPA levels in participants receiving
both formulations. Formal equivalence
methods and set margins for non-inferiority
are not being used, as the trial was not
designed, nor powered, to examine this
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TABLE 4 Summary of changes to the SAP from the protocol (continued )
Protocol SAP Justification
The protocol does not include
information on the secondary end
points being derived from the FFQ
The SAP includes the prespecified
secondary end point ‘Dietary fish and
other seafood intake at baseline and
at the end of the study’ in section
2.9.2 (Secondary end points). The
corresponding statistical analysis is
specified in section 6.3 (Secondary
analyses)
It will be important to determine whether
there is an imbalance between groups in
the intake of dietary fish and seafood or
any change in such intake during trial
participation. This variable will also be
used as a covariate in a sensitivity analysis
of the primary end point
The protocol does not include the
MAP as an end point. The protocol
states ‘the total number of adenomas
per participant at BCSP surveillance
colonoscopy’
The mean adenoma number per
person has been included in the
secondary end points for adenomas,
advanced adenomas and serrated
adenomas in section 2.9.2
(Secondary end points). This has also
been added to the statistical analyses
in section 6.3 (Secondary analyses)
The MAP is now established as a
colonoscopic end point, in addition to
the ADRa
The protocol states that ‘If fewer than
5% of participants have missing data
for the primary end point then
complete-case analysis will be
performed’
The protocol states that ‘Losses to
follow-up and protocol violations will
be treated as missing data for the ITT
population’
Section 3 of the SAP (General analysis
considerations) provides information
about the participant populations
being used in the trial and procedures
for the investigation and use of missing
data. In summary, the primary end
point will be analysed for all
participants in the ITT population. The
proportion of participants who have
missing data will be reported, and the
interpretation of the primary analysis
will take into account this proportion.
A per-protocol analysis will be
performed as a sensitivity analysis,
which will exclude participants with
major protocol violations (which will be
defined prior to release of treatment
allocation)
The primary analyses should be based
on the ITT population. In accordance
with the ITT principle, all participants
should be included in the ITT population
(i.e. the data for participants who have
violated the protocol should be included)
The per-protocol population criteria
were stated as ‘More than 50% of
trial medication returned in total;
inadvertent use of OTC medication
containing aspirin, NSAIDs or fish oil
for more than 2 weeks in total;
surveillance colonoscopy occurs
outside the allowed time windows
(48–52 weeks after the last complete
screening BCSP colonoscopy, or
60–64 weeks for participants
undergoing a repeat full colonoscopy
within 3 months of trial screening)’
Section 3.1 in the SAP (Analysis
populations) includes suggestions
about what major protocol violations
may result in exclusion from the
per-protocol population. It also
states that specific criteria will be
determined in a meeting prior to
treatment codes being revealed
Data review prior to treatment
unblinding will provide information
about what protocol violations and
deviations occurred during the trial and
will allow judgements about the criteria
for exclusion from the per-protocol
population to be made
Serrated adenomas There was no specific end point or
analysis relating to serrated adenomas
detailed in the protocol. The SAP
prespecifies end points of ‘The number
of participants with a recurrence of
serrated adenoma at the first BCSP
surveillance colonoscopy’ and
‘The number of serrated adenomas
per participant at the first BCSP
surveillance colonoscopy’ in section
2.9.2 (Secondary end points). The
corresponding statistical analysis is
specified in section 6.3 (Secondary
analyses)
The serrated adenoma is now established
as a marker of malignant potential
arising from a molecular pathway distinct
from the traditional adenoma–carcinoma
sequence. Therefore, the serrated
adenoma should be analysed separately
from the conventional adenoma
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Sample size
The original sample size estimate of 904 participants (to ensure 768 evaluable patients and assuming a 15%
loss to follow-up) in trial protocol versions 1–3 was based on a RCT of the same dose and preparation of
EPA-FFA in FAP patients,67 a meta-analysis of aspirin RCTs49 and detailed 2007–8 audit data from the South
of Tyne and Tees BCSP centres.
For the protocol revision in May 2012 (related to inclusion of patients who required a repeat endoscopic
procedure during the 3-month screening window), the sample size was re-estimated using audit data on
surveillance colonoscopy in 1189 patients classified as ‘high risk’ in 2010, from the North-East BCSP hub
TABLE 5 Summary of changes to the SAP post database lock
Change from SAP Justification
Change to planned analysis: recruiting site rather than
BCSP centre was used as a covariate in the primary analysis
An additional sensitivity analysis was performed that
treated BSCP centre and site as random effects in a
multilevel model
After database lock and release of the treatment codes, it
was discovered that the randomisation had stratified by site
rather than by BCSP centre. As site was nested in BCSP
centre, the balance across treatment groups through
stratification was maintained for BCSP centre
Additional secondary end point and analyses: the number
of participants with at least one conventional colorectal
adenoma and the number of conventional colorectal
adenomas per participant were analysed in the same way
as for serrated adenomas
Because the number of participants with at least one
serrated adenoma and the number of serrated adenomas
per participant had been analysed, as well as the ADRa and
MAP for total colorectal adenomas, it was felt that similar
data for conventional colorectal adenomas should be
reported
Additional sensitivity analyses: the sensitivity analyses for
the primary outcome were analysed without adjustment for
repeat colonoscopy, as supportive analyses. Similarly, the
secondary outcomes were analysed without adjustment as
supportive analyses
Data on whether or not participants had had a repeat
colonoscopy were not collected from the start of the trial.
Therefore, there were no data for the first 61 participants.
This meant that the data from these participants were not
included in the analysis. It was felt important to investigate
the robustness of these results by including the additional
participants, although the potential confounding effect of
different endoscopic procedures (full colonoscopy, partial
colonoscopy or FS) could not be taken into account
Additional sensitivity analyses: two further sensitivity
analyses were performed. One adjusted for the baseline
EPA level and the other adjusted for oily fish intake
It was felt that both of these variables could have an impact
on the primary outcome. It was therefore deemed appropriate
to perform analyses including these variables in the model
Unplanned exploratory end points and analyses: colorectal
adenoma size analysed with adjustment for histology type,
taking into account multiple adenomas per participant
FAP RCTs have consistently measured and analysed
colorectal adenoma number and size. Given the secondary
outcome data on colorectal adenoma number, colorectal
adenoma size was felt to represent an important exploratory
analysis
Modification of the definition of advanced adenoma: the
definition in the protocol and SAP was changed from
‘≥ 10mm diameter, high-grade dysplasia or tubulo-villous/
villous histology’ to ‘≥ 10mm diameter, high-grade
dysplasia or villous histology’
Data collected on colorectal adenoma characteristics at
surveillance colonoscopy did not allow tubulo-villous
adenomas to be distinguished from tubular adenomas so
that the ‘advanced’ definition was based on villous histology
alone, not tubulo-villous histology
Modification of the definition of the ITT population: the
definition of the ITT population included all participants
who had been randomised. However, the population
analysed excluded two participants who were withdrawn
immediately after randomisation
Two participants were randomised and then immediately
withdrawn from the trial. They had no trial data (including
baseline data collected), and therefore could not contribute
to the trial. They were excluded from the ITT population
Analysis of safety data: the summaries detailed in the SAP
were amended. AEs and ADRs were not summarised by
preferred term. GI AEs and ADRs were summarised by
preferred term and formulation. In addition, GI ADRs were
summarised according to severity and preferred term
GI AEs and ADRs were the most commonly reported. It was
therefore judged to be useful to summarise these AEs and
ADRs by preferred term. AEs and ADRs for all other system
organ classes were not summarised by preferred term, given
their low frequency and severity
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(nine BCSP centres) and the Southern BCSP hub (17 BCSP centres). A total of 930 (78%) patients went straight
to surveillance after a single screening colonoscopy. Colorectal ADRa data at surveillance colonoscopy were
available for 738 patients and, of these, one or more colorectal adenomas were detected in 465 (63%)
patients. Corresponding figures for ‘high-risk’ patients having a repeat partial colonoscopy or FS within
3 months of an initial screening colonoscopy showed that one or more adenomas were detected at first
surveillance colonoscopy in 59 out of 110 (54%) patients, and for patients having a repeat full colonoscopy,
one or more adenomas were detected in 56 out of 83 (67%). The overall ADRa at first surveillance colonoscopy
was 62%, which was consistent with the original estimate of 60%; therefore, the sample size remained
unchanged.
To detect a minimum 18% relative reduction in adenoma risk in each two-group comparison [less than
the 22% reduction in polyp number compared with placebo in the FAP trial67 and below the absolute
reduction in polyp number at 1 year (38%) in aspirin RCTs49] from a 60% adenoma recurrence rate at
surveillance colonoscopy to 49%, 678 evaluable ‘high-risk’ individuals were required to be randomised
equally to the four treatment groups, with 80% power at a 5% two-sided significance level.
Standard practice for 2 × 2 factorial designs, in the absence of an interaction, bases the sample size
estimate on the two-group comparison of treatment versus placebo (and divides the total equally between
the four groups). With the sample size of 678 based on this method, there is, in fact, a slight reduction in
power (to 75%), which arises if both treatments work, because then the overall comparison for treatment
A is not 0.49 versus 0.6, but is 0.445 versus 0.545 (averaging over the placebo and treatment B groups).
To keep power at 80% for the above figures, a simulation using Stata® version 10 (StataCorp LP, College
Station, TX, USA) and employing the proposed analysis method indicated that 192 individuals were
required per group (a total of 768 evaluable ‘high-risk’ individuals).
In trial protocol versions 1–3, a 15% drop-out rate was assumed. However, feedback from BCSP sites and
experience from the first few months of the trial suggested that the drop-out rate of ‘high-risk’ BCSP patients was
< 15%. Allowing for a 10% drop-out rate, the proposed sample size increased to 768/0.9 = 853 individuals.
For the purposes of the trial extension granted by the EME board in 2014, we proposed a revised realistic
recruitment target of 755, which provided 71% power to detect the same effect size as above, still
assuming a 10% drop-out rate.
Analysis plan
A SAP was finalised prior to database lock and release of treatment codes to the statistician. All summaries
and statistical analyses were conducted using Stata version 15.0.
Analysis populations
l Intention-to-treat population: all randomised participants with post-randomisation data. Analysis was
according to the treatment group to which they were randomised.
l Safety population: all randomised participants who had at least one dose of trial medication. Analysis
was according to the treatment they actually received.
l Per-protocol population: all randomised participants not deemed to have a major protocol violation.
Major protocol violations that resulted in exclusion from the per-protocol population were –
¢ had not taken sufficient medication (participants who had taken ≤ 75% of their expected EPA
and/or ≤ 50% of their expected aspirin)
¢ found to be ineligible post-randomisation
¢ any use of OTC medication containing aspirin, NSAIDs or fish oil for > 2 weeks during the
treatment period.
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The final composition of the per-protocol population was determined by final data review prior to the
treatment codes being revealed.
Analysis of the primary end point was based on the ITT population. The analysis was repeated based on
the per-protocol population. This was considered supportive to the primary analysis.
Analyses of all secondary end points, with the exception of AEs, were based on the ITT population.
Summaries of the AEs were based on the safety population.
Missing data
Sensitivity analyses were performed to support the primary analyses. All secondary analyses assumed that
the data were missing at random and no imputation was performed.
Primary outcome
The primary outcome was the number of participants with one or more colorectal adenomas detected at
the first BCSP surveillance colonoscopy 12 months after the screening examination (the ADRa).
The primary outcome was analysed by an ‘at-the-margins’ approach,110 after first examining whether or not
there was any evidence of an interaction between EPA and aspirin. An ‘at-the-margins’ approach analyses all
participants randomised to EPA (i.e. EPA+ aspirin plus EPA+ placebo aspirin, combined) versus all participants
not randomised to EPA (i.e. placebo EPA + aspirin plus placebo EPA+ placebo aspirin, combined), and all
participants randomised to aspirin versus all participants not randomised to aspirin. Given that there was no
evidence of an interaction, the log relative risk was estimated using a mixed-effects log-binomial regression
model, with BCSP site included as a random effect, and the risk differences and ratios presented. Both
interventions were fitted simultaneously and the analysis was adjusted for ‘repeat colorectal endoscopic
procedure within 3 months required’ and BCSP site. This was a change to the analyses defined in the SAP,
which stated that BCSP centre would be included as a random effect.
Sensitivity analyses for the primary outcome
The following sensitivity analyses were performed on the primary end point:
l Analysis using the per-protocol population.
l Analysis as a multilevel model. Some BCSP centres comprise multiple hospital sites; therefore,
a sensitivity analysis was conducted in which both BCSP centre and site were treated as random effects
in a multilevel model.
l Multiple imputation of missing primary end-point data.
l Further adjustment of baseline variables with any marked imbalance, if appropriate.
l Investigation of the effect of treatment adherence using complier-average causal effect (CACE)
estimation methods.111,112 ITT analysis does not represent the treatment effect of non-compliance with
treatment; therefore, CACE analysis was deemed to be important if any treatment effect was directly
affected by the level of compliance. The percentage of the required total dose taken by participant from
randomisation to first surveillance colonoscopy (both in binary and continuous form) was included in
the model as an instrumental variable to estimate such an effect.
l Further adjustment for EPA capsule formulation, that is EPA-FFA (or placebo) or EPA-TG (or placebo).
l Further adjustment for oily fish intake.
l Further adjustment for baseline RBC EPA levels.
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Secondary outcomes
l The total number of colorectal adenomas per participant at the 12-month BCSP surveillance
colonoscopy was analysed using a Poisson regression model. The incidence rate ratio (IRR) and 95% CIs
were presented.
l The number of participants with an ‘advanced’ colorectal adenoma (≥ 10 mm maximum dimension,
high-grade dysplasia or villous histology) at the first BCSP surveillance colonoscopy (advanced ADRa)
was analysed using a log-binomial regression model. The risk difference and 95% CIs were presented.
l The number of ‘advanced’ colorectal adenomas per participant at the first BCSP surveillance colonoscopy
(advanced MAP) was analysed using a Poisson regression model. The IRR and 95% CIs were presented.
l The number of participants with one or more conventional colorectal adenomas at surveillance
colonoscopy (conventional ADRa) was derived from the total and serrated adenoma data and was
analysed using a log-binomial regression model. Risk difference and 95% CIs were presented.
l The number of conventional colorectal adenomas per participant at surveillance colonoscopy
(conventional MAP) was derived from the total and serrated adenoma data and was analysed using a
Poisson regression model. The IRR and 95% CIs were presented.
l The number of participants with one or more serrated adenomas at surveillance colonoscopy
(serrated ADRa) was analysed using a log-binomial regression model. The risk difference and 95% CIs
were presented.
l The number of serrated adenomas per participant at surveillance colonoscopy (serrated MAP) was
analysed using a Poisson regression model. The IRR and 95% CIs were presented.
l The region of the colorectum (right colon: any part of the colon proximal to the splenic flexure; left
colon: the rectum and the colon at/distal to the splenic flexure) that colorectal adenomas were detected
at the first BCSP surveillance colonoscopy was explored, using a Poisson random-effects model with
bivariate response (corresponding to adenoma counts in the left and right colon), in which treatment
and a baseline adenoma count were independent variables together with random intercepts
corresponding to participant and BCSP site. The IRR and 95% CIs were presented.
l The number of ‘high-risk’ participants reclassified as ‘intermediate risk’ after the first BCSP surveillance
colonoscopy was analysed using a log-binomial regression model. The risk difference and 95% CIs
were presented.
l The number of participants with CRC detected prior to, or at, the first BCSP surveillance were to be
summarised descriptively; however, there were no participants with CRC.
l The levels of RBC EPA and rectal mucosal EPA were summarised at baseline (RBC only) and at visits 4
(RBC only) and 6 for those receiving EPA-FFA and those receiving EPA-TG. In addition, the change from
baseline to visits 4 and 6 were summarised.
l The levels of DHA, AA and the EPA-to-AA ratio were summarised at baseline (RBC only) and at visits 4
(RBC only) and 6 (RBC and rectal mucosal) for those receiving EPA-FFA and those receiving EPA-TG.
In addition, the change from baseline to visits 4 and 6 were summarised for RBC samples.
l Dietary fish and other seafood intake (oily fish and total) at baseline (visit 1) and at the end of the trial
(visit 6 or 7) were summarised by treatment group.
Safety analyses
Adverse events were summarised for the safety population, that is all participants who received at least
one dose of trial medication. Summaries were based on the IMP that the participant received, irrespective
of randomisation.
Both AEs and treatment-emergent ADRs were summarised by system organ class. GI AEs were also
summarised by preferred term and by formulation. ADRs were summarised by severity using the preferred
term. The worst case (i.e. severe and/or related to trial treatment) was assumed if severity or causality were
missing, unless otherwise stated.
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Clinically significant bleeding episodes (i.e. haemorrhagic stroke or acute GI bleeding requiring hospital
admission or investigation) were identified by the chief investigator using a manual search of the full list of
AEs and SAEs.
Common GI AEs associated with ω-3 PUFA and/or aspirin use were presented separately as clinically
meaningful symptom categories, which were defined by the chief investigator.
Serious adverse reactions and ADRs that led to trial discontinuation were summarised by treatment group
and preferred term.
All treatment-emergent ADRs were listed.
Exploratory analyses
l Colorectal adenoma size was estimated using a multilevel model, adjusting for colorectal adenoma
histology type and number of colorectal adenomas per individual.
l Rectal and RBC EPA levels were plotted against the individual number of total, conventional, serrated
and left- and right-sided colorectal adenomas by treatment group.
l A correlation between rectal mucosal and RBC EPA levels at 12 months was investigated by graph and
the correlation coefficient was calculated.
METHODS
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Chapter 3 Results
Parts of this chapter have been reproduced from Hull et al.1 © 2018 The Author(s). Published by Elsevier Ltd.
This is an Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Recruitment and follow-up
Between November 2011 and June 2016, 3911 ‘high-risk’ individuals were screened for eligibility, of
whom 3202 (82%) were not randomised (Table 6 and Figures 2–4). The mean duration from receipt of
local research and development (R&D) approval to FPFV for the 53 sites that randomised patients was
6.3 months. Conversion from screening to randomisation of patients did not appear to be influenced by
the size of the site or the number of patients undergoing screening colonoscopy. Sites did report that the
time taken to undertake trial screening and recruitment (as well as limited availability of, and changes to,
research staff) were reasons for low recruitment.
TABLE 6 Site set-up, screening and recruitment, by site
Site
number
R&D approval
date Date of FPFV
Time from
R&D approval
to FPFV
(months)
Patients
Screened (n) Recruited (n) Randomised (%)
1 18 August 2011 7 February 2012 6 121 19 16
2 23 September 2011 24 November 2011 2 123 14 11
3 17 April 2012 22 May 2012 1 92 18 20
4 31 August 2012 29 November 2012 3 114 20 18
5 20 September 2011 23 April 2012 7 151 37 25
6 19 August 2011 20 February 2012 6 77 20 26
7 5 May 2011 31 May 2012 13 56 9 16
8 20 July 2011 23 March 2012 8 100 30 30
9 14 June 2011 21 June 2012 12 147 12 8
10 25 August 2011 10 October 2012 14 73 6 8
11 30 June 2011 18 January 2012 7 120 23 19
12 27 June 2011 21 March 2012 9 53 9 17
13 8 February 2012 N/A N/A 9 0 0
14 5 July 2011 12 April 2012 9 107 27 25
15 13 January 2012 15 March 2012 2 89 25 28
16 11 April 2011 30 January 2012 10 64 11 17
17 2 June 2011 12 January 2012 7 66 6 9
18 24 April 2012 27 June 2013 14 45 6 13
20 17 February 2012 25 April 2012 2 53 21 40
22 6 July 2012 18 December 2012 5 26 8 31
24 29 August 2012 9 January 2013 4 8 1 13
25 10 April 2012 29 May 2012 2 103 12 12
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TABLE 6 Site set-up, screening and recruitment, by site (continued )
Site
number
R&D approval
date Date of FPFV
Time from
R&D approval
to FPFV
(months)
Patients
Screened (n) Recruited (n) Randomised (%)
26 7 November 2012 10 February 2015 27 22 5 23
27 5 May 2011 11 November 2011 6 93 24 26
28 7 December 2011 2 February 2012 2 177 35 20
29 27 July 2011 9 February 2012 6 14 1 7
30 5 July 2012 N/A N/A 8 0 0
31 18 August 2011 23 May 2012 9 1 1 100
32 23 August 2011 30 August 2012 12 92 11 12
33 11 April 2012 25 June 2013 14 51 12 24
34 22 March 2012 29 October 2012 7 44 9 20
35 30 March 2012 10 July 2012 3 44 12 27
36 14 September 2012 15 March 2013 6 95 9 9
37 8 March 2013 22 August 2013 6 85 10 12
38 18 September 2012 11 January 2013 4 133 10 8
39 10 October 2012 12 November 2012 1 28 4 14
40 5 October 2012 26 October 2012 1 97 22 23
41 13 September 2012 11 March 2013 6 76 12 16
42 10 September 2012 9 January 2013 4 30 6 20
43 23 January 2013 N/A N/A 12 0 0
44 6 November 2012 14 February 2013 3 89 15 17
45 12 October 2012 17 January 2013 3 62 12 19
47 23 January 2013 N/A N/A 9 0 0
49 6 September 2012 20 November 2012 2 52 15 29
50 and
51
9 November 2012 16 January 2013 4 231 47 16
52 16 August 2012 11 October 2013 14 141 9 6
53 17 August 2012 23 January 2013 5 124 29 23
54 20 August 2012 21 September 2012 1 48 16 33
55 3 October 2012 4 January 2013 3 16 4 25
56 28 August 2012 18 September 2013 13 59 8 14
57 23 October 2012 11 April 2013 6 59 10 17
58 19 July 2012 11 October 2012 3 33 5 15
60 12 November 2012 17 June 2013 7 35 6 17
61 1 February 2013 17 April 2013 2 19 6 32
62 5 September 2012 10 October 2012 1 24 8 33
63 7 September 2015 21 April 2016 7 11 2 18
Total 3911 709
N/A, not available.
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BCSP patients identified as ‘high risk’
(n = 3911)
Randomised
[n = 709 (18%)]
Excluded
[n = 3202 (82%)]
EPA + aspirin
(n = 177)
• Received at least one dose of
   trial medication, n = 171
• Did not start medication, n = 6
• Withdrew immediately, n = 0
Surveillance colonoscopy
 performed
(n = 161)
Colonoscopy not performed
(n = 16)
Primary outcome collected
(n = 161)
• AE,
a
 n = 2
• Lost to follow-up, n = 4
• Withdrew consent, n = 7
• Other, n = 2
• Reason missing, n = 1
EPA + placebo aspirin
(n = 179)
• Received at least one dose of
   trial medication, n = 177
• Did not start medication, n = 1
• Withdrew immediately, n = 1
Surveillance colonoscopy
 performed
(n = 154)
Colonoscopy not performed
(n = 24)
Primary outcome collected
(n = 153)
• AE, n = 1
• Lost to follow-up, n = 7
• Withdrew consent, n = 12
• Other, n = 4
Data missing 
(n = 1)
Placebo EPA + aspirin
(n = 177)
• Received at least one dose of
   trial medication, n = 174
• Did not start medication, n = 2
• Withdrew immediately, n = 1
Surveillance colonoscopy
 performed
(n = 163)
Colonoscopy not performed
(n = 13)
Primary outcome collected
(n = 163)
• AE, n = 1
• Lost to follow-up, n = 3
• Withdrew consent, n = 5
• Required more than one repeat
   colonoscopy, n = 4
Placebo + placebo
(n = 176)
• Received at least one dose of
   trial medication, n = 175
• Did not start medication, n = 1
• Withdrew immediately, n = 0
Surveillance colonoscopy
 performed
(n = 163)
Colonoscopy not performed
(n = 13)
Primary outcome collected
(n = 163)
• Death, n = 1
• AE, n = 1
• Lost to follow-up, n = 2
• Withdrew consent, n = 8
• Other, n = 1
• Not willing to give written informed consent, n = 981 (31%)
• Unknown, n = 42 (1%)
Not willing to take part/unknown
[n = 1023 (32%)]
Ineligible
[n = 2179 (68%)]
• Regular prescribed/OTC aspirin/NSAID (> 3 doses/week),
   n = 594 (19%)
• Need for more than one repeat 3-month colonoscopy or FS, 
   n = 328 (10%)
• Known bleeding diathesis or anti-coagulants or anti-platelet
   therapy, n = 313 (10%)
• Inability to comply with study procedures or agents, n = 264 (8%)
• Aspirin intolerance, n = 197 (6%)
• Malignant change in an adenoma, n = 120 (4%)
• Current or planned use of fish oil supplements
   (> 3 doses/week), n = 101 (3%)
• Serious medical illness interfering with study participation,
   n = 93 (3%)
• Active or previous peptic ulcer disease (not on proton pump 
   inhibitor therapy), n = 45 (1%)
• Previous or planned colorectal resection, n = 33 (1%)
• Fish or seafood allergy, n = 24 (1%)
• Previous or newly diagnosed inflammatory bowel disease,
   n = 17 (1%)
• Current methotrexate use of 15 mg/week or more, n = 15 (< 0.5%)
• Taking part in another intervention clinical trial, n = 12 (< 0.5%)
• Severe liver impairment, n = 12 (< 0.5%)
• Known clinical diagnosis/gene carrier CRC predisposition,
   FAP or HNPCC, n = 6 (< 0.5%)
• Severe renal failure, n = 5 (< 0.5%)
FIGURE 2 Flow of participants through the trial. a, AE was an option to discontinue from the trial in an earlier
version of the CRF; however, this option was removed in later versions. HNPCC, hereditary non-polyposis colon
cancer.
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Overall, 2179 (56%) patients met one or more of the exclusion criteria (see Figure 4). The other 1023
individuals either did not wish to take part in the trial or were not randomised for unknown reasons. The
most frequent reasons for no randomisation were not being willing to give written consent [n = 981 (25%)],
taking more than three doses per week of a prescribed/OTC aspirin/NSAID [n = 594 (15%)], the need for
more than one repeat colonoscopy or FS [n = 328 (8%)] and known bleeding diathesis or anticoagulant use
or antiplatelet therapy [n = 313 (8%)]. Overall, only 18% (n = 709) of screened ‘high-risk’ individuals were
randomised (see Figure 2).
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FIGURE 4 Actual monthly trial recruitment.
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FIGURE 3 Cumulative trial recruitment by month.
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By 12 June 2016 (the date stipulated by the MHRA as the end date for randomisation related to the
approved shelf life of the second capsule IMP (90% EPA-TG), 709 patients had been randomised, which
was 83% of the target (n = 853). Reduced recruitment between February and October 2014 (see Table 6
and Figures 3 and 4) was related to diminishing stocks of active and placebo EPA-FFA at sites, prior to the
introduction of 90% EPA-TG IMP in November 2014. The mean number of randomisations per month
during the whole recruitment phase of the trial was 13. Excluding the run-in period of 12 months, during
which sites opened at a variable rate, and the period when capsule IMP stocks were diminishing (February
to October 2014), the mean number of randomisations per month was 16 (range 7–26 per month).
Of the 709 participants randomised, 177 participants were randomised to receive EPA + aspirin, 179 were
randomised to receive EPA + placebo aspirin, 177 were randomised to receive placebo EPA + aspirin and
176 were randomised to receive placebo EPA + placebo aspirin (see Figure 2). Two participants withdrew
immediately after randomisation; one was randomised to EPA + placebo aspirin and one was randomised
to placebo EPA + aspirin (see Figure 2).
A total of 422 (60%) participants were randomised to active or placebo EPA-FFA and 287 (40%)
participants were randomised to active or placebo 90% EPA-TG. Participants took only one form of
capsule IMP (EPA-FFA or EPA-TG) in all cases.
A total of 641 participants (90% of those randomised) underwent surveillance colonoscopy, with
endoscopic data being available for 640 of these participants (see Figure 2). The main reasons for not
performing surveillance colonoscopy were withdrawal of consent and loss to follow-up (Table 7 and see
Figure 2). The ‘other’ reasons for discontinuation in the trial were the participant was withdrawn because
of being randomised in error (n = 3), the histology report confirmed a malignant polyp and the participant
was referred to MDT for review, failure to comply with trial treatment as a result of ongoing medical
problems, the participant being prescribed aspirin and development of cancer (all n = 1).
Baseline characteristics
Baseline characteristics were well balanced across all four treatment groups with respect to demographic
data, medical history and baseline colorectal adenoma details (Table 8).
TABLE 7 Discontinuation in the trial
Reason
Trial group, n (%)
EPA+ aspirin
(N= 177)
EPA+ placebo
aspirin (N= 178)
Placebo EPA+ aspirin
(N= 176)
Placebo+ placebo
(N= 176)
Total discontinued in trial 16 (9) 24 (13) 13 (7) 13 (7)
Death 0 (0) 0 (0) 0 (0) 1 (1)
AE 2 (1) 1 (1) 1 (1) 1 (1)
Lost to follow-up 4 (2) 7 (4) 3 (2) 2 (1)
Withdrew consent 7 (4) 12 (7) 5 (3) 8 (5)
Required more than one repeat
colonoscopy
0 (0) 0 (0) 4 (2) 0 (0)
Other 2 (1) 4 (2) 0 (0) 1 (1)
Missing 1 (1) 0 (0) 0 (0) 0 (0)
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TABLE 8 Baseline characteristics
Characteristic
Trial group
Total
(N= 707)
EPA+ aspirin
(N= 177)
EPA+ placebo
aspirin (N= 178)
Placebo EPA+
aspirin (N= 176)
Placebo+
placebo (N= 176)
Age at enrolment (years)
Mean (SD) 65.6 (4.7) 65.2 (4.5) 65.3 (4.5) 65.2 (4.6) 65.3 (4.6)
Median (IQR) 66.4 (62.3–68.6) 64.9 (62.2–68.5) 64.8 (62.2–68.5) 64.8 (62.3–68.6) 65.3 (62.2–68.6)
Sex, n (%)
Male 146 (82) 138 (78) 140 (80) 139 (79) 563 (80)
Female 31 (18) 40 (22) 36 (20) 37 (21) 144 (20)
Body mass index (kg/m2), n (%)
Underweight (< 18.5) 0 (< 0.5) 2 (1) 1 (1) 0 (< 0.5) 3 (< 0.5)
Normal (18.5–24.9) 39 (22) 29 (16) 23 (13) 32 (18) 123 (17)
Overweight (25.0–29.9) 77 (44) 77 (43) 81 (46) 76 (43) 311 (44)
Obese (≥ 30) 61 (34) 70 (39) 71 (40) 68 (39) 270 (38)
Diabetes
Ever diagnosed?
n (%) 15 (8) 24 (13) 18 (10) 24 (14) 81 (11)
Years since first diagnosis
Mean (SD) 8.0 (5.3) 8.5 (5.8) 9.3 (5.3) 10.8 (5.5) 9.3 (5.5)
Median (IQR) 5.0 (5.0–12.0) 7.0 (5.0–10.5) 8.5 (5.0–12.0) 10.0 (6.5–14.0) 8.0 (5.0–12.0)
Cigarette smoking, n (%)
Current smoker 32 (18) 13 (7) 27 (15) 34 (19) 106 (15)
Ex-smoker 80 (45) 96 (54) 89 (51) 82 (47) 347 (49)
Never smoked 65 (37) 69 (39) 60 (34) 60 (34) 254 (36)
Cigarettes smoked per day (current smoker)
None 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
1–10 11 (6) 6 (3) 12 (7) 16 (9) 45 (6)
11–20 17 (10) 6 (3) 12 (7) 12 (7) 47 (7)
≥ 21 3 (2) 1 (1) 3 (2) 6 (3) 13 (2)
Missing 1 (1) 0 (0) 0 (0) 0 (0) 1 (< 0.5)
Units of alcohol per week, n (%)
None 27 (15) 28 (16) 26 (15) 29 (16) 110 (16)
1–7 51 (29) 68 (38) 64 (36) 51 (29) 234 (33)
8–21 60 (34) 41 (23) 58 (33) 55 (31) 214 (30)
≥ 22 38 (21) 39 (22) 28 (16) 41 (23) 146 (21)
Missing 1 (1) 2 (1) 0 (0) 0 (0) 3 (< 0.5)
Medical history,a n (%)
Abdominal pain/dyspepsia 41 (23) 40 (22) 41 (23) 36 (20) 158 (22)
Diarrhoea 9 (5) 19 (11) 15 (9) 19 (11) 62 (9)
Halitosis 5 (3) 5 (3) 5 (3) 5 (3) 20 (3)
Bleeding 14 (8) 20 (11) 18 (10) 20 (11) 72 (10)
Stroke 1 (1) 0 1 (1) 1 (1) 3 (< 0.5)
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TABLE 8 Baseline characteristics (continued )
Characteristic
Trial group
Total
(N= 707)
EPA+ aspirin
(N= 177)
EPA+ placebo
aspirin (N= 178)
Placebo EPA+
aspirin (N= 176)
Placebo+
placebo (N= 176)
Colorectal adenoma characteristics
Total number of
adenomas
856 892 927 856 3531
Adenomas per participant
Mean (SD) 4.8 (2.3) 5.0 (2.2) 5.3 (2.7) 4.9 (2.6) 5.0 (2.5)
Median (IQR) 4 (3–6) 5 (3–6) 5 (3–6) 4 (3–5) 4 (3–6)
‘Advanced’b adenomas per participant
Mean (SD) 1.1 (0.9) 1.3 (1.0) 1.2 (0.9) 1.2 (0.9) 1.2 (0.9)
Median (IQR) 1 (1–1) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2)
Size of largest adenoma (mm) per participant
Mean (SD) 14.3 (7.3) 14.8 (6.9) 14.3 (6.9) 13.7 (5.6) 14.3 (6.7)
Median (IQR) 13 (10–17) 13.5 (11–18) 13 (10–18) 12.5 (10–16) 13 (10–17)
At least one adenoma
proximal to splenic
flexure, n (%)
144 (81) 146 (82) 153 (87) 141 (80) 584 (83)
Histology type,c n (%)
Conventional 809 (95) 844 (95) 895 (97) 812 (95) 3360 (95)
Tubular/tubulo-villous 803 (94) 834 (93) 885 (95) 807 (94) 3329 (94)
Villous 6 (< 1) 10 (1) 10 (1) 5 (1) 31 (1)
Serrated 21 (2) 30 (3) 18 (2) 22 (3) 91 (3)
Not sent to
histopathology
21 (2) 16 (2) 13 (2) 18 (2) 68 (2)
Missing 5 (1) 2 (< 1) 1 (< 1) 4 (< 1) 12 (< 1)
High-grade dysplasia,c n (%)
No 811 (95) 841 (94) 874 (94) 796 (93) 3322 (94)
Yes 21 (2) 33 (4) 40 (4) 41 (5) 135 (4)
Missing 24 (3) 18 (2) 13 (1) 19 (2) 74 (2)
Participants with any regular prescribed medication prior to trial entry
n (%) 92 (52) 93 (52) 88 (50) 81 (46) 354 (50)
Participants who had any of the following regular prescribed medications,a n (%)
Statin 55 (31) 54 (30) 51 (29) 50 (28) 210 (30)
Calcium 0 (0) 3 (2) 3 (2) 1 (< 1) 7 (1)
Calcium+ vitamin D 4 (2) 1 (< 1) 4 (2) 2 (1) 11 (2)
Metformin 9 (5) 12 (7) 11 (6) 14 (8) 46 (7)
Glitazone 0 (0) 1 (< 1) 1 (< 1) 1 (< 1) 3 (< 1)
Proton pump inhibitor 20 (11) 27 (15) 24 (14) 19 (11) 90 (13)
Aspirin 1 (< 1) 0 (0) 0 (0) 0 (0) 1 (< 1)
Fish oil 2 (1) 4 (2) 2 (1) 1 (< 1) 9 (1)
Non-aspirin NSAID 5 (3) 4 (2) 1 (< 1) 1 (< 1) 11 (2)
Other 48 (27) 34 (19) 37 (21) 34 (19) 153 (22)
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The mean age of participants was 65 years. A male-to-female ratio of approximately 4 : 1 was observed,
which reflects the sex distribution of ‘high-risk’ patients in the English BCSP.95,99 A total of 581 (82%)
participants were overweight; of these, 270 (38%) were obese. Despite the high prevalence of excess body
weight, the prevalence of known type 2 diabetes was low, and only approximately half of the participants
were on regular prescribed drugs at trial entry; the drug was usually a statin, proton pump inhibitor or
metformin. Baseline drug use was balanced across the treatment groups.
There was a slight imbalance across groups with respect to smoking status, with fewer current smokers in
the EPA + placebo aspirin group.
Overall, 158 (22%) participants had a medical history of abdominal pain or dyspepsia, which is consistent
with the high prevalence of these symptoms in the general population.113 Ten per cent of participants
recorded a prior episode of bleeding and 20 (3%) reported halitosis at baseline. A medical history of
symptoms and clinical events at baseline relevant to EPA and/or aspirin therapy was balanced across the
treatment groups. Fewer participants reported diarrhoea at trial entry in the EPA + aspirin group than in
the other three groups.
‘High-risk’ participants had a mean of five colorectal adenomas and one advanced colorectal adenoma
at entry screening colonoscopy. Of 3531 evaluable colorectal adenomas at baseline, 3360 (97%) were
conventional (tubular/tubulo-villous and villous) and 91 (3%) were serrated adenomas. Overall, 584 (83%)
‘high-risk’ participants had at least one colorectal adenoma proximal to the splenic flexure at screening
colonoscopy. Screening colonoscopy findings were balanced across the treatment groups (see Table 8).
Compliance with the allocated intervention
Compliance with both capsule and tablet IMPs was excellent, with mean percentage compliance levels,
calculated by capsule/tablet counting, of between 94% and 97%. A total of 10 participants never took
any dose of either capsules or tablets and a further seven participants took only one of the treatments
(EPA/placebo EPA or aspirin/placebo aspirin) (Table 9).
Concomitant medication during the trial
During the trial intervention phase, approximately one-quarter of participants started regular prescribed
medication, in addition to existing drugs, which included a statin, calcium + vitamin D supplement,
metformin, proton pump inhibitors, aspirin, fish oil and a non-aspirin NSAID. Slightly more participants
started regular, concomitant medication in the placebo + placebo group (Table 10).
TABLE 8 Baseline characteristics (continued )
Characteristic
Trial group
Total
(N= 707)
EPA+ aspirin
(N= 177)
EPA+ placebo
aspirin (N= 178)
Placebo EPA+
aspirin (N= 176)
Placebo+
placebo (N= 176)
Participants who required repeat endoscopy at trial entry, n (%)
No 133 (75) 128 (72) 133 (76) 136 (77) 530 (75)
Yes 34 (19) 33 (19) 24 (14) 25 (14) 116 (16)
Missing 10 (6) 17 (10) 19 (11) 15 (9) 61 (9)
IQR, interquartile range.
a Not mutually exclusive; some participants reported more than one category.
b Diameter of ≥ 10mm, high-grade dysplasia or tubulo-villous/villous histology.
c Adenoma-level data.
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TABLE 9 Adherence to trial medication
Adherence
Trial group
EPA+ aspirin
(N= 177)
EPA+ placebo
aspirin (N= 178)
Placebo EPA+
aspirin (N= 176)
Placebo+ placebo
(N= 176)
Participants who never started taking
either of capsules or tablets, n (%)
7 (4) 2 (1) 4 (2) 4 (2)
Never started either, n (%) 6 (3) 1 (1) 2 (1) 1 (1)
Never started capsules but started
tablets, n (%)
1 (1) 0 (0) 1 (1) 1 (1)
Never started tablets but started
capsules, n (%)
0 (0) 1 (1) 1 (1) 2 (1)
Capsules taken as percentagea of total expected
Mean (SD) 96 (15) 94 (13) 95 (12) 95 (14)
Median (IQR) 100 (97–100) 99 (96–100) 100 (97–100) 100 (97–100)
Minimum, maximum 10, 197 27, 101 40, 123 20, 100
Tablets taken as percentagea of total expected
Mean (SD) 97 (8) 97 (9) 97 (6) 97 (9)
Median (IQR) 100 (98–100) 99 (97–100) 100 (98–100) 100 (98–100)
Minimum, maximum 10, 100 27, 101 55, 100 71, 196
IQR, interquartile range.
a Percentage compliance with medication was calculated based on the total number of calculated doses when participants
were taking the medication as a proportion of the total number of expected doses. The period during which participants
should have taken medication was between randomisation and the first surveillance colonoscopy. If participants discontinued
and did not have the surveillance colonoscopy, then the period was between randomisation and the last date known to
be taking medication.
TABLE 10 Concomitant medication during the trial
Concomitant medication
Trial group
EPA+ aspirin
(N= 177)
EPA+ placebo
aspirin (N= 178)
Placebo EPA+
aspirin (N= 176)
Placebo+ placebo
(N= 176)
Participants starting regular prescribed
medication during the trial, n (%)
42 (24) 43 (24) 42 (24) 55 (31)
Number of participants who started the following regular prescribed medicationsa
Statins 6 12 6 9
Calcium + vitamin D 1 1 0 0
Metformin 1 2 3 3
Proton pump inhibitors 5 13 8 12
Aspirin 3 6 1 5
Fish oil 1 1 0 1
Non-aspirin NSAIDs 13 9 16 23
Other 25 17 17 23
a Not mutually exclusive as some participants reported more than one.
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Dietary fish intake before trial participation
Most participants completed a FFQ at baseline; there were similar percentages across dietary fish intake
categories in each of the treatment groups. The total fish and oily fish intake at baseline was similar across
the four treatment groups (Table 11).
Polyunsaturated fatty acid levels in trial participants
Given the importance of the comparison of EPA levels in individuals randomised to either FFA or TG
formulations of EPA, to determine if it was appropriate to pool the primary and secondary outcome data
for these groups, PUFA data are presented below before the analyses for the primary and other secondary
outcomes.
The RBC EPA level was measured as an accepted biomarker of tissue EPA exposure, as well as the rectal
mucosal EPA level measured at the end of the intervention period.
Red blood cell EPA and rectal mucosal EPA levels were compared between each treatment group, at each
time point and between users of EPA-FFA and EPA-TG formulations. As expected, active EPA groups had
higher RBC levels of EPA than placebo EPA users after the intervention began (Figures 5–7). RBC EPA levels
were similar between participants, who received either active FFA or TG formulations of EPA, at baseline,
mid-treatment and at the end of the intervention period (see Figures 5–7). Moreover, the increase in
TABLE 11 Dietary fish and other seafood intake at baseline
Dietary fish intake
Trial group, n (%)
EPA+ aspirin
(N= 177)
EPA+ placebo
aspirin (N= 178)
Placebo EPA+
aspirin (N= 176)
Placebo+ placebo
(N= 176)
Participants who completed FFQ at
baseline
177 (100) 176 (99) 173 (98) 174 (99)
Total fish intake at baseline
Never 4 (2) 7 (4) 4 (2) 11 (6)
Low 12 (7) 13 (7) 9 (5) 10 (6)
Medium 97 (55) 92 (52) 109 (63) 97 (56)
High 51 (29) 52 (30) 44 (25) 44 (25)
Missinga 13 (7) 12 (7) 7 (4) 12 (7)
Oily fish intake at baseline
Never 48 (27) 52 (30) 43 (25) 42 (24)
Low 54 (31) 52 (30) 53 (31) 69 (40)
Medium 41 (23) 46 (26) 52 (31) 42 (24)
High 32 (18) 23 (13) 22 (13) 20 (11)
Missinga 2 (1) 3 (2) 3 (2) 1 (1)
a The FFQ was completed; however, the data were not evaluable.
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RBC EPA level from baseline to the 6-month and 12-month time points for all participants was similar across
the two EPA formulations and for rectal mucosal EPA levels at 12 months (Table 12) (see Figures 5–7). There
was also no clear difference in RBC or rectal mucosal DHA content between EPA-FFA and EPA-TG users
(Table 13; see also Table 12).
Rectal mucosal EPA levels at the end of the intervention period were higher in those who received EPA-TG
than in those who received EPA-FFA, but with substantial overlap between the two groups (Figure 8). This
was not reflected in the rectal mucosal EPA-to-AA ratio at the end of the intervention period, which was
similar for both EPA-FFA and EPA-TG users (Table 14).
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FIGURE 5 The RBC EPA levels by formulation and by trial group at baseline.
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FIGURE 6 The RBC EPA levels by formulation and by trial group at 6 months.
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FIGURE 7 The RBC EPA levels by formulation and by trial group at 12 months.
TABLE 12 The RBC EPA levels in those who received capsule IMP as EPA-FFA or EPA-TG (active EPA groups only)
RBC and rectal mucosal EPA levelsa
EPA
Total (N= 355)FFA (N= 212) TG (N= 143)
RBC EPA levela
Baseline
Mean (SD) 0.6 (0.6) 0.5 (0.4) 0.6 (0.5)
Median (IQR) 0.5 (0.3–0.8) 0.4 (0.3–0.7) 0.5 (0.3–0.8)
Minimum, maximum 0.0, 4.7 0.0, 1.8 0.0, 4.7
n 181 128 309
6 months
Mean (SD) 2.0 (1.3) 1.9 (1.4) 1.9 (1.3)
Median (IQR) 1.9 (0.9–2.9) 1.6 (0.9–2.7) 1.8 (0.9–2.8)
Minimum, maximum 0.0, 6.6 0.0, 8.2 0.0, 8.2
n 164 108 272
12 months
Mean (SD) 1.9 (1.4) 1.6 (1.0) 1.8 (1.3)
Median (IQR) 1.7 (0.9–2.8) 1.4 (0.8–2.2) 1.6 (0.9–2.4)
Minimum, maximum 0.1, 5.6 0.0, 4.9 0.0, 5.6
n 157 100 257
Absolute change in RBC EPA levela from baseline at 6 months
Mean (SD) 1.3 (1.4) 1.3 (1.4) 1.3 (1.4)
Median (IQR) 1.3 (0.3–2.3) 1.1 (0.4–2.2) 1.2 (0.3–2.3)
Minimum, maximum –4.5, 6.1 –1.7, 7.2 –4.5, 7.2
n 151 103 254
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TABLE 12 The RBC EPA levels in those who received capsule IMP as EPA-FFA or EPA-TG (active EPA groups only)
(continued )
RBC and rectal mucosal EPA levelsa
EPA
Total (N= 355)FFA (N= 212) TG (N= 143)
Absolute change in RBC EPA levela from baseline at 12 months
Mean (SD) 1.2 (1.4) 1.1 (1.1) 1.2 (1.2)
Median (IQR) 1.0 (0.1–2) 0.9 (0.3–1.6) 1.0 (0.2–1.9)
Minimum, maximum –3.0, 5.2 –0.8, 4.2 –3.0, 5.2
n 143 95 238
Rectal mucosal EPA levela at 12 months
Mean (SD) 1.3 (1.0) 1.8 (1.1) 1.5 (1.1)
Median (IQR) 1.1 (0.6–1.7) 1.6 (1.0–2.3) 1.3 (0.7–2.0)
Minimum, maximum 0.0, 5.2 0.4, 5 0.0, 5.2
n 153 96 249
IQR, interquartile range.
a PUFA data are percentage of total fatty acids.
TABLE 13 The DHA, AA and EPA-to-AA ratio levels for those who received capsule IMP as EPA-FFA or EPA-TG
(active EPA groups only)
RBC levelsa
EPA
Total (N= 355)FFA (N= 212) TG (N= 143)
RBC DHA levela
Baseline
Mean (SD) 2.1 (1.4) 2.3 (1.8) 2.2 (1.5)
Median (IQR) 2.0 (1.0–2.9) 2.1 (1.0–3.0) 2.0 (1.0–2.9)
Minimum, maximum 0.1, 7.7 0.1, 9.7 0.1, 9.7
n 181 128 309
6 months
Mean (SD) 2.0 (1.2) 1.6 (1.2) 1.8 (1.2)
Median (IQR) 2.0 (1.0–2.5) 1.5 (0.6–2.0) 1.7 (0.8–2.4)
Minimum, maximum 0.0, 7.5 0.1, 6.8 0.0, 7.5
n 164 108 272
12 months
Mean (SD) 2.2 (1.5) 1.9 (1.1) 2.1 (1.4)
Median (IQR) 2.2 (1.3–2.8) 1.9 (1.2–2.3) 1.9 (1.2–2.7)
Minimum, maximum 0.1, 14.4 0.0, 6.6 0.0, 14.4
n 157 100 257
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TABLE 13 The DHA, AA and EPA-to-AA ratio levels for those who received capsule IMP as EPA-FFA or EPA-TG
(active EPA groups only) (continued )
RBC levelsa
EPA
Total (N= 355)FFA (N= 212) TG (N= 143)
Change from baseline at 6 months
Mean (SD) –0.2 (1.4) –0.5 (1.6) –0.3 (1.5)
Median (IQR) –0.2 (–0.9 to 4.0) –0.4 (–1.2 to 3.0) –0.2 (–1.0 to 3.0)
Minimum, maximum –4.5, 5.4 –8.6, 3.7 –8.6, 5.4
n 151 103 254
Change from baseline at 12 months
Mean (SD) –0.1 (1.4) –0.3 (1.7) –0.2 (1.5)
Median (IQR) –0.2 (–0.9 to 8.0) –0.3 (–1.4 to 7.0) –0.2 (–1.1 to 7.0)
Minimum, maximum –4.2, 4.3 –7.7, 2.8 –7.7, 4.3
n 143 95 238
RBC AA levela
Baseline
Mean (SD) 6.3 (3.9) 7.0 (4.9) 6.6 (4.4)
Median (IQR) 5.8 (3.7–8.2) 6.3 (3.9–9.0) 5.9 (3.7–8.3)
Minimum, maximum 0.4, 27.9 0.5, 32.1 0.4, 32.1
n 181 128 309
6 months
Mean (SD) 5.6 (2.9) 5.5 (3.3) 5.5 (3.1)
Median (IQR) 5.8 (3.5–7.2) 4.7 (2.7–7.8) 5.4 (2.9–7.2)
Minimum, maximum 0.1, 18.5 0.3, 16.6 0.1, 18.5
n 164 108 272
12 months
Mean (SD) 6.1 (3.7) 6.1 (3.1) 6.1 (3.4)
Median (IQR) 6 (3.8–7.7) 5.8 (3.8–7.9) 5.9 (3.8–7.7)
Minimum, maximum 0.3, 26.1 0.0, 13.3 0.0, 26.1
n 157 100 257
Change from baseline at 6 months
Mean (SD) –0.8 (3.8) –1.1 (4.8) –0.9 (4.2)
Median (IQR) –0.9 (–2.6 to 1.0) –0.9 (–3.2 to 1.9) –0.9 (–3.0 to 1.3)
Minimum, maximum –14.6, 10.4 –25.9, 7.3 –25.9, 10.4
n 151 103 254
Change from baseline at 12 months
Mean (SD) –0.3 (4.1) –0.8 (5.1) –0.5 (4.5)
Median (IQR) –0.6 (–2.8 to 2.1) –0.6 (–3.9 to 2.3) –0.6 (–3.0 to 2.2)
Minimum, maximum –11.9, 13.1 –22.9, 7.9 –22.9, 13.1
n 143 95 238
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
TABLE 13 The DHA, AA and EPA-to-AA ratio levels for those who received capsule IMP as EPA-FFA or EPA-TG
(active EPA groups only) (continued )
RBC levelsa
EPA
Total (N= 355)FFA (N= 212) TG (N= 143)
RBC EPA-to-AA ratio levela
Baseline
Mean (SD) 0.1 (0.1) 0.1 (0.0) 0.1 (0.1)
Median (IQR) 0.1 (0.1–1.0) 0.1 (0.1–1.0) 0.1 (0.1–1.0)
Minimum, maximum 0, 0.6 0, 0.3 0, 0.6
n 181 128 309
6 months
Mean (SD) 0.4 (0.2) 0.3 (0.2) 0.4 (0.2)
Median (IQR) 0.4 (0.2–5.0) 0.3 (0.2–4.0) 0.4 (0.2–5.0)
Minimum, maximum 0, 0.8 0, 0.7 0, 0.8
n 164 108 272
12 months
Mean (SD) 0.3 (0.2) 0.3 (0.1) 0.3 (0.2)
Median (IQR) 0.3 (0.2–4.0) 0.2 (0.2–4.0) 0.3 (0.2–4.0)
Minimum, maximum 0, 0.8 0, 0.7 0, 0.8
n 157 100 257
Change from baseline at 6 months
Mean (SD) 0.3 (0.2) 0.3 (0.2) 0.3 (0.2)
Median (IQR) 0.3 (0.1–4.0) 0.3 (0.1–4.0) 0.3 (0.1–4.0)
Minimum, maximum –0.5, 0.7 –0.1, 0.6 –0.5, 0.7
n 151 103 254
Change from baseline at 12 months
Mean (SD) 0.2 (0.2) 0.2 (0.1) 0.2 (0.2)
Median (IQR) 0.2 (0.1–3.0) 0.2 (0.1–3.0) 0.2 (0.1–3.0)
Minimum, maximum –0.3, 0.7 –0.1, 0.6 –0.3, 0.7
n 143 95 238
IQR, interquartile range.
a PUFA data are percentage of total fatty acids.
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FIGURE 8 Rectal mucosal EPA levels by formulation and by trial group at 12 months.
TABLE 14 Rectal mucosal PUFA levels for those who received capsule IMP as EPA-FFA or EPA-TG (active EPA
groups only)
Rectal mucosal levelsa at 12 months
EPA
Total (N= 355)FFA (N= 212) TG (N= 143)
EPA levela
Mean (SD) 1.3 (1.0) 1.8 (1.1) 1.5 (1.1)
Median (IQR) 1.1 (0.6–1.7) 1.6 (1.0–2.3) 1.3 (0.7–2)
Minimum, maximum 0.0, 5.2 0.4, 5.0 0.0, 5.2
n 153 96 249
DHA levela
Mean (SD) 0.9 (0.6) 1.2 (0.4) 1.0 (0.5)
Median (IQR) 0.7 (0.5–1.4) 1.2 (1.0–1.4) 1.0 (0.6–1.4)
Minimum, maximum 0.1, 4.3 0.4, 2.1 0.1, 4.3
n 153 96 249
AA levela
Mean (SD) 4.4 (2.8) 5.8 (1.6) 5.0 (2.5)
Median (IQR) 3.5 (2.3–6.3) 5.5 (4.7–6.5) 5.0 (2.8–6.4)
Minimum, maximum 0.3, 17.7 1.9, 11.4 0.3, 17.7
n 153 96 249
EPA-to-AA ratio levela
Mean (SD) 0.3 (0.2) 0.3 (0.2) 0.3 (0.2)
Median (IQR) 0.3 (0.2–0.4) 0.3 (0.2–0.4) 0.3 (0.2–0.4)
Minimum, maximum 0.0, 0.9 0.1, 8.0 0.0, 0.9
n 153 96 249
IQR, interquartile range.
a PUFA data are percentage of total fatty acids.
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As there was no clear difference in RBC or rectal mucosal EPA incorporation, or EPA-to-AA ratio, between
those allocated EPA-FFA and those allocated EPA-TG, it was felt appropriate to combine primary and
secondary outcome data from those who received either type of capsule IMP.
Analysis populations
The ITT population was defined as all randomised participants with post-randomisation data (Table 15).
Participants in the ITT population were analysed regardless of adherence to their allocated group and
without imputation for missing data. Although 709 participants were randomised, two participants
withdrew immediately and provided no data. Therefore, 707 participants were included in the ITT
population (see Table 15). All baseline summaries and efficacy analyses were based on this population.
Data from surveillance colonoscopy at 12 months was available for 640 participants.
The per-protocol population included all participants who had taken sufficient medication (participants
who had taken > 75% of expected capsules and/or > 50% of expected tablets), were not found to be
ineligible post randomisation and had not used any OTC medication containing aspirin, NSAIDs or fish oil
during the treatment period. The population comprised 659 participants and was used for one of the
sensitivity analyses to determine the robustness of the primary analysis.
The safety population was defined as all participants who took at least one dose of allocated treatment.
It comprised 697 participants. The 10 participants who did not receive active or placebo EPA or aspirin
were excluded from this population.
Primary outcome
Colorectal adenoma data from the 12-month surveillance colonoscopy were available for 640 participants:
161 (91%), 153 (86%), 163 (93%) and 163 (93%) (percentage of the total number of participants in each
group) in the EPA + aspirin, EPA + placebo aspirin, placebo EPA + aspirin and placebo EPA + placebo aspirin
groups, respectively. The median time between randomisation and the 12-month surveillance colonoscopy
was between 344 and 348 days in the four treatment groups (Table 16).
Of 161 participants in the EPA + aspirin group, 98 (61%) had at least one colorectal adenoma (the ADRa)
at the surveillance colonoscopy, whereas 97 out of 153 participants (63%) in the EPA + placebo aspirin
group had at least one colorectal adenoma (the ADRa) at the surveillance colonoscopy. The ADRa was
61% (100/163) in the placebo EPA + aspirin group and 61% (100/163) in the placebo EPA + placebo
aspirin group.
TABLE 15 Summary of analysis populations
Participants
Trial group (n)
Total (n)EPA+ aspirin
EPA+ placebo
aspirin
Placebo
EPA+ aspirin
Placebo+
placebo
Randomised 177 179 177 176 709
Excluded from ITT population as a result of
withdrawal immediately after randomisation
0 1 1 0 2
Included in ITT population 177 178 176 176 707
Included in per-protocol population 156 172 163 168 659
Included in safety population 170 177 174 176 697
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When summarised according to factorial margins, the ADRa was similar across interventions, with an ADRa
of 195 (62%) for those who received active EPA versus an ADRa of 200 (61%) for those who did not
receive EPA, and an ADRa of 198 (61%) for individuals who received active aspirin versus an ADRa of 197
(62%) for those who did not receive aspirin (62%) (see Table 16).
Primary outcome analysis
The test of interaction showed that there was no evidence of any interaction between EPA and aspirin for
the ADRa (p = 0.85). Therefore, primary and secondary outcomes were analysed according to factorial
margins, that is the treatment effects for EPA and aspirin were reported separately.
Table 17 shows adjusted risk differences of the ADRa for the treatment effect of EPA and aspirin. The
point estimates and 95% CIs for both EPA and aspirin showed that there was no evidence of a statistically
significant difference. These analyses were adjusted for whether or not the participant had a repeat
endoscopic procedure (i.e. full colonoscopy, partial colonoscopy or FS) and included BCSP site as a
random effect. Supportive analyses that were not adjusted by repeat colonoscopy showed similar
results (see Appendix 4, Table 40).
TABLE 17 Between-group comparisons of ADRa
Risk difference and ratio EPA vs. no EPA Aspirin vs. no aspirin
Adjusted by site as a random effect and by repeat colonoscopy at baseline (n = 588)
Risk difference (95% CI) (%); p-value –0.9 (–8.8 to 6.9); 0.813 –0.6 (–8.5 to 7.2); 0.876
Risk ratio (95% CI) 0.98 (0.87 to 1.12) 0.99 (0.87 to 1.12)
TABLE 16 Summary of the primary outcome data
Primary outcome data
Trial group
EPA+ aspirin
(N= 177)
EPA+ placebo
aspirin
(N= 178)
Placebo
EPA+ aspirin
(N= 176)
Placebo+ placebo
(N= 176)
Participants with colorectal adenoma data
at 12 months (n)
161 153 163 163
Median (IQR) days from randomisation to
surveillance colonoscopy
348 (337–364) 349 (333–363) 348 (335–364) 344 (334–360)
Participants with one or more colorectal
adenomas at surveillance colonoscopy
(ADRa), n (%)
98 (61) 97 (63) 100 (61) 100 (61)
Factorial margins Active EPA
(n = 314)
Placebo EPA
(n = 326)
Active aspirin
(n = 324)
Placebo aspirin
(n = 316)
Participants with one or more colorectal
adenomas at surveillance colonoscopy,
n (%)
195 (62) 200 (61) 198 (61) 197 (62)
IQR, interquartile range.
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The point estimates for EPA and aspirin were –0.9% and –0.6%, respectively, with 95% CIs that included
zero, indicating no statistically significant difference from no treatment for both interventions. The trial was
designed to detect an absolute ADRa difference of 10%. Figure 9 and Table 17 show that the lower limit
of the 95% CIs did not reach –10% for either EPA or aspirin.
Sensitivity analyses for the primary outcome
Several sensitivity analyses were conducted to investigate the robustness of the primary analysis. Although
the point estimates and 95% CIs varied between different analyses, they were supportive of the primary
analysis (Table 18 and Figure 10).
The multilevel model included both BCSP centre and site as random effects to account for sites embedded
within the same BCSP (see Figure 10).
TABLE 18 Sensitivity analyses of the ADRa with adjustment for repeat colonoscopy
Analysis
Estimate (95% CI)
EPA vs. no EPA Aspirin vs. no aspirin
Using per-protocol population (risk difference) (%) –0.6 (–8.7 to 7.4) –0.6 (–8.7 to 7.4)
Multilevel model treating recruiting centre and site as random effects
(odds ratio)
0.96 (0.68 to 1.34) 0.97 (0.70 to 1.34)
Multiple imputation of missing data (risk difference) (%) 0.1 (–7.3 to 7.6) –0.7 (–8.3 to 6.8)
Adjustment of baseline variables with imbalancea (risk difference) (%) –0.7 (–8.5 to 7.1) –0.7 (–8.5 to 7.1)
Adjustment of oily fish intake during the trial (risk difference) (%) –2.5 (–11.1 to 6.0) –2.4 (–11.0 to 6.1)
CACE analysis taking account of treatment adherence
Binary adherence (risk difference) (%) –1.0 (–9.9 to 7.9) –0.7 (–8.5 to 7.1)
Continuous adherence (risk difference) (%) –1.2 (–10.0 to 7.5) –0.8 (–8.8 to 7.1)
Adjustment of EPA formulation (risk difference) (%) –0.9 (–8.8 to 6.9) –0.4 (–8.3 to 7.4)
Adjustment of baseline RBC EPA (risk difference) (%) –4.2 (–12.6 to 4.2) 2.3 (–6.0 to 10.6)
a Adjusted for sex, whether or not diagnosed with diabetes mellitus, and smoking status.
– 0.2 – 0.1 0.0 0.1 0.2
Favours active EPA Favours placebo
EPA treatment effect
Aspirin treatment effect
– 0.009 (– 0.088 to 0.069)
Adjusted risk 
difference (95% CI)
– 0.006 (– 0.085 to 0.072)
FIGURE 9 Forest plot of the treatment effect of EPA and aspirin on the ADRa. The blue vertical line represents the
prespecified target reduction of ADRa (10%). Adjusted by site as a random effect and by repeat colonoscopy at
baseline.
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Secondary outcomes
Secondary outcomes were analysed in a similar way to the primary outcome. Results were summarised
according to the outcome type, that is the risk difference for the binary outcome (ADRa) and the IRR for
count outcomes (Tables 19–25 and Figure 17). Point estimates and CIs reported are according to factorial
margins, that is EPA compared with no EPA and aspirin compared with no aspirin.
Summary data on colorectal adenomas reported at surveillance colonoscopy are listed in Table 19.
– 0.2 – 0.1 0.0 0.1 0.2
Favours EPA Favours placebo
Adjusted risk
difference (95% CI)
(a)
Per-protocol analysis
Multiple imputation of missing data
Adjustment of baseline variables
Adjustment of oily fish intake
Adjustment of binary adherence
Adjustment of continuous adherence
Adjustment of EPA formulation
Adjustment of baseline RBC EPA
– 0.006 (– 0.087 to 0.074)
0.001 (– 0.073 to 0.076)
– 0.007 (– 0.085 to 0.071)
– 0.025 (– 0.111 to 0.060)
– 0.010 (– 0.099 to 0.079)
– 0.012 (– 0.100 to 0.075)
– 0.009 (– 0.088 to 0.069)
– 0.042 (– 0.126 to 0.042)
– 0.2 – 0.1 0.0 0.1 0.2
Favours aspirin Favours placebo
Adjusted risk
difference (95% CI)
(b)
Per-protocol analysis
Multiple imputation of missing data
Adjustment of baseline variables
Adjustment of oily fish intake
Adjustment of binary adherence
Adjustment of continuous adherence
Adjustment of EPA formulation
Adjustment of baseline RBC EPA
– 0.006 (– 0.087 to 0.074)
– 0.007 (– 0.083 to 0.068)
– 0.007 (– 0.085 to 0.074)
– 0.024 (– 0.110 to 0.061)
– 0.007 (– 0.085 to 0.071)
– 0.008 (– 0.088 to 0.071)
– 0.004 (– 0.083 to 0.074)
0.023 (– 0.060 to 0.106)
0.5 1.0 1.5
EPA treatment effect
Aspirin treatment effect
0.96 (0.68 to 1.34)
Adjusted odds ratio
(95% CI)
(c)
0.97 (0.70 to 1.34)
Favours treatment Favours no treatment
FIGURE 10 Forest plots for the sensitivity analyses of the ADRa. (a) EPA vs. placebo; (b) aspirin vs. placebo; and
(c) multilevel model. Results using the multilevel model are presented as odds ratios, whereas all other sensitivity
analyses are presented using the risk difference. Adjusted by site as a random effect and by repeat colonoscopy at
baseline. Some analyses were adjusted by further variables.
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TABLE 19 Summary statistics of secondary colorectal adenoma outcomes
Secondary colorectal adenoma
outcomes
Trial group
EPA+ aspirin
(N= 177)
EPA+ placebo
aspirin (N= 178)
Placebo
EPA+ aspirin
(N= 176)
Placebo+ placebo
(N= 176)
Participants with colorectal
adenoma data at 12 months (n)
161 153 163 163
Overall number of colorectal
adenomas
166 238 209 231
Overall number of advanced
colorectal adenomas
9 8 11 12
Histology of colorectal adenomas (n)
Conventional 155 205 194 220
Serrated 4 21 10 8
Missing 7 12 5 3
Location of colorectal adenomas (n)
Left 58 98 101 93
Right 108 140 107 138
Missing 0 0 1 0
TABLE 20 The analysis results of total colorectal adenomas with adjustment for repeat colonoscopy and BCSP site
Trial group
EPA+ aspirin
(n= 161)
EPA+ placebo
aspirin (n= 153)
Placebo
EPA+ aspirin
(n= 163)
Placebo+ placebo
(n= 163)
Total number of colorectal adenomas per participant
Mean (SD) 1.0 (1.2) 1.6 (2.1) 1.3 (1.6) 1.4 (2.0)
Median (IQR) 1 (0–1) 1 (0–2) 1 (0–2) 1 (0–2)
Minimum, maximum 0, 6 0, 10 0, 13 0, 16
Incidence rate for total number of colorectal adenomas per person per year
Mean (SD) 1.1 (1.3) 1.6 (2.2) 1.3 (1.7) 1.5 (2.1)
Median (IQR) 1 (0–1.2) 1 (0–2.1) 1 (0–2.1) 1.1 (0–2.2)
Minimum, maximum 0, 6.7 0, 10.8 0, 13.5 0, 16.6
Incidence rate by margins EPA No EPA Aspirin No aspirin
Mean (SD) 1.3 (1.8) 1.4 (1.9) 1.2 (1.5) 1.6 (2.1)
Median (IQR) 1 (0–2) 1 (0–2.1) 1 (0–2) 1 (0–2.2)
Minimum, maximum 0, 10.8 0, 16.6 0, 13.5 0, 16.6
EPA vs. no EPA Aspirin vs. no aspirin
IRR (95% CI) 0.91 (0.79 to 1.05) 0.78 (0.68 to 0.90)
IQR, interquartile range.
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TABLE 21 Analysis of advanced colorectal adenomas with adjustment for repeat colonoscopy and BCSP site
Trial group
EPA+ aspirin
(N= 161)
EPA+ placebo
aspirin
(N= 153)
Placebo
EPA+ aspirin
(N= 163)
Placebo+ placebo
(N= 163)
Participant with any advanced colorectal
adenoma (advanced ADRa), n (%)
8 (5) 8 (5) 10 (6) 11 (7)
EPA vs. no EPA Aspirin vs. no aspirin
Risk difference for number of participants
with any advanced colorectal adenomas
(95% CI) (%)
–0.6 (–4.4 to 3.1) –0.3 (–4.1 to 3.5)
Number of advanced colorectal adenomas per participant
Mean (SD) 0.1 (0.3) 0.1 (0.2) 0.1 (0.3) 0.1 (0.3)
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Minimum, maximum 0, 2 0, 1 0, 2 0, 2
Incidence rate for number of advanced colorectal adenomas per person per year
Mean (SD) 0.1 (0.3) 0.1 (0.2) 0.1 (0.3) 0.1 (0.3)
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Minimum, maximum 0, 2.1 0, 1.2 0, 2.1 0, 2.1
Incidence rate by margins EPA No EPA Aspirin No aspirin
Mean (SD) 0.1 (0.3) 0.1 (0.3) 0.1 (0.3) 0.1 (0.3)
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Minimum, maximum 0, 2.1 0, 2.1 0, 2.1 0, 2.1
EPA vs. no EPA Aspirin vs. no aspirin
IRR (95% CI) 0.82 (0.43 to 1.56) 0.99 (0.52 to 1.86)
IQR, interquartile range.
TABLE 22 Analysis of conventional colorectal adenomas with adjustment for repeat colonoscopy and BCSP site
Trial group
EPA+ aspirin
(N= 161)
EPA+ placebo
aspirin
(N= 153)
Placebo
EPA+ aspirin
(N= 163)
Placebo+ placebo
(N= 163)
Participants with any conventionala
colorectal adenomas (conventional
ADRa), n (%)
88 (55) 83 (54) 91 (56) 92 (56)
EPA vs. no EPA Aspirin vs. no aspirin
Risk difference for number of participants
with any conventionala adenomas
(95% CI) (%)
–3.3 (–11.2 to 4.7) 1.7 (–6.2 to 9.6)
Number of conventional colorectal adenomas per participant
Mean (SD) 1.0 (1.2) 1.4 (1.9) 1.2 (1.6) 1.4 (2)
Median (IQR) 1 (0–1) 1 (0–2) 1 (0–2) 1 (0–2)
Minimum, maximum 0, 6 0, 10 0, 13 0, 16
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TABLE 22 Analysis of conventional colorectal adenomas with adjustment for repeat colonoscopy and BCSP site
(continued )
Trial group
EPA+ aspirin
(N= 161)
EPA+ placebo
aspirin
(N= 153)
Placebo
EPA+ aspirin
(N= 163)
Placebo+ placebo
(N= 163)
Incidence rate for number of conventional colorectal adenomas per person per year
Mean (SD) 1.0 (1.3) 1.4 (2) 1.2 (1.7) 1.4 (2.1)
Median (IQR) 1 (0–1.1) 1 (0–2.1) 1 (0–2.1) 1 (0–2.1)
Minimum, maximum 0, 6.7 0, 10.8 0, 13.5 0, 16.6
Incidence rate by margins EPA No EPA Aspirin No aspirin
Mean (SD) 1.2 (1.7) 1.3 (1.9) 1.1 (1.5) 1.4 (2)
Median (IQR) 1.0 (0–1.9) 1.0 (0–2.1) 1.0 (0–1.9) 1.0 (0–2.1)
Minimum, maximum 0, 10.8 0, 16.6 0, 13.5 0, 16.6
EPA vs. no EPA Aspirin vs. no aspirin
IRR (95% CI) 0.86 (0.74 to 0.99) 0.82 (0.71 to 0.94)
IQR, interquartile range.
a Post hoc analysis.
TABLE 23 Analysis of serrated colorectal adenomas with adjustment for repeat colonoscopy and BCSP site
Trial group
EPA+ aspirin
(N= 161)
EPA+ placebo
aspirin
(N= 153)
Placebo
EPA+ aspirin
(N= 163)
Placebo+ placebo
(N= 163)
Participants with any serrated colorectal
adenomas (serrated ADRa), n (%)
4 (2) 11 (7) 6 (4) 7 (4)
EPA vs. no EPA Aspirin vs. no aspirin
Risk difference for number of participants
with any serrated adenomas (95% CI)
(%)
0 (–3.2 to 3.2) –2.7 (–6.1 to 0.7)
Number of serrated colorectal adenomas per participant
Mean (SD) 0.0 (0.2) 0.1 (0.7) 0.1 (0.4) 0.0 (0.2)
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Minimum, maximum 0, 1 0, 8 0, 4 0, 2
Incidence rate for number of serrated colorectal adenomas per person per year
Mean (SD) 0.0 (0.2) 0.1 (0.8) 0.1 (0.3) 0.1 (0.3)
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Minimum, maximum 0, 1.1 0, 8.6 0, 3.4 0, 2.2
Incidence rate by margins EPA No EPA Aspirin No aspirin
Mean (SD) 0.1 (0.6) 0.1 (0.3) 0.0 (0.3) 1.0 (0.6)
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Minimum, maximum 0, 8.6 0, 3.4 0, 3.4 0, 8.6
EPA vs. no EPA Aspirin vs. no aspirin
IRR (95% CI) 1.44 (0.79 to 2.60) 0.46 (0.25 to 0.87)
IQR, interquartile range.
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TABLE 24 Analysis of left colorectal adenomas with adjustment for repeat colonoscopy and BCSP site
Trial group
EPA+ aspirin
(N= 161)
EPA+ placebo
aspirin
(N= 153)
Placebo
EPA+ aspirin
(N= 163)
Placebo+ placebo
(N= 163)
Participants with any left colorectal
adenomas (left ADRa), n (%)
42 (26) 58 (38) 65 (40) 55 (34)
EPA vs. no EPA Aspirin vs. no aspirin
Risk difference for number of participants
with any left colorectal adenomas
(95% CI) (%)
–7.8 (–15.5 to –0.2) –1.8 (–9.4 to 5.8)
Number of left colorectal adenomas per participant
Mean (SD) 0.4 (0.7) 0.6 (10.1) 0.6 (0.9) 0.6 (1.0)
Median (IQR) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1)
Minimum, maximum 0, 3 0, 5 0, 5 0, 5
Incidence rate for number of left colorectal adenomas per person per year
Mean (SD) 0.4 (0.7) 0.7 (10.1) 0.6 (0.9) 0.6 (1.0)
Median (IQR) 0 (0–0.9) 0 (0–1.1) 0 (0–1.1) 0 (0–1)
Minimum, maximum 0.0, 3.3 0.0, 5.4 0.0, 4.4 0.0, 5.6
Incidence rate by margins EPA No EPA Aspirin No aspirin
Mean (SD) 0.5 (0.9) 0.6 (1.0) 0.5 (0.8) 0.6 (10.1)
Median (IQR) 0 (0–1) 0 (0–1.1) 0 (0–1) 0 (0–1.1)
Minimum, maximum 0.0, 5.4 0.0, 5.6 0.0, 4.4 0.0, 5.6
EPA vs. no EPA Aspirin vs. no aspirin
IRR (95% CI) 0.75 (0.60 to 0.94) 0.85 (0.69 to 1.06)
IQR, interquartile range.
TABLE 25 Analysis of right colorectal adenomas with adjustment for repeat colonoscopy and BCSP site
Trial group
EPA+ aspirin
(N= 161)
EPA+ placebo
aspirin
(N= 153)
Placebo
EPA+ aspirin
(N= 163)
Placebo+ placebo
(N= 163)
Participants with any right colon
adenomas (right ADRa), n (%)
69 (43) 72 (47) 63 (39) 66 (40)
EPA vs. no EPA Aspirin vs. no aspirin
Risk difference for number of participants
with any right colon adenomas
(95% CI) (%)
6.0 (–1.9 to 13.9) –3.1 (–11.0 to 4.7)
Number of right colon adenomas per participant
Mean (SD) 0.7 (1.0) 0.9 (1.5) 0.7 (1.3) 0.8 (1.7)
Median (IQR) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1)
Minimum, maximum 0, 6 0, 9 0, 13 0, 16
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
54
The median number of colorectal adenomas per participant at the 12-month surveillance colonoscopy was
1 for all four trial groups (see Table 20). The median incidence rate was 1 colorectal adenoma per person
per year for all four groups. However, fewer colorectal adenomas were detected in the combination
EPA + aspirin group (see Table 19), with a reduced total MAP value (see Table 20).
The factorial margin analysis revealed that the IRR for EPA versus no EPA was 0.91 (95% CI 0.79 to 1.05)
in favour of EPA (see Table 20). The IRR for aspirin versus no aspirin was 0.78 (95% CI 0.68 to 0.90). The
distribution of individual total colorectal adenoma counts was similar across all four groups (see Figure 11).
The advanced ADRa was 8 (5%) in participants who received both EPA and aspirin, as well as EPA + placebo
aspirin, but was 10 (6%) and 11 (7%) in participants who received placebo EPA + aspirin and placebo
EPA + placebo aspirin, respectively (see Table 21). Risk differences for the advanced ADRa for EPA and aspirin
were –0.6% and –0.3%, respectively. The mean incidence rate was 0.1 advanced colorectal adenomas per
person per year. Analysis of the advanced MAP ‘at the margins’ revealed IRRs of 0.82 for EPA and 0.99 for
aspirin, but with 95% CIs crossing unity. The distribution of individual advanced colorectal adenoma counts
was similar across all four groups (Figure 12).
The conventional ADRa was 55% for EPA + aspirin (88/161), 54% for EPA + placebo aspirin (83/153) and
56% for both placebo EPA + aspirin (91/163) and placebo EPA + placebo aspirin (92/163) (see Table 22).
Risk differences for EPA and aspirin were –3.3% and 1.7%, respectively. The median incidence rate was
1 conventional adenoma per person per year for all four groups, with a lower mean value for the
combined EPA + aspirin group (see Table 22). IRRs for the number of conventional colorectal adenomas
were 0.86 (95% CI 0.74 to 0.99) for EPA versus no EPA and 0.82 (95% CI 0.71 to 0.94) for aspirin versus
no aspirin (see Table 22). The distribution of individual conventional colorectal adenoma counts was similar
across all four groups (Figure 13).
TABLE 25 Analysis of right colorectal adenomas with adjustment for repeat colonoscopy and BCSP site (continued )
Trial group
EPA+ aspirin
(N= 161)
EPA+ placebo
aspirin
(N= 153)
Placebo
EPA+ aspirin
(N= 163)
Placebo+ placebo
(N= 163)
Incidence rate for number of right colon adenomas per person per year
Mean (SD) 0.7 (1.1) 1.0 (1.6) 0.7 (1.4) 0.9 (1.8)
Median (IQR) 0.0 (0.0–1.1) 0.0 (0.0–1.1) 0.0 (0.0–1.1) 0.0 (0.0–1.1)
Minimum, maximum 0.0, 6.7 0.0, 10.4 0.0, 13.5 0.0, 16.6
Incidence rate by margins EPA No EPA Aspirin No aspirin
Mean (SD) 0.8 (1.4) 0.8 (1.6) 0.7 (1.3) 0.9 (1.7)
Median (IQR) 0.0 (0.0–1.1) 0.0 (0.0–1.1) 0.0 (0.0–1.1) 0.0 (0.0–1.1)
Minimum, maximum 0.0, 10.4 0.0, 16.6 0.0, 13.5 0.0, 16.6
EPA vs. no EPA Aspirin vs. no aspirin
IRR (95% CI) 1.02 (0.85 to 1.22) 0.73 (0.61 to 0.88)
IQR, interquartile range.
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FIGURE 11 Distribution of the total number of colorectal adenomas per participant at 12 months by trial group.
(a) EPA + aspirin; (b) EPA + placebo aspirin; (c) placebo EPA + aspirin; and (d) placebo + placebo.
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FIGURE 12 Distribution of the number of advanced colorectal adenomas per participant at 12 months by trial group.
(a) EPA + aspirin; (b) EPA + placebo aspirin; (c) placebo EPA + aspirin; and (d) placebo + placebo.
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FIGURE 13 Distribution of the number of conventional colorectal adenomas per participant at 12 months by trial
group. (a) EPA+ aspirin; (b) EPA+ placebo aspirin; (c) placebo EPA+ aspirin; and (d) placebo+ placebo.
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The serrated ADRa values were small for all treatment groups: 4 (2%) for EPA + aspirin, 11 (7%) for
EPA + placebo aspirin, 6 (4%) for placebo EPA + aspirin and 7 (4%) for placebo EPA + placebo aspirin (see
Table 23). The risk differences for the serrated ADRa were 0% (95% CI –3.2% to 3.2%) for EPA and –2.7%
(95% CI –6.1% to 0.7%) for aspirin. The median incidence rate was zero for all four groups and the mean
incidence rate was 0.1 serrated adenomas per person per year for all trial groups except the EPA + aspirin
group, which was zero. IRRs for the number of serrated adenomas were 1.44 (95% CI 0.79 to 2.60) for EPA
versus no EPA and 0.46 (95% CI 0.25 to 0.87) for aspirin versus no aspirin (see Table 23). The distribution
of individual serrated colorectal adenoma counts was similar across all four groups (Figure 14).
The distribution of individual left-sided colorectal adenoma counts in each treatment group is shown in
Figure 15. Risk differences for the number of participants with at least one left colorectal adenoma (left
ADRa) were –7.8% for EPA versus no EPA (95% CI –15.5% to –0.2%) and –1.8% for aspirin versus no
aspirin (95% CI –9.4% to 5.8%). The mean incidence rate ranged from 0.4 to 0.7 left colorectal adenomas
per person per year. IRRs for left MAP were 0.75 (95% CI 0.60 to 0.94) for EPA versus no EPA and 0.85
(95% CI 0.69 to 1.06) for aspirin versus no aspirin (see Table 24).
For the number of participants with at least one right-sided colorectal adenoma (right ADRa), the risk
differences were 6% (95% CI –1.9% to 13.9%) for EPA versus no EPA and –3.1% (95% CI –11% to
4.7%) for aspirin versus no aspirin. The mean incidence rate ranged from 0.7 to 1.0 right colorectal
adenomas per person per year. IRRs were 1.02 (95% CI 0.85 to 1.22) for EPA versus no EPA and 0.73
(95% CI 0.61 to 0.88) for aspirin versus no aspirin (see Table 25). The distribution of individual right-sided
colorectal adenoma counts in each treatment group is shown in Figure 16.
Following the 12-month surveillance colonoscopy, the majority of BCSP patients were reclassified as being
at intermediate risk: 146 (91%) participants were reclassified as being at intermediate risk at follow-up in
the EPA + aspirin group, compared with 128 (84%) in the EPA + placebo aspirin group, 140 (86%) in the
placebo EPA + aspirin group and 147 (90%) in the placebo EPA + placebo aspirin group (Table 26). The risk
differences for EPA versus no EPA and aspirin versus no aspirin were small (–0.2% and 0.9%, respectively).
Adjusted IRRs and 95% CIs for the secondary MAP data are summarised in Figure 17. Risk differences and
95% CIs for the secondary ADRa data are summarised in Figure 18.
Although potential trends may have been observed in the secondary colorectal adenoma data, consideration
needs to be given to the large number of analyses that were undertaken (and, therefore, the potential for
spuriously significant results), the small sample numbers for some of the colorectal adenoma subtypes and
the potential dependencies between the variables.
Number of participants with colorectal cancer detected prior to or at first surveillance
colonoscopy
There was no report of any CRC detected at the 12-month surveillance colonoscopy or during the
intervention phase of the trial.
Dietary fish intake during trial participation
Approximately 80% of participants completed a FFQ at 12 months, with similar percentages in each of the
four treatment groups (Table 27). The total fish and oily fish intakes at 12 months were similar across the
four treatment groups (see Table 27), as was the proportion of individuals changing intake level between
baseline and the end of trial participation (Table 28). Approximately 50% of each treatment group
remained at the same level of oily fish intake during the trial.
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FIGURE 14 Distribution of the number of serrated colorectal adenomas per participant at 12 months by trial group.
(a) EPA + aspirin; (b) EPA + placebo aspirin; (c) placebo EPA + aspirin; and (d) placebo + placebo.
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FIGURE 15 Distribution of the number of left colorectal adenomas per participant at 12 months by trial group.
(a) EPA + aspirin; (b) EPA + placebo aspirin; (c) placebo EPA + aspirin; and (d) placebo + placebo.
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FIGURE 16 Distribution of the number of right colorectal adenomas per participant at 12 months by trial group.
(a) EPA + aspirin; (b) EPA + placebo aspirin; (c) placebo EPA + aspirin; and (d) placebo + placebo.
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TABLE 26 Analysis of participant reclassification as intermediate risk with adjustment for repeat colonoscopy and
BCSP site
Trial group
EPA+ aspirin
(N= 161)
EPA+ placebo
aspirin
(N= 153)
Placebo
EPA+ aspirin
(N= 163)
Placebo+ placebo
(N= 163)
Participants reclassified as being at
intermediate risk at follow-up, n (%)
146 (91) 128 (84) 140 (86) 147 (90)
EPA vs. no EPA Aspirin vs. no aspirin
Risk difference for number of participants
reclassified as being at intermediate risk at
12 months (95% CI) (%)
–0.2 (–5.4 to 5.1) 0.9 (–14.1 to 6.2)
0.05 0.50 1.00 2.00 3.00
Favours EPA Favours placebo
Total adenomas per participant
Advanced adenomas per participant
Conventional adenomas per participant
Serrated adenomas per participant
Left colon adenomas per participant
Right colon adenomas per participant
0.91 (0.79 to 1.05)
0.82 (0.43 to 1.56)
0.86 (0.74 to 0.99)
1.44 (0.79 to 2.60)
0.75 (0.60 to 0.94)
1.02 (0.85 to 1.22)
Adjusted IRR (95% CI)
(a)
0.05 0.50 1.00 2.00 3.00
Favours aspirin Favours placebo
Total adenomas per participant
Advanced adenomas per participant
Conventional adenomas per participant
Serrated adenomas per participant
Left colon adenomas per participant
Right colon adenomas per participant
0.78 (0.68 to 0.90)
0.99 (0.52 to 1.86)
0.82 (0.71 to 0.94)
0.46 (0.25 to 0.87)
0.85 (0.69 to 1.06)
0.73 (0.61 to 0.88)
Adjusted IRR (95% CI)
(b)
FIGURE 17 Forest plots for secondary MAP analysis. (a) EPA vs. placebo; and (b) aspirin vs. placebo. Adjusted by site
as a random effect and by repeat colonoscopy at baseline.
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– 0.2 – 0.1 0.0 0.1 0.2
Favours EPA Favours placebo
Advanced ADR
Conventional ADR
Serrated ADR
Left colon ADR
Right colon ADR
Reclassified as intermediate risk
– 0.006 (– 0.044 to 0.031)
– 0.033 (– 0.112 to 0.047)
0.000 (– 0.032 to 0.032)
– 0.078 (– 0.155 to – 0.002)
0.060 (– 0.019 to 0.139)
– 0.002 (– 0.054 to 0.051)
Adjusted risk
difference (95% CI)
(a)
– 0.2 – 0.1 0.0 0.1 0.2
Favours aspirin Favours placebo
Advanced ADR
Conventional ADR
Serrated ADR
Left colon ADR
Right colon ADR
Reclassified as intermediate risk
– 0.003 (– 0.041 to 0.035)
0.017 (– 0.062 to 0.096)
– 0.027 (– 0.061 to 0.007)
– 0.018 (– 0.094 to 0.058)
– 0.031 (– 0.110 to 0.047)
0.009 (– 0.141 to 0.062)
Adjusted risk
difference (95% CI)
(b)
FIGURE 18 Forest plots for secondary ADRa analysis. (a) EPA vs. placebo; and (b) aspirin vs. placebo. Adjusted by
site as a random effect and by repeat colonoscopy at baseline.
TABLE 27 Dietary fish and other seafood intake during the trial
Dietary fish intake
Trial group, n (%)
EPA+ aspirin
(N= 177)
EPA+ placebo
aspirin (N= 178)
Placebo EPA+ aspirin
(N= 176)
Placebo+ placebo
(N= 176)
Participants who completed
FFQ at 12 months
138 (78) 135 (76) 143 (81) 146 (89)
Total fish intake at 12 months
Never 3 (2) 3 (2) 3 (2) 11 (8)
Low 6 (4) 7 (5) 8 (6) 12 (8)
Medium 77 (56) 74 (55) 85 (59) 82 (56)
High 45 (33) 41 (30) 34 (24) 32 (22)
Missinga 7 (5) 10 (7) 13 (9) 9 (6)
Oily fish intake at 12 months
Never 33 (24) 38 (28) 36 (25) 42 (29)
Low 40 (29) 37 (28) 40 (28) 46 (32)
Medium 35 (26) 39 (29) 47 (33) 38 (26)
High 26 (19) 16 (12) 15 (10) 17 (12)
Missinga 4 (3) 5 (4) 5 (3) 3 (2)
a FFQ was received; however, data were not evaluable.
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Safety
The safety population comprised 697 participants who received at least one dose of EPA or aspirin, or their
respective placebos (see Table 15).
Overall, there were no safety concerns in participants receiving either EPA or aspirin. There was an excess
of AEs and SAEs in participants receiving EPA + placebo aspirin (Table 29). In this group, 13 participants
reported five or more (87 in total) AEs, which resulted in this imbalance (see Table 29). A larger proportion
of participants receiving EPA + placebo aspirin reported at least one ADR, with 57 (32%) individuals
reporting 119 ADRs. This excess was contributed to by five participants who reported five or more ADRs.
Fewer SAEs were reported in the EPA + aspirin group. Five (3%) participants reported at least one SAE,
compared with 7% who reported at least one SAE in all the other treatment groups. Only nine SAEs were
felt to be related to trial medication.
The majority of AEs and ADRs were mild in severity in each of the treatment groups.
Gastrointestinal disorders were the most frequently reported AE (Table 30), with 209 participants reporting
at least one GI AE. A larger number of GI AEs were reported in the EPA + placebo aspirin group, contributed
by an excess of individuals who reported multiple GI AEs. However, the distribution of GI AEs was similar
across the other three groups (Table 31).
There was an excess of diarrhoea, abdominal pain and nausea in those allocated active EPA (Table 32). The
excess of mild to moderate diarrhoea was most prominent in the group receiving EPA alone. There did not
appear to be any consistent differences in the reporting of GI AEs between individuals receiving EPA-FFA
and those receiving EPA-TG (see Table 32).
Post database lock and code release, the chief investigator summarised all GI AEs according to symptoms
that are commonly associated with fish oil intake, categorised as diarrhoea, upper GI symptoms, lower
abdominal symptoms, eructation/halitosis and other. These were summarised by the treatment group and
EPA formulation that the participants received. There were no notable differences between the formulations
in each trial treatment group (see Appendix 5).
TABLE 28 Change of dietary fish intake during the trial
Change of dietary
fish intake
Trial group, n (%)
EPA+ aspirin
(N= 177)
EPA+ placebo aspirin
(N= 178)
Placebo EPA+ aspirin
(N= 176)
Placebo+ placebo
(N= 176)
Change of fish intake at 12 months compared with baseline
Stayed the samea 80 (45) 80 (45) 86 (50) 84 (48)
Reduced intake 21 (12) 18 (10) 22 (13) 26 (15)
Increased intake 23 (13) 18 (10) 18 (10) 15 (9)
Missing 53 (30) 62 (35) 50 (28) 51 (29)
Change of oily fish intake at 12 months compared with baseline
Stayed the same 65 (37) 66 (38) 78 (45) 77 (44)
Reduced intake 33 (19) 32 (18) 32 (19) 32 (18)
Increased intake 36 (20) 30 (17) 26 (15) 31 (18)
Missing 43 (24) 50 (28) 40 (23) 36 (20)
a Based on intake categories described in Table 3.
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TABLE 29 Participants who had any AE or SAE from first dose of IMP
AEs, ADRs and SAEs
Trial group
EPA+ aspirin
(N= 170)
EPA+ placebo
aspirin
(N= 177)
Placebo EPA+ aspirin
(N= 174)
Placebo+ placebo
(N= 176)
Participants who reported any AE, n (%) 76 (45)a 82 (46) 68 (39) 78 (44)
Total number of AEs 129 211 154 160
Severity of all AEs (n)
Mild 110 161 122 119
Moderate 18 47 28 33
Severe 1 2 4 5
Missing 0 1 0 3
AEs per participant, n (%)
0 94 (55) 95 (54) 106 (61) 98 (56)
1 41 (24) 35 (20) 31 (18) 43 (24)
2 24 (14) 18 (10) 15 (9) 10 (6)
3 6 (4) 11 (6) 10 (6) 16 (9)
4 3 (2) 5 (3) 6 (3) 3 (2)
5 2 (1) 7 (4) 3 (2) 2 (1)
> 5 0 (0) 6 (3) 3 (2) 4 (2)
Participants who reported any ADRs, n (%) 43 (25) 57 (32) 41 (24) 38 (22)
Total number of ADRs 63 119 83 63
Severity of ADRs (n)
Mild 50 96 61 44
Moderate 13 22 19 17
Severe 0 1 3 0
Missing 0 0 0 2
Number of ADRs per participant, n (%)
0 127 (75) 120 (68) 133 (76) 138 (78)
1 28 (16) 28 (16) 18 (10) 23 (13)
2 11 (6) 13 (7) 13 (7) 9 (5)
3 3 (2) 7 (4) 5 (3) 4 (2)
4 1 (1) 4 (2) 3 (2) 1 (1)
5 0 (0) 2 (1) 1 (1) 0 (0)
> 5 0 (0) 3 (2) 1 (1) 1 (1)
Participants who reported any SAE, n (%) 5 (3) 12 (7) 12 (7) 13 (7)
Total number of SAEs 6 16 17 16
Number of SAEs per participant, n (%)
0 165 (97) 165 (93) 162 (93) 163 (93)
1 4 (2) 9 (5) 10 (6) 11 (6)
2 1 (1) 2 (1) 0 (0) 1 (1)
3 0 (0) 1 (1) 1 (1) 1 (1)
4 0 (0) 0 (0) 1 (1) 0 (0)
Number of SAEs related to IMP 1 1 7 0
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TABLE 30 Summary of AEs by MedDRA system organ class
AEs
Trial group (n)
EPA+ aspirin
EPA+ placebo
aspirin
Placebo
EPA+ aspirin Placebo+ placebo
Participants in the safety population 170 177 174 176
Participants reporting at least one AE 76 82 68 78
Cardiac disordersa 1 1 0 2
Congenital, familial and genetic disorders 0 1 0 0
Ear and labyrinth disorders 1 1 0 1
Eye disorders 1 0 0 0
GI disorders 68 146 86 85
General disorders and administration site
conditions
4 2 2 6
Hepatobiliary disorders 0 2 0 0
Immune system disorders 0 1 1 1
Infections and infestations 14 14 15 12
Injury, poisoning and procedural
complications
7 5 11 6
Investigations 3 3 0 1
Metabolism and nutrition disorders 0 1 3 0
Musculoskeletal and connective tissue
disorders
12 9 10 13
Neoplasms: benign, malignant and
unspecified (including cysts and polyps)
1 0 3 3
Nervous system disorders 4 6 7 6
Psychiatric disorders 1 0 0 2
Renal and urinary disorders 4 1 5 2
Reproductive system and breast disorders 1 0 0 2
Respiratory, thoracic and mediastinal
disorders
3 9 3 3
Skin and subcutaneous tissue disorders 3 4 5 9
Social circumstances 0 0 0 1
Surgical and medical procedures 3 2 0 2
Vascular disorders 1 3 0 3
MedDRA, Medical Dictionary for Regulatory Activities.
a Event-level data.
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TABLE 31 Summary of GI AEs by treatment group
GI AEs
Trial group
EPA+ aspirin
EPA+ placebo
aspirin
Placebo
EPA+ aspirin Placebo+ placebo
Participants in safety population (n) 170 177 174 176
Number of participants with any GI
AE, n (%)
47 (28) 67 (38) 44 (25) 51 (29)
Total number of GI AEs 68 146 86 85
Number of GI AEs per participant
1 30 29 20 32
2 14 17 13 10
3 2 9 7 6
4 1 8 2 1
5 0 3 1 1
> 5 0 1 1 1
TABLE 32 Summary of GI AEs by preferred term name, treatment group and EPA formulation
GI AEs
Trial group
EPA+ aspirin
EPA+ placebo
aspirin
Placebo
EPA+ aspirin Placebo+ placebo
FFA TG FFA TG FFA TG FFA TG
Participants in safety population (n) 99 71 107 70 99 75 109 167
Participants reporting at least one
GI AE, n (%)
25 (25) 22 (31) 43 (40) 24 (34) 24 (24) 20 (27) 38 (35) 13 (19)
GI AE (n)
Abdominal discomfort 0 0 2 3 0 2 2 0
Abdominal distension 0 2 0 1 0 0 1 0
Abdominal pain 3 2 14 13 6 1 9 3
Abdominal pain lower 0 0 2 0 0 0 3 0
Abdominal pain upper 2 1 4 1 1 0 3 0
Anal haemorrhage 0 0 1 0 0 0 2 0
Anal inflammation 0 0 0 0 0 1 0 0
Anal pruritus 0 0 0 1 0 0 0 0
Breath odour 1 0 3 0 0 1 4 0
Change of bowel habit 0 0 0 0 1 1 0 0
Constipation 6 2 5 1 2 4 3 0
Defaecation urgency 0 0 3 0 0 0 0 1
Diarrhoea 8 2 23 15 11 9 6 6
Dyspepsia 5 11 8 7 6 8 14 4
Epigastric discomfort 0 1 0 0 0 0 0 0
Eructation 0 3 2 0 0 0 1 0
Faeces discoloured 0 0 1 1 0 0 2 0
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Similar to the profile of AEs, there were more ADRs reported in the EPA + placebo aspirin group than in
the other three groups (Table 33). The most commonly reported ADRs across all treatment groups were
GI disorders. The distribution of GI ADRs across the four groups was similar (Table 34) (see Appendix 4,
Tables 41 and 43).
There were a small number of SAEs reported (Table 35) (see Appendix 4, Table 42). The most frequently
reported SAEs were cardiac and GI disorders. Among the nine cardiac disorders, five were episodes of
atrial fibrillation (AF) and all of these were reported in the EPA + placebo aspirin group. Three were reported
by one participant and two additional participants reported one each. Three myocardial infarctions were
reported by participants: one in the EPA + placebo aspirin group, two in the placebo EPA + aspirin group and
one in the placebo + placebo group. One participant in the placebo EPA + aspirin group had an arrhythmia.
Eight ADRs led to trial discontinuation for four participants, one from each of the four trial groups.
The eight ADRs came from six preferred term names (Table 36).
TABLE 32 Summary of GI AEs by preferred term name, treatment group and EPA formulation (continued )
GI AEs
Trial group
EPA+ aspirin
EPA+ placebo
aspirin
Placebo
EPA+ aspirin Placebo+ placebo
FFA TG FFA TG FFA TG FFA TG
Flatulence 1 0 2 2 1 1 3 3
Frequent bowel movements 1 0 1 0 0 0 3 0
Gastric haemorrhage 0 0 1 0 0 0 0 0
Gastritis 0 0 1 0 0 1 0 0
GI sounds are abnormal 1 0 0 0 0 0 0 0
Gastro-oesophageal reflux disease 0 3 1 0 0 4 4 2
Gingival polyp 0 0 0 0 0 0 1 0
Haematochezia 0 0 1 0 4 1 0 0
Haemorrhoidal haemorrhage 0 0 1 0 0 2 0 0
Haemorrhoids 0 1 0 0 1 0 0 0
Hiatus hernia 0 0 1 0 1 1 0 0
Melaena 0 0 1 0 0 1 0 0
Mouth haemorrhage 0 0 0 0 1 0 0 0
Nausea 5 2 5 6 2 1 0 3
Oesophagitis 0 0 1 0 0 0 0 0
Proctalgia 0 0 1 0 0 0 0 0
Rectal haemorrhage 4 0 2 2 4 3 1 1
Rectal tenesmus 0 0 1 0 0 0 0 0
Retching 0 1 0 0 0 0 0 0
Tongue discolouration 0 0 1 0 0 0 0 0
Tongue eruption 0 0 1 0 0 0 0 0
Tongue haemorrhage 0 0 0 0 1 0 0 0
Vomiting 0 0 2 1 2 0 0 0
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TABLE 33 Summary of ADRs by MedDRA system organ class
ADRs
Trial group
EPA+ aspirin
EPA+ placebo
aspirin
Placebo
EPA+ aspirin Placebo+ placebo
Participants in the safety population (n) 170 177 174 176
Participants reporting at least one ADR,
n (%)
43 (25) 57 (32) 41 (24) 38 (22)
Total number of ADRs 63 119 83 63
GI disorders (n) 46 110 69 58
General disorders and administration
site conditions (n)
4 0 0 1
Infections and infestations (n) 1 0 0 0
Injury, poisoning and procedural
complications (n)
4 1 3 0
Investigations (n) 1 0 0 0
Metabolism and nutrition disorders (n) 0 1 1 0
Musculoskeletal and connective tissue
disorders (n)
0 0 0 1
Nervous system disorders (n) 3 3 4 0
Psychiatric disorders (n) 1 0 0 0
Renal and urinary disorders (n) 2 0 3 0
Respiratory, thoracic and mediastinal
disorders (n)
1 2 2 0
Skin and subcutaneous tissue
disorders (n)
0 2 1 3
MedDRA, Medical Dictionary for Regulatory Activities.
TABLE 34 Distribution of GI ADRs
GI ADRs
Trial group
EPA+ aspirin
EPA+ placebo
aspirin
Placebo
EPA+ aspirin Placebo+ placebo
Total number of GI ADRs 46 110 69 58
Number of GI ADRs
1 20 26 16 22
2 11 13 10 7
3 0 7 4 4
4 1 4 4 1
5 0 3 1 0
6 0 1 0 1
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TABLE 35 Summary of SAEs by MedDRA system organ class
SAEs
Trial group
EPA+ aspirin
EPA+ placebo
aspirin
Placebo
EPA+ aspirin Placebo+ placebo
Participants in the safety population (n) 170 177 174 176
Participants reporting at least one SAE,
n (%)
5 (3) 12 (7) 12 (7) 13 (7)
Total number of SAEs 6 16 17 16
Cardiac disorders (n) 0 6 2 1
GI disorders (n) 0 2 5 2
General disorders and administration
site conditions (n)
1 1 0 1
Hepatobiliary disorders (n) 0 1 0 0
Infections and infestations (n) 1 2 2 3
Injury, poisoning and procedural
complications (n)
0 0 1 0
Investigations (n) 0 0 1 0
Neoplasms: benign, malignant and
unspecified (including cysts and polyps)
(n)
2 2 0 4
Nervous system disorders (n) 0 0 2 1
Psychiatric disorders (n) 0 0 0 2
Respiratory, thoracic and mediastinal
disorders (n)
1 2 1 0
Vascular disorders (n) 1 0 3 2
MedDRA, Medical Dictionary for Regulatory Activities.
TABLE 36 Summary of ADRs that led to trial discontinuation
ADRs that led to trial
discontinuation
Trial group
EPA+ aspirin
(N= 170)
EPA+ placebo
aspirin
(N= 177)
Placebo
EPA+ aspirin
(N= 174)
Placebo+ placebo
(N= 176)
Participants who discontinued the trial
because of an ADR, n (%)
1 (1) 1 (1) 1 (1) 1 (1)
ADR by preferred term name (n)
Abdominal pain 1 0 0 0
Atrial fibrillation 0 3 0 0
Deep-vein thrombosis 0 0 0 1
Lymphoma 0 0 1 0
Melaena 0 1 0 0
Skin disorder 0 0 0 1
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Clinically significant acute upper gastrointestinal bleeding episodes
No haemorrhagic strokes were reported during the trial. A manual search of AEs and SAEs revealed six acute
upper GI bleeding events that were considered by the chief investigator to be of clinical significance. These
were ‘oesophageal haemorrhage’ (in the placebo EPA + aspirin group), ‘gastro-oesophageal reflux disease’
(in the placebo EPA + aspirin group) and ‘alcohol withdrawal syndrome’ (in placebo EPA + placebo aspirin
group), which were all reported as SAEs, and ‘gastric haemorrhage’ (in the EPA + placebo aspirin group)
and two cases of ‘melaena’ (in the EPA + placebo aspirin and placebo EPA + aspirin groups), which were
recorded as AEs. It is possible that one of the cases of melaena (in a participant receiving EPA + placebo
aspirin) was a SAE because the participant had been hospitalised, but this event was recorded specifically as
an AE by the site. All tables reflect this categorisation.
Deaths
One death was reported during the trial. During contact made to arrange visit 5, site staff were made aware
that a participant had died from bladder cancer, which was deemed to be unrelated to the intervention.
Protocol deviations
Protocol deviations were reported for between 64% and 73% of participants in each treatment group.
Most deviations were judged to be minor, with the majority being trial visits outside the time window.
The number and types of deviations appeared similar between treatment groups.
There were 11 deviations related to randomisation error (Table 37). Ten of these were as a result of
participants being ineligible, and one participant was randomised prior to consent. None of these errors
occurred in participants who were randomised to the placebo + placebo group. There was no reason to
suspect that the deviation was related to the treatment group to which the participant had been randomised.
TABLE 37 Listing of treatment randomisation error deviations
Treatment group Detailsa
Included in
per-protocol
population?
Outcome
collected?
EPA+ aspirin Not eligible No Yes
Placebo EPA+ aspirin Patient not eligible for trial as was intermediate risk No Yes
EPA+ placebo aspirin Patient does not meet inclusion criteria; withdrawn from trial No No
Placebo EPA+ aspirin Participant did not fulfil inclusion criteria as had only two polyps
> 10mm, but was still considered a high-risk patient by the BCSP
No Yes
Placebo EPA+ aspirin Patient has three adenomas and all less than the required
measurement for patient to be included in the trial
No No
Placebo EPA+ aspirin Randomised in error. Patient had hyperplastic polyps No Yes
EPA+ aspirin Randomised in error. Patient had four adenomas; however, none
was more than 10mm
No Yes
EPA+ placebo aspirin Patient should not have been included as had had previous BCSP
colon – this not first BCSP colon
Yes Yes
EPA+ placebo aspirin Patient randomised prior to consent, as patient prescription needed
to be signed by PI, and he [was] not available at site on day of
consent. Patient did not want to consent then come back for
prescription on another day
Yes Yes
EPA+ aspirin Incorrectly recruited due to confusion of the term ‘high risk’ No No
Placebo EPA+ aspirin Patient randomised at age 74 in error due to randomisation
database allowing the patient in by accident
Yes No
a Verbatim description from trial site staff member.
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Exploratory analyses
Colorectal adenoma size
Given the decrease in total colorectal adenoma number associated with EPA and aspirin treatment,
colorectal adenoma size was analysed consistent with size analysis in previous RCTs of chemoprevention
agents in FAP patients.55,67 Colorectal adenoma size was summarised within each participant across each
treatment group. Analyses were based on the within-participant mean value (Table 38).
The adjusted mean difference between the EPA and no EPA groups was –0.47 mm (i.e. the mean
adenoma size was smaller in those receiving EPA than in those not receiving EPA). The mean adjusted
difference between the aspirin and no aspirin groups was 0.42 mm (i.e. the mean adenoma size was
bigger in those receiving aspirin than in those not receiving aspirin). There was no statistically significant
difference between EPA and placebo users, or between aspirin and placebo users.
Relationship between individual colorectal adenoma number and eicosapentaenoic
acid levels
The relationship between the change in RBC EPA levels at 12 months from baseline and secondary
outcomes, according to EPA factorial margin, was also investigated descriptively by plotting individual
values. There was no evidence of a clear relationship between individual increase in RBC EPA level and
total colorectal adenoma number (Figure 19). This was also the case for the rectal EPA level at 12 months.
The fact that there were three ‘outlier’ individuals in the placebo EPA group who had a large increase in
RBC EPA level during the intervention phase suggests that ‘contamination’ by own-use ω-3 PUFA intake
may have occurred in these cases (see Figure 19).
TABLE 38 Analysis of colorectal adenoma size
Adenoma size
Trial group
EPA+ aspirin
(N= 177)
EPA+ placebo
aspirin (N= 178)
Placebo
EPA+ aspirin
(N= 176)
Placebo+ placebo
(N= 176)
Participants with colorectal
adenoma data at 12 months (n)
161 153 163 163
Participants with at least one
colorectal adenoma (n)
98 97 100 100
Participants with mean colorectal
adenoma size available (n)
97 97 100 100
Participants with mean colorectal
adenoma size missing (n)
1 0 0 0
Size (mm)a of adenoma at 12 months
Mean (SD) 3.5 (2.3) 3.3 (2.2) 4.2 (3.3) 3.7 (2.4)
Median (IQR) 3.0 (2.0–3.5) 3.0 (2.0–4.0) 3.5 (2.3–5.0) 3.0 (2.0–4.4)
Minimum, maximum 1, 12 1, 15 1.0, 28.5 1, 15
EPA vs. no EPA Aspirin vs. no aspirin
Adjustedb difference in means
(95% CI)
–0.47 (–1.04 to 0.98) 0.42 (–0.14 to 0.99)
IQR, interquartile range.
a The mean was calculated within participants then the overall mean of the means within participants.
b Adjusted by histology type (i.e. conventional/serrated) and recruiting site. Estimates were mean difference, taking into
account multiple adenomas per participant.
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Relationship between red blood cell and rectal mucosal eicosapentaenoic acid levels in
participants
The relationship between RBC and rectal mucosal EPA levels at 12 months was of moderate strength,
with a correlation coefficient of 0.455 (Figure 20).
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FIGURE 19 Change in RBC EPA levels at 12 months from baseline against total number of colorectal adenomas per
participant by EPA treatment groups. (a) Placebo EPA; and (b) active EPA.
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FIGURE 20 Scatterplot of the individual rectal mucosal EPA level against the corresponding RBC EPA level at
12 months.
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Chapter 4 Discussion
Parts of this chapter have been reproduced from Hull et al.1 © 2018 The Author(s). Published by Elsevier Ltd.
This is an Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Summary of colorectal adenoma findings
The seAFOod polyp-prevention trial found no evidence of an effect of either EPA or aspirin on the primary
end point of the proportion of individuals with one or more colorectal adenomas at the 12-month surveillance
colonoscopy (the ADRa) in patients deemed ‘high risk’ in the English BCSP. Overall, ≈60% of trial participants
had at least one colorectal adenoma at surveillance colonoscopy. The trial was designed to detect an absolute
difference between groups of 10 percentage points, or a relative difference of 18%, assuming an ADRa
of 60% in the double placebo group. The 95% CIs for the primary analyses excluded a difference of this
magnitude on ADRa for both treatments. Moreover, the primary outcome data were robust to sensitivity
analyses.
Secondary analyses of the effects of EPA and aspirin on colorectal adenoma number provided evidence of
chemopreventive activity of both agents. Aspirin was effective at reducing the total number of colorectal
adenomas per participant, but there was no evidence of an effect on total MAP by EPA. Other secondary
analyses suggested that there are colorectal adenoma subtype- and site-selective effects of EPA and aspirin.
Participants randomised to EPA had a reduced number (MAP) and ADRa for conventional dysplastic colorectal
adenomas in the left colon and rectum compared with those randomised to placebo. Participants randomised
to aspirin had a reduced number of adenomas in the right colon, particularly for serrated adenomas, and also
a reduced risk of conventional colorectal adenomas. An exploratory analysis found no evidence of any effect
of either EPA or aspirin on recurrent colorectal adenoma size.
Colorectal adenoma end points
The ADRa was chosen as the primary end point, on historical grounds that previous ‘sporadic’ polyp-prevention
trials had all used this binary measure of the presence of any colorectal adenoma at surveillance colonoscopy
as the primary measure of colorectal adenoma risk.49 We expected the high ADRa at the 1-year surveillance
colonoscopy of ‘high-risk’ individuals in the English BCSP compared with previous polyp-prevention trials.98
The high ADRa in the seAFOod trial population of obese, male-predominant ‘polyp formers’ will also have been
driven by the uniformly excellent colonoscopy quality in the BCSP, in which the ADRa figures prominently as an
individual QA measure.38,95,97 It is noteworthy that those previous aspirin RCTs with the highest placebo ADRa
{47.1% [Aspirin and Folate Polyp-Prevention Study (AFPPS)114] and 53.4% [APACC115]} reported the smallest
(statistically insignificant) risk reduction associated with aspirin (risk ratio 0.88 and 0.95, respectively) compared
with the other two aspirin RCTs,49 despite the overwhelming evidence for a CRC chemoprevention effect of
aspirin.43–48 Therefore, the use of the ADRa as a biomarker of chemoprevention efficacy in screening cohorts
undergoing high-quality colonoscopic assessment with a high ADRa must be questioned.
By contrast, previous chemoprevention RCTs in FAP patients with a large colorectal adenoma burden
have reported efficacy based on colorectal adenoma number and size.55,67,116 Moreover, three of the four
previous aspirin ‘sporadic’ polyp-prevention trials have reported colorectal adenoma multiplicity as a
secondary outcome.115,117,118 Therefore, adenoma number was stipulated as a secondary end point in the
seAFOod trial. Reduction in colorectal adenoma multiplicity is widely accepted as an indicator of anti-CRC
activity in pre-clinical studies.61 More recently, adenoma number has gained credence as a biomarker in
‘sporadic’ colorectal adenoma prevention RCTs,39 driven by increasing use of MAP as an outcome measure
in colonoscopy QA studies.38 Moreover, colorectal adenoma number predicts future CRC incidence and
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mortality in population-based observational studies.40–42 We suggest that subsequent chemoprevention
RCTs utilise MAP as the primary measure of chemopreventative efficacy, especially in ‘high-risk’ study
populations with a high ADRa, in which the ADRa will be a relatively insensitive measure of colorectal
adenoma risk. The recent polyp-prevention RCT of metformin did indeed employ co-primary end points of
colorectal adenoma incidence (ADRa) and number (MAP).39
Site and adenoma subtype specificity of the chemopreventive effects of
aspirin and eicosapentaenoic acid
All three aspirin RCTs, which reported colorectal adenoma number as a secondary outcome,115,117,118
demonstrated a significant reduction in total MAP in the aspirin group compared with the placebo group.
The APACC trial reported total MAP data at the 12-month colonoscopic follow-up, similar to the seAFOod
trial.115,119 Coupled with the known CRC-preventative properties of aspirin demonstrated during observational
follow-up of large-scale aspirin RCTs,46–48 our data (and those from the previous polyp-prevention trials)115,117,118
justify colorectal adenoma number as a clinically relevant biomarker of CRC risk in CRC chemoprevention
trials, in addition to the ADRa. The similar magnitude decrease in colorectal adenoma number that we
observed for aspirin in the seAFOod trial compared with the previous aspirin RCTs suggests that the reductions
in colorectal adenoma number that we have reported are likely to be genuine and be clinically meaningful
for CRC risk reduction. However, we do acknowledge that the number of secondary comparisons that have
been made increases the possibility that findings could be spurious.
With increased understanding that different colorectal carcinogenesis pathways exist, improved insight
into differential effects of chemopreventive agents on distinct colorectal adenoma types is of paramount
importance. Chemopreventive activity of EPA against conventional colorectal adenomas (but not serrated
lesions), based on both MAP and ADRa outcomes, is consistent with the known efficacy of the same dose
of EPA-FFA in FAP patients67 with rectal adenomas, which are conventional, wholly dysplastic lesions
occurring on a background of germline mutation of one APC allele and tumour initiation after loss of
heterozygosity of the other APC allele.120 By contrast, we report that EPA has no chemopreventive activity
against serrated adenomas. Based on secondary colorectal adenoma number analysis, a possible signal
that EPA use may actually increase serrated lesion risk requires careful examination in future studies of ω-3
PUFA supplementation/dietary intake and CRC risk, in which there is stratification based on location and
the different molecular subtypes of CRC.
By contrast, the effect of aspirin on proximal colorectal adenoma multiplicity was partly explained by the
strong preventative activity against serrated lesions. The seAFOod trial data add to an existing body of
evidence that the reduction in CRC incidence and mortality by aspirin is explained by a dominant effect
on proximal CRC, with less preventative efficacy against distal CRC.47,48 Post hoc analysis of data from the
AFPPS trial114 has revealed that risk of right-sided (but not left-sided) serrated polyps was lower in those
allocated aspirin than in those allocated placebo.121 Moreover, a meta-analysis of observational studies of
lifestyle factors and serrated polyp risk has reported that serrated polyp risk is decreased in aspirin users
(relative risk 0.81, 95% CI 0.67 to 0.99).122
The seAFOod trial data suggest that aspirin also has some antineoplastic activity against conventional
adenomas. However, in contrast with EPA, aspirin (100–600 mg daily) has not been demonstrated to have
efficacy against rectosigmoid polyps in FAP RCTs,123,124 which is consistent with the dominant ‘right-sidedness’
of aspirin chemopreventative activity.47,48
Only two previous ‘sporadic’ polyp-prevention trials have reported an a priori analysis of colorectal adenoma
risk related to location in the colorectum.114,125 In the RCT of the selective COX-2 inhibitor rofecoxib, there
was no differential effect on ADRa dependent on location in either the right or left colon.125 In the AFPPS trial,
no differential effects of aspirin on right or left ADRa were observed, similar to the seAFOod trial data.121
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There has been no location-dependent analysis of colorectal adenoma number in a polyp-prevention trial prior
to the seAFOod trial.
The seAFOod trial data, in combination with greater insight into the molecular pathogenesis of early stages
of colorectal carcinogenesis,4 should prompt a paradigm shift in polyp-prevention trials driving data
collection on colorectal adenoma subtype (conventional adenoma vs. serrated polyp) and tumour location
(proximal/right vs. distal/left), leading to evaluation of stratified chemoprevention. It remains unclear whether
or not the biology of the early stages of colorectal carcinogenesis during initiation and growth of a colorectal
adenoma differs significantly such that rectal lesions should be classified separately from colonic neoplasia.
At the present time, available evidence suggests that the molecular pathologies of colorectal adenomas from
the rectum and distal colon do not differ significantly.126
Dose considerations
The seAFOod trial evaluated 300 mg of aspirin daily based on the random-effects meta-analysis of aspirin
polyp-prevention RCTs that demonstrated a significant colorectal adenoma risk reduction at doses of
300–325 mg daily, particularly for advanced lesions (risk ratio 0.71, 95% CI 0.56 to 0.92 for advanced
ADRa), albeit in subjects approximating to ‘intermediate-risk’ surveillance populations.49 Observational data
on CRC risk suggest that lower daily doses of aspirin are likely to have ‘right-predominant’ effects on
colorectal adenoma multiplicity similar to those reported herein.48
The FFA-equivalent dose of 2 g of EPA daily was based on the same dose of EPA-FFA that demonstrated
efficacy in the proof-of-concept RCT in FAP patients.67 This is a relatively high daily amount of ω-3 PUFA,
which would be difficult to provide using more widely available fish oil or re-esterified TG formulations.65
Restricted supply of the original EPA-FFA formulation, beyond TMG control, meant that we had to switch
the IMP to an EPA-TG formulation and matching placebo during the recruitment phase of the trial. This,
however, provided a unique (originally unplanned) opportunity to compare ‘bioavailability’ of two EPA
formulations, with the same FFA dose, in the context of prolonged dosing in a RCT. The data suggest that
there is no meaningful difference in tissue EPA incorporation, measured by RBC membrane and rectal
mucosal EPA levels, between EPA-FFA and EPA-TG. Therefore, colonoscopic outcome data from the two
populations receiving either EPA-FFA/placebo or EPA-TG/placebo were combined.
Mechanistic considerations
We have not yet addressed the mechanistic basis for differential chemopreventive activity of EPA along
the colorectum. Conventional dysplastic ‘sporadic’ colorectal adenomas are found along the length of
the colon and can exhibit molecular features compatible with CIN, MSI and CIMP+ pathways, but with
proportionally more CIN+ lesions in the distal colon.4,23 Therefore, differential activity of EPA against the
distinct molecular CRC subtypes should be investigated, particularly in view of the absence of any efficacy
signal against serrated lesions that are predominantly CIMP+ and often exhibit features of MSI.4,21,23
We cannot rule out that differences in mucosal EPA levels explain colorectal site selectivity of the modest
chemopreventive activity of EPA. There are no human data describing ω-3 PUFA levels in different regions
of the colorectum. However, rodent data suggest that there is no gradient in mucosal EPA exposure along
the colon.127 One clinical study has measured ω-3 PUFA levels in the sigmoid colon (but not the rectum).128
However, data from this Japanese study cannot be compared with the rectal mucosal PUFA levels measured
in the seAFOod trial because of profound differences in baseline characteristics of the two study populations,
including dietary ω-3 PUFA intake.128
We have recently reported that mixed ω-3 PUFA supplementation is associated with an increase in
short-chain fatty acid (SCFA)-producing bacterial genera such as Lactobacillus and Bifidobacteria in faecal
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samples.129 Although SCFA levels are believed to be higher in the caecum and ascending colon than in the
distal colon,130 the SCFA receptor free fatty acid receptor (FFAR) 2, also known as GPR43, is expressed at
higher levels in the left colon.131 Therefore, a valid hypothesis is that differential antineoplastic activity of
EPA may relate to increased antineoplastic SCFA-FFAR2 signalling in the distal versus proximal colon.132
Both EPA and aspirin inhibit the COX enzymes COX-1 and COX-2.57 Independent reports have described
how expression of COX-2, which is believed to play a critical role in intestinal tumorigenesis,54 is higher in
distal colonic neoplasms than in the proximal colonic lesions.133,134 Differential expression and activity of
COX-1 in colorectal adenomas in different parts of the colorectum has not been studied. Differences in
gene expression in non-neoplastic mucosa and baseline colorectal adenoma characteristics that may
predict response to EPA and/or aspirin deserve further investigation.
The mechanism of the CRC-preventative activity of aspirin remains unclear despite intense scrutiny over
several years.44,45 Postulated mechanisms of action include COX-dependent and COX-independent activity,
either directly on colorectal epithelial cells or indirectly via the antiplatelet activity of aspirin.45 More recently,
subversion of the host anti-tumour immune response by COX-dependent PGE2 has been reported,135 which
is abrogated by aspirin, thus driving more effective host anti-tumour immunosurveillance. This mechanism
of action may explain the preferential antineoplastic activity of aspirin against proximal colonic neoplasms,
which are more likely to exhibit a higher neo-antigenic load (and hence potential to stimulate a host
anti-tumour immune response) as a result of defective DNA MMR in MSI tumours.136
Combination colorectal cancer chemoprevention
The individual effects of EPA and aspirin on colorectal adenoma number beg the question of the
antineoplastic activity of combined treatment, which, given the single agent effects apparent on the
‘at-the-margins’ analysis, one might expect to be apparent for total colorectal adenoma number. The trial
was powered to be able to detect only a major interaction between EPA and aspirin with an ‘inside-the-table’
analysis of this 2 × 2 factorial RCT. Comparison between the four treatment groups highlighted that total
and left-sided colorectal adenoma multiplicity was lower in the combined EPA and aspirin treatment group,
consistent with efficacy of both agents on left-sided, conventional colorectal adenomas. A key objective
of future work, in order to translate the seAFOod trial findings into clinical application, will be to apply
precision/personalised medicine principles to pose the question regarding which individuals might gain most
from chemoprevention with one or both agents, based on baseline colorectal adenoma characteristics
and/or other mucosal biomarkers.
Use of the NHS Bowel Cancer Screening Programme for a
polyp-prevention trial
The rationale for the study of a ‘high-risk’ population undergoing 1-year surveillance colonoscopy within the
English BCSP was based on data from previous aspirin polyp-prevention trials that suggested that colorectal
adenoma risk reduction associated with aspirin use was already evident (and exceeded the risk reduction
at 3–4 years) at 1 year, combined with the high ADRa.49 The relatively short follow-up duration raises the
question of how far colorectal adenoma outcomes at 12 months simply reflect missed colorectal neoplasia
from the screening examination. However, BCSP data98,100 and other reports137,138 have confirmed that the
colorectal adenoma yield at 12 months from baseline assessment is significantly higher than the yield from
a procedure within 3 months of the index assessment, implying that de novo colorectal adenoma growth
contributes significantly to colorectal adenoma ‘recurrence’ rather than solely ‘missed lesions’. In reality,
colorectal adenomas detected at a 12-month endoscopic procedure will almost certainly represent a mixed
population of ‘new’ and ‘missed’ lesions, even after the highest-quality colonoscopic examination, but this
does not negate the role of the colorectal adenoma as a biomarker of chemoprevention efficacy (related to
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regression of existing colorectal adenomas, as well as inhibition of new growth), as accepted in proof-of-
concept FAP RCTs.37
The low yield of advanced colorectal adenomas in the seAFOod trial is probably explained by the short
surveillance interval and high-quality colonoscopic colorectal adenoma clearance achieved in the BCSP,
but also the rather stringent ‘advanced’ lesion definition, which required complete (100%) ‘villousness’
of conventional dysplastic adenomas, unlike previous observational and intervention studies that have
included lesions with > 25% ‘villousness’ in the definition of ‘advanced’ colorectal adenoma.32,139
Using the English BCSP as a vehicle for the seAFOod trial provided several advantageous features to the
design and performance of the trial, including strict, protocol-driven colonoscopy screening and surveillance
procedures, uniform colonoscopy, and histopathology performance and reporting.95–97 In particular, strict
timing of the 12-month surveillance colonoscopy in the seAFOod trial was a major advantage over previous
‘sporadic’ polyp-prevention trials undertaken in non-screening settings49,125,141 and was essential for interpretable
PUFA biomarker data at 12 months. The trial population had a strong male predominance, mirroring BCSP
practice,95 which limits the generalisability of the data to women. The high prevalence of overweight and
obesity in the trial population probably indicates the major contribution of excess body weight to early-stage
colorectal carcinogenesis,140 and is highly relevant to general CRC chemoprevention in non-screening
populations given the high prevalence of overweight and obesity in many areas of the world.142
A large number (nearly 4000) of individuals stratified as ‘high risk’ after BCSP screening colonoscopy were
identified and screened by participating trial sites, as expected from BCSP data pertaining to the prevalent
screening round, which suggested that ‘high-risk’ features were detected in 9.8–10.3% of screening
colonoscopies (Public Health England, 2009, personal communication).95 However, since the seAFOod trial
opened for recruitment, subsequent incident screening rounds have detected less colorectal neoplasia and
more recent BCSP data demonstrate that ‘high-risk’ features make up only 8.3% of screening colonoscopy
outcomes (Public Health England, 2009, personal communication). The reduction in incidence of ‘high-risk’
colorectal neoplasia probably contributed to the slower than expected recruitment during the trial.
Only 18% of ‘high-risk’ individuals were randomised. This is a higher screen success rate than in several
previous polyp-prevention trials that reported a trial screening success rate,141,143 but lower than we
anticipated. Exclusion criteria included concomitant use of anticoagulants or antiplatelet agents, including
existing aspirin use (19%). In addition, a higher than expected proportion of patients (31%) declined to be
screened for and participate in the trial, despite the fact that the trial design did not entail an additional
colonoscopy and that venepuncture for blood sampling was optional. Trial acceptability was lower than
expected from a cohort of patients who had already engaged fully with a multistage screening process and
who had been informed that they had ‘high-risk’ colorectal neoplasia necessitating surveillance colonoscopy
in 12 months’ time. Formal data pertaining to reasons for declining participation were not collected on the
basis that any individual did not need to provide a reason for his or her decision. However, an informal
review showed that reasons for declining participation at screening included concern about risk associated
with the IMP (particularly aspirin) and unwillingness to start medication when previously not taking any
regular drugs, but also, conversely, unwillingness to add further medication to an existing drug regimen.
The screen failure rate varied significantly between the BCSP sites despite the strict, uniform inclusion
criteria based on BCSP practice and an identical BCSP screen pathway used at all BCSP sites. Several patient
(e.g. differential prevalence of comorbidities requiring antiplatelet/anticoagulant use in different regions of
England) and research staff factors (e.g. research time available to PI and SSPrs, as well as CRN-funded RN
support) contributed to marked differences in recruitment efficiency. In addition, BCSP screening colonoscopy
activity varied widely across individual sites, thereby limiting the identification of ‘high-risk’ individuals at
some sites. Recognition of the most-suitable BCSP sites for any similar polyp-prevention trial will be key to
improving recruitment efficiency, particularly when ‘high-risk’ individuals remain a relatively fixed proportion
(7–9%) of guaiac FOBt-positive patients. A general theme (but with notable exceptions) was that BCSP sites
that utilised CRN-funded research staff best had a higher recruitment rate. This may reflect insufficient time
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that many BCSP staff have available for research and/or some SSPrs having limited understanding of clinical
trials research and a protectionist approach towards patients; these need to be addressed prior to a future
polyp-prevention trial set in the BCSP.
The switch from guaiac FOBt to FIT in the UK BCSP programmes may alter colorectal neoplasia incidence
rates relevant to future trial recruitment projections.
Safety and tolerability of eicosapentaenoic acid and aspirin
Overall, safety and tolerability of both agents was excellent, with no excess of clinically significant bleeding
events, even in the combined treatment group. However, we did mandate stopping IMP before and after
any planned invasive procedures (including polypectomy at repeat endoscopy) in the unlikely event that the
combined antiplatelet activity of EPA and aspirin increased bleeding risk. Excellent tolerability of EPA and
aspirin contributed to high compliance levels and trial retention, with limited drop-out.
Eicosapentaenoic acid was associated with an excess of mild to moderate GI AEs, including diarrhoea. Although
ω-3 PUFA products have an excellent safety profile and daily doses of up to 4 g are ‘generally recognized
as safe’ (GRAS) by the US Food and Drug Administration (FDA), mild to moderate GI AEs are recognised,
commonly diarrhoea, dyspepsia, eructation (burping) and an unpleasant ‘fishy’ taste.144 These GI symptoms
often occur in the general population unrelated to dietary or ‘nutraceutical’ ω-3 PUFA intake.113 Therefore,
we confirmed that the treatment groups were well matched for prevalent GI symptoms at baseline.
Dose-related ω-3 PUFA-related GI symptoms can occur.65,144,145 However, an open clinical question has been
whether or not prolonged dosing with the different forms of EPA and mixed ω-3 PUFAs (FFA vs. TG vs. EE)
available in ‘nutraceutical’ preparations is associated with differential GI tolerability.65 The seAFOod trial
data do not indicate any major difference in GI tolerability between the same FFA-equivalent dose of the
EPA-FFA and EPA-TG formulations in the context of a 12-month intervention trial.
Mild to moderate GI AEs, particularly diarrhoea and abdominal pain, were more common in those allocated
to EPA alone, as opposed to EPA plus aspirin. A valid hypothesis is that aspirin co-therapy is causally
protective for ω-3 PUFA intolerance. This requires further investigation in the context of subsequent studies
of combined antineoplastic activity of both agents.
Five episodes of AF were reported in three participants, all of whom were allocated active EPA alone.
Several RCTs have investigated ω-3 PUFA supplementation for primary and secondary prevention of AF
that are summarised in recent American Heart Association guidelines on ω-3 PUFA use and prevention of
CVD.146 Overall, there is no supportive evidence for use of ω-3 PUFAs for AF prevention. There has been
no signal in any previous RCT of increased AF risk in ω-3 PUFA users.146
An important component of the trial was dietary ω-3 PUFA analysis to exclude significant change in dietary
ω-3 PUFA intake prompted by participant-facing trial information, prior to consent, that suggested possible
anti-CRC activity of EPA. Using the established short-form EPIC FFQ,108 we confirmed that there was no
evidence of increased fish intake during the intervention phase and that the four treatment groups were
well matched on dietary fish intake at baseline and at the end of trial participation.
Biomarkers of omega-3 polyunsaturated fatty acid tissue exposure
The seAFOod trial biobank obtained excellent coverage considering the geographical spread of a large number
of trial sites. There was widespread engagement from SSPrs and RNs at sites, with careful sample handling and
storage at sites prior to temperature-controlled transport to the biobank in Bradford. The trial protocol outlines
the lipid mediator analyses that were originally proposed.100 At the start of the trial, measurement of RBC PUFA
levels was planned in only a small subset of participants. However, the capsule IMP switch necessitated the
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measurement of PUFA levels in all RBC and rectal mucosal samples to provide the strongest possible evidence that
the trial cohorts exposed to EPA-FFA and EPA-TG gained equivalent exposure to EPA and could be combined for
primary and secondary outcome analysis. Therefore, many planned measurements were not carried out, but
these should be performed in the future if further funding can be obtained for biomarker analysis.
Baseline RBC PUFA values in the seAFOod trial cohort were comparable with previous cross-sectional UK
studies and data from other Western countries with relatively low population ω-3 PUFA levels and dietary
fish intake.147 Despite self-reported compliance being excellent by capsule counting, the increase in RBC
EPA levels observed in EPA users was highly variable, a phenomenon that has been seen in several
previous ω-3 PUFA studies, in which individual RBC fatty acid profiles have been measured.88,129,148 The
explanation for large variations in RBC membrane EPA levels, despite uniform dosing, remains unclear and
requires further investigation in the large trial cohort. There was no evidence that COX inhibition by
concurrent aspirin use is associated with higher RBC membrane or rectal mucosal EPA content.
To our knowledge, this is the first large-scale RCT evidence that oral administration of EPA results in
incorporation of EPA in the rectum. There was a medium-strength correlation between the RBC % EPA
value at 12 months and the rectal mucosal % EPA content. The RBC membrane EPA and DHA content is
considered to be the best proxy biomarker of tissue ω-3 PUFA exposure.84,148 Further exploratory analysis
of the seAFOod trial data is required to explore the predictive value of the rectal mucosal EPA level for
individual EPA efficacy against left-sided colorectal neoplasia. Integration of dietary ω-3 PUFA intake,
baseline PUFA levels and ‘nutraceutical’ EPA dosing is needed in a treatment-independent analysis of the
relationship between EPA level and colorectal adenoma recurrence risk during surveillance. A similar
analysis performed in the context of the WELCOME trial149 of ω-3 PUFA use in patients with non-alcoholic
fatty liver disease provided new insights into the role of DHA in treatment of that condition.
There was no evidence of significant conversion of EPA to DHA in either RBC membranes or rectal
mucosa, consistent with previous human data from EPA intervention trials.67,87 Therefore, the trial data
do not support the concept of EPA as the ‘universal ω-3 PUFA donor’, which can substitute for mixed
EPA-DHA preparations. The question of whether or not equivalent doses of EPA alone, DHA alone or a
EPA-DHA mix have different antineoplastic activity in the intestine has been tested only in rodents, in
which equivalent anti-CRC effects have been observed.61 Equivalent bioactivity of EPA and DHA in a CRC
chemoprevention context cannot be assumed from the seAFOod trial; this will be a critical public-facing
message from the trial to minimise incorrect assumptions about, and use of, mixed ω-3 PUFA preparations
in the context of CRC chemoprevention. The majority of prescription and health supplement ω-3 PUFAs
are a mix of EPA and DHA with a smaller proportion of other PUFAs.150 However, separate EPA formulations
are licensed for treatment of severe hypertriglyceridaemia and are marketed as health supplements.144,151
The low cost and excellent safety/tolerability profile of EPA, combined with existing health claims regarding
ω-3 PUFAs, means that, even with modest CRC chemopreventative activity, it may be adopted widely in a
cancer-prevention setting by the public.
‘Contamination’ of the treatment groups by participant use of OTC formulations is an ever-present risk in
placebo-controlled trials of agents that are available for purchase by the public. The seAFOod trial fatty acid
analysis allows us to speculate about possible placebo contamination by ‘own’ ω-3 PUFA use by identifying
those individuals who were randomised to placebo EPA who had a rise in RBC EPA level. Further analysis of
concomitant changes in DHA levels is now required. Individual RBC ω-3 PUFA profiles suggest that placebo
contamination, if it did occur, was very rare and did not interfere with the findings pertaining to EPA use.
Aspirin use entails a small, but significant, risk of serious harm from GI and intracranial bleeding.152 This has
hampered translation of the significant body of evidence supporting the CRC chemopreventative properties
of aspirin into routine clinical practice. The seAFOod trial data add to this body of evidence and emphasise
the chemopreventative activity of aspirin against proximal and serrated neoplasms, which are widely
considered to be more ‘missable’ at colonoscopy and contribute significantly to the burden of interval CRC.
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Concluding remarks
In summary, the seAFOod polyp-prevention trial has demonstrated that the ω-3 PUFA EPA (2 g of FFA daily)
and aspirin (300 mg daily) did not reduce colorectal adenoma risk (measured by the ADRa) at a 1-year
surveillance colonoscopy in ‘high-risk’ individuals with colorectal neoplasia in the English BCSP. However,
chemopreventative efficacy of both agents was observed, as measured by the reduction in colorectal
adenoma number per patient at surveillance colonoscopy. The colorectal adenoma subtype- and location-
dependent specificity of EPA and aspirin are consistent with previous observations. Existing data on CRC
risk reduction by aspirin suggest that the colorectal adenoma risk reduction observed for both agents is
likely to translate into a clinically meaningful decrease in long-term CRC risk. Both agents were safe and
well tolerated in patients aged 55–75 years with ‘high-risk’ colorectal neoplasia, although EPA therapy
alone was associated with a slight excess of mild to moderate GI AEs. There was no difference in
tolerability of the two EPA formulations used in the trial.
Results in context
Despite several decades of research into the efficacy of several drug (e.g. aspirin, selective COX-2 inhibitors)
and nutrient (e.g. folic acid, vitamin D, ω-3 PUFAs) interventions for chemoprevention of CRC, meaningful
translation into clinical practice has yet to occur.153 The weight of the evidence that long-term (> 5 years) use
of aspirin is associated with a ≈25% decrease in the risk of CRC incidence and mortality, particularly marked
for proximal CRC (the predominant interval CRC type during colonoscopy screening and surveillance, as well
as the CRC type not afforded protection by FS screening),46–48 makes the lack of ‘effectiveness’ trials driving
clinical use of this agent even more surprising.
One reason for this lack has been the dependency on the polyp-prevention trial, using the colorectal
adenoma as an accepted surrogate biomarker of CRC risk,49 in the absence of direct data regarding how a
decrease in either colorectal adenoma incidence (ADRa) or number (MAP) translate into subsequent CRC
risk reduction.
Historically, the ADRa has been favoured as the colorectal adenoma end point of choice in polyp-prevention
trials. The ADRa may be considered the most relevant end point related to the use of a CRC chemoprevention
agent to reduce the frequency of, or need for, endoscopic surveillance of patients with previous colorectal
neoplasia, stratification for which is based largely on colorectal adenoma incidence.30–33 Whether or not
the use of a CRC chemoprevention agent will lead to a significant reduction in the amount of surveillance
colonoscopy performed is a question that can be addressed only by ‘effectiveness’ studies in which long-term
use of a concurrent chemoprevention agent and surveillance colonoscopy requirement are observed using a
‘big-data’ linkage approach or perhaps a ‘point-of-care’ randomised trial.
Reduction in colorectal adenoma multiplicity (MAP) arguably has more biological meaning as a read-out
of reduced colorectal neoplastic risk associated with a potential CRC chemoprevention agent, hence its
widespread use in FAP trials and pre-clinical studies.37,61 This read-out is more suited to consideration of a
chemoprevention agent for long-term CRC risk reduction, as opposed to more efficient use of colonoscopic
surveillance for benign colorectal neoplasia. Consistent with use of colorectal adenoma number as a
biomarker of future CRC risk in chemoprevention trials, observational data suggest that colorectal adenoma
multiplicity at baseline endoscopy is associated with increased CRC incidence and mortality compared with
the general population.40–42 Moreover, a pooled analysis of eight prospective colonoscopy surveillance
studies reported that initial colorectal adenoma number at colonoscopy predicts subsequent advanced
colorectal neoplasia (advanced colorectal adenoma and CRC combined), in a stepwise manner with
increasing baseline colorectal adenoma number.139
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The seAFOod trial data on colorectal adenoma number, as well as existing MAP data for aspirin,115,117,118
should focus more attention on the further validation of colorectal adenoma number as a colonoscopic
end point, particularly given that colonoscopy performance and reporting has improved significantly,
leading to better routine data quality on colorectal adenoma characteristics.
Strengths and limitations
Trial design
A key strength of the seAFOod trial was integration in the English BCSP, which continues colonoscopic
surveillance in the BCSP, unlike in Scotland, where ongoing surveillance responsibility is passed to general
endoscopy services. This provided several advantages to the trial, including:
l consistent high-quality colonoscopy performance and reporting above that available in general
colonoscopy populations
l accurate screening colonoscopy data from the BCSP, with which to predict screening colonoscopy
outcomes for recruitment projections
l uniform, protocol-driven care within the BCSP, particularly the small window for the 12-month
surveillance colonoscopy in the BCSP, despite high procedural pressure in NHS endoscopy units
l use of a ‘high-risk’ surveillance cohort and 1-year colonoscopy outcomes, which minimised the
intervention period compared with previous polyp-prevention trials,34–36,141,143 with consequent time and
cost savings.
Another strength was the comprehensive seAFOod trial biobank with careful QA control. The biobank will
be critical for further biomarker-driven, stratified analysis of the trial data. Availability of dietary and tissue
biomarker data for the ω-3 PUFA intervention allowed interpretation of the EPA effect on colorectal
outcomes, analysis of which could be confounded by dietary and OTC ω-3 PUFA exposure.
The small number of advanced colorectal adenomas found during the seAFOod trial is a limitation and
probably relates to the short surveillance interval, as well as the excellent quality of the clearance screening
colonoscopy. Previous polyp-prevention trials have reported an advanced ADRa of ≈10% in the placebo
group of patient populations, approximating to combined ‘high-risk’ and ‘intermediate-risk’ BCSP patients
with more heterogeneous follow-up (1–5 years).34,36,141,143 Detailed data on advanced ADRa and MAP at
surveillance colonoscopy were not available from the BCSP when the seAFOod trial was designed but are
now available from the seAFOod trial and other reports98 in order to determine the feasibility of using
advanced neoplasia as a primary or main secondary outcome.
As the first chemoprevention CTIMP in the BCSP, the outcome and performance data from the seAFOod trial
will be invaluable for any future polyp-prevention trial (see Chapter 5, Recommendations for research). The
seAFOod trial has established the BCSP as a realistic vehicle for interventional research during the endoscopy
phase of the patient pathway.
Trial performance
Failure to reach the recruitment target
Although the BCSP sites provided a large number of potential ‘high-risk’ trial participants at a constant
rate, consistent with well-characterised colonoscopy outcomes after guaiac FOBt screening,95 recruitment
of ‘high-risk’ individuals after screening colonoscopy (18%) was significantly lower than projected (60%)
owing to several factors, which included:
l Exclusion because of increasing use of antiplatelet agents, such as clopidogrel, although concurrent
aspirin use (19%) occurred almost as predicted from pilot data (20%).
l Exclusion because of the need for additional endoscopic assessment in the BCSP, which varied significantly
across BCSP sites/different BCSP colonoscopists and had not been reported prior to trial design.
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l Unwillingness of patients to take part in the trial. Acceptability of the trial was not tested in a pilot
study, nor subjected to broader PPI assessment prior to opening, except for the lay input provided by
the PPI representative in the application team (a BCSP colonoscopy patient) and the review inherent in
both Research Ethics Service and BCSP Research Advisory Committee assessments. Assumptions about
a high acceptability level for the trial were based on the necessary prior engagement of ‘high-risk’
individuals in the BCSP, the recent provision of a diagnosis that stratified potential participants who
were at a higher risk of future CRC, and a short intervention period prior to a subsequent routine
colonoscopy with no change to normal BCSP practice. Anecdotally, a major reason for unwillingness to
join this CTIMP after the screening colonoscopy was patient relief at not having CRC (all patients are
informed that there is a 1 in 10 chance of CRC at colonoscopy, prior to the procedure) and a strong
desire to ‘forget about my colon for a while’, at least until surveillance colonoscopy.
l Limited research experience of some BCSP staff, coupled with reluctance to discuss research
participation during routine clinical care episodes, may have contributed to a high screen failure rate.
There was a lengthy ‘lag time’ at many sites between local R&D approval and FPFV, which contributed
significantly to reduced overall recruitment.
Although recruitment reached only 83% (n = 709) of the target (853 randomised participants), we do not
believe that the smaller sample size affected the primary results of the trial because the 95% CI for the risk
difference in ADRa for both EPA and aspirin did not include –10%. Therefore, assuming no change in the
point estimate, a larger sample size would tend only to decrease the width of the CI, thereby moving the
lower 95% CI limit further from the hypothesised absolute risk difference of –10%.
Capsule investigational medicinal product switch
The need to switch capsule IMP during the trial was unforeseen, beyond the control of the TMG and very
disruptive to recruitment for at least 12 months, especially for BCSP sites that exhausted IMP stock and
had to suspend recruitment for several months.
The potential consequences of a switch in one of the IMPs for analysis of the trial results was given very
careful consideration. After extensive discussions between the TMG, oversight committees and the funder
(which also sought anonymous peer review), it was concluded that the proposed replacement active IMP
(90% EPA-TG) was sufficiently similar to the original active IMP (EPA-FFA) in terms of content, FFA-equivalent
dose and probable bioavailability to continue the trial, on the basis that colorectal adenoma outcome data
from those who received EPA-FFA or EPA-TG could almost certainly be combined. This potential threat to
trial integrity has now become a unique aspect of the trial whereby two different (2-g FFA dose equivalent)
EPA formulations have been compared in a RCT, demonstrating no clear difference in either tolerability or
EPA bioavailability (as measured by RBC and rectal mucosal EPA content) during dosing over several months.
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Chapter 5 Conclusions
Parts of this chapter have been reproduced from Hull et al.1 © 2018 The Author(s). Published by Elsevier Ltd.
This is an Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Implications for health care
Although there was no difference in the ADRa across treatment groups in the seAFOod trial, the decrease
in total colorectal adenoma number associated with aspirin and its selectivity for proximal colorectal
adenomas and serrated polyps adds to a substantial body of evidence that, although aspirin use is
associated with overall CRC risk reduction in unselected groups,46–48 there are patient groups for whom,
and clinical situations in which, additional benefit from aspirin chemoprevention might be gained. For
example, these data are the first randomised trial data to bolster the argument that individuals with the
rare, but increasingly recognised (in screening programmes), hyperplastic-serrated polyposis syndrome
might benefit from aspirin prophylaxis, as well as those with ‘sporadic’ serrated polyps.154 Moreover,
further evidence that there is proximal colonic selectivity for aspirin CRC chemoprevention highlights
potential uses of aspirin in concert with FS screening and for reduction of clinically important PCCRCs,
which are more commonly proximal than screen-detected CRCs.15
In the absence of any effect of 2 g of EPA daily on the total colorectal ADRa in the seAFOod trial and
numerically small effects on colorectal number (MAP) and incidence rate (ADRa) in the left/distal colorectum
only, no firm guidance about ‘nutraceutical’ EPA use, dietary ω-3 PUFA intake or use of RBC ω-3 PUFA as
a predictive risk biomarker, in the context of CRC risk reduction, can be made prior to further exploratory,
hypothesis-generating analysis of the seAFOod trial data and biobank samples (see Recommendations for
research). However, even small chemoprevention benefit from EPA is likely to be accepted and taken up
by a significant proportion of the public, who might consider that ω-3 PUFAs have wider health benefits.
Recommendations for research
The seAFOod trial data available to date will stimulate a debate about how the colorectal adenoma is
best used as an ‘efficacy’ RCT end point. The colorectal adenoma can be viewed solely as an endoscopic
biomarker of carcinogenic potential, and hence CRC risk, but also as a clinically important lesion, the
presence of which prompts endoscopic removal and stratification for future endoscopy, with implications
for endoscopy provision. This distinction is key to how CRC chemoprevention is viewed: as a long-term
strategy for reduction in CRC risk and/or as adjuvant therapy for those in endoscopic screening/surveillance
programmes with a view to decreasing need for colonoscopy. The lack of effect on total ADRa of either
EPA or aspirin (and absence of any short-term reduction in colonoscopy frequency with no shift from
‘high’ to ‘intermediate’ risk classification) argues against a role as adjuvant therapy for those in endoscopic
screening/surveillance programmes. By contrast, a reduction in MAP suggests chemopreventive activity that
may manifest eventually as reduced CRC incidence. It will be important to determine long-term colonoscopy
and CRC outcomes in the seAFOod trial participants using routinely collected BCSP data and National
Cancer Registration and Analysis Service (NCRAS) data. Trial participants have already provided consent
for use of long-term, post-trial data. Although the small sample size of the seAFOod trial cohort is likely to
provide insufficient CRC diagnoses to provide a meaningful comparison, analysis of subsequent colonoscopy
frequency and colorectal adenoma outcomes should be able to test whether or not short-term treatment
provides longer-term chemoprevention of colorectal adenomas (with the weakness that ongoing aspirin or
ω-3 PUFA use will not be known). An Office for Data Release request to Public Health England will be made
prior to gaining approval from the BCSP Research Advisory Committee for this follow-up study.
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Future ‘effectiveness’ evaluation of the two seAFOod trial interventions will be dependent on whether or
not colorectal adenoma number (MAP) is used as a CRC risk biomarker. Including the seAFOod trial, there
are now four independent RCTs (Table 39) that have reported on colorectal adenoma number associated
with aspirin use.115,117,118 A key piece of work will be to attempt a meta-analysis of the colorectal adenoma
number data from these trials to derive an overall colorectal adenoma risk reduction ratio for aspirin use
that can be aligned with the observational data on CRC risk reduction, to propose a clinically meaningful
MAP reduction value.
The observation that both EPA and aspirin have selectivity for CRC chemopreventive activity based on
colorectal adenoma type and location prompts the question as to whether or not a precision-stratified-
medicine approach to CRC chemoprevention can be taken whereby baseline colorectal adenoma features
can be used to predict the type and/or location of colorectal adenoma recurrence and, therefore, best
‘personalised’ chemoprevention with a given chemoprevention agent. The detailed trial data set on
endoscopic and histological features of baseline colorectal adenomas can be used to investigate the
relationship between baseline colorectal adenoma features (location, type, number) and recurrence in the
placebo-only group of the seAFOod trial. Other post-polypectomy tissue biomarkers may have utility for
prediction of aspirin and EPA efficacy, such as tissue COX-2 expression.83 A recent study has demonstrated
that COX-2 and 15-prostaglandin dehydrogenase (PGDH) expression (combined to provide a surrogate
marker of tissue PGE2 content) in baseline colorectal adenomas predicts the chemopreventive efficacy of
the selective COX-2 inhibitor celecoxib,155 building on the previous data from the APACC trial.83 To this
end, formalin-fixed, paraffin-embedded (FFPE) polypectomy specimens from the screening colonoscopy
from the seAFOod trial placebo group can be obtained, as detailed in the trial protocol.100 Other, novel,
tissue biomarkers based on the proposed mechanism of action of the type and location specificity of EPA
and aspirin can also be tested, for example FFAR2 protein expression in FFPE polypectomy specimens, but
also in the non-neoplastic rectal mucosal samples available in the seAFOod trial biobank. Rectal mucosal
samples will be invaluable for investigation of any ‘field effect’ mucosal biomarker with predictive value for
colorectal adenoma type recurrence.
The intriguing observation that combined EPA and aspirin use in the seAFOod trial was associated with
fewest total and left-sided colorectal adenomas, when comparing across the four treatment groups,
suggests that the two agents might have an additive relationship for CRC chemoprevention (with the
additional, beneficial feature that aspirin co-therapy may improve tolerability of EPA treatment). In the first
instance, an exploratory analysis of the predictive value of the baseline/post-intervention RBC and/or post-
intervention rectal mucosal EPA level for the reduction in total and left MAP associated with aspirin should
be performed in order to strengthen the case for an ‘efficacy’ RCT of combined aspirin–EPA (or mixed ω-3
PUFA) treatment or stratified (by baseline EPA level) aspirin use.
Two large RCTs of mixed ω-3 PUFA treatment are due to report in the near future. The ASCEND (A Study
of Cardiovascular Events iN Diabetes) trial (NCT00135226)156 is a 2 × 2 factorial study of long-term (median
7.5 years) ω-3 PUFAs (840 mg of EPA/DHA EEs daily) and aspirin (100 mg daily) treatment for prevention of
cardiovascular and cerebrovascular events in patients with diabetes (n = 15,480). Cancer outcomes are a
secondary end point with the ability to continue with post-trial follow-up. VITAL (VITamin D and OmegA 3
TABLE 39 Summary of MAP data from aspirin polyp-prevention trials
Study Dose (mg) Duration
Total MAP (SD)
Statistical testPlacebo Active
Sandler et al.118 325 Median 12.8 months 0.49 (0.99) 0.30 (0.87) p = 0.003
Benamouzig et al.115 160/300 12 months 0.86 (0.30) 0.45 (0.15) p = 0.01
Logan et al.117 300 Mean 3–3.5 years 0.47 (0.92) 0.31 (0.70) p = 0.015
The seAFOod trial 300 12 months 1.6 (2.1) 1.2 (1.5) IRR 0.78 (95% CI 0.68 to 0.90)
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TriaL) (NCT01169259) is a 2 × 2 factorial study of the same dose and formulation of ω-3 PUFAs (840 mg of
EPA/DHA EEs) and vitamin D3 (2000 IU daily) in 25,871 participants.157 Colorectal cancer is a specified
secondary outcome. It will be very interesting to interpret the results of the ASCEND trial and VITAL in the
light of the seAFOod trial data, particularly in relation to CRC location. It should be noted that both trials
tested a smaller dose of mixed ω-3 PUFAs than the daily dose of EPA employed in the seAFOod trial.
The data on recruitment performance and placebo group outcomes will be invaluable for any future CRC
chemoprevention RCT set in the BCSP. A key lesson is that the ADRa seems to lack discriminatory power,
at least in the ‘high-risk’ colorectal adenoma cohort investigated in the seAFOod trial, given that the
intervention with known chemopreventive efficacy (aspirin) did not demonstrate an ADRa signal.
As discussed earlier, the comprehensive data set of PUFA levels in RBCs and rectal mucosa at baseline and
after ‘nutraceutical’ EPA intervention should prompt an analysis of the predictive value of individual ‘EPA
status’ at baseline and after intervention, independent of allocation to active EPA or placebo, for colorectal
adenoma reduction. An understanding of whether or not ‘EPA high’ status is associated with reduced
colorectal adenoma recurrence, regardless of whether or not EPA supplementation was provided, may
have important consequences for dietary ω-3 PUFA guidelines and possible measurement of ω-3 PUFA
status for CRC risk stratification.
The seAFOod trial biobank is also a rich resource of pre- and post-treatment plasma and urine samples,
with which to extend and strengthen the tissue biomarker analysis. For example, parallel measurement of
urinary PGE-M levels (the main metabolite of PGE2) may provide further insight into the use of baseline
colorectal adenoma COX-2/15-PGDH/PGE2 status127 and was originally specified in the trial protocol.100
The possible additive relationship between EPA and aspirin observed for total and left MAP justifies the
use of the biobank repository to address the hypothesis that RvE1 is measurable in plasma samples from
individuals treated with EPA, with and without aspirin, as described in the trial protocol.100
The seAFOod trial data should drive several studies aimed at understanding the mechanism(s) of action of
both interventions. Differential preventative activity against conventional and serrated pathway lesions by
EPA and aspirin has highlighted the relatively poor characterisation of the molecular phenotype of colorectal
adenomas compared with CRC,4,154 as well as the continuing lack of understanding of mechanism(s) of
action of both agents. Further in vitro studies (using human CRC cells) of aspirin and EPA should use
representative cellular models of CIN, MSI-H and CIMP+ phenotypes.158 The tumour immunology of the
colorectal adenoma has been largely ignored, perhaps because of the relative difficulty in collecting
sufficient, fresh human colorectal adenoma tissue and absence of a suitable animal model.159 However,
regulation of host immune surveillance as a mechanism of primary CRC chemoprevention activity remains a
valid hypothesis for both seAFOod trial interventions.160 We have recently reported that mixed ω-3 PUFA
treatment is associated with an increase in abundance of SCFA-producing bacteria in the colon.129 The
hypothesis that the propensity for EPA benefit in the distal colorectum relates to increased anticarcinogenic
SCFA-FFAR2 signalling132 should now be tested by measuring stool SCFA concentrations in human studies,
in parallel with FFAR2 expression studies using rectal mucosa from the seAFOod trial biobank.
The seAFOod trial biobank contains a blood leucocyte sample for genomic DNA extraction for nearly all
participants, as well as individual participant consent to perform genetic single nucleotide polymorphism
studies relevant to CRC risk and both interventions. The results of the ω-3 PUFA biomarker analyses above
will generate hypotheses about which genetic polymorphisms that are known to control ω-3 PUFA
levels,161 for example fatty acid desaturase (FADS) genes, should be characterised in parallel with the
dietary analysis.
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Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to
anonymised data may be granted following review.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 2 Aspirin Summary of Product
Characteristics
Reproduced with permission from Bayer AG.
Prescribing information
(Summary of Product Characteristics / SPC)
1. Name of drug product
Aspirin® protect 300 mg
Enteric-coated tablet
Acetylsalicylic acid 
2. Qualitative and quantitative composition 
1 enteric-coated tablet contains: 300 mg acetylsalicylic acid (Ph.Eur.).
For the full list of excipients, see section 6.1. 
3. Presentation
Enteric-coated tablets 
4. Clinical data
4.1 Indications
Reinfarction prophylaxis.
Note: 
Aspirin protect 300 mg is not foreseen for the treatment of pain. 
4.2 Posology and method of administration
Posology
For reinfarction prophylaxis 
A daily dose of one Aspirin protect 300 mg enteric-coated tablets (equivalent to 300 mg
acetylsalicylic acid per day) is recommended.
Method of administration 
The enteric-coated tablets should be taken with plenty of water, preferably at least 30 min
before a meal. 
Enteric-coated tablets should not be crushed, broken or chewed in order to ensure release in
the alkaline environment of the intestine.
For treatment of acute myocardial infarction, the first tablet should be bitten or chewed.
Aspirin protect 300 mg is intended for long-term use. The attending doctor must decide on 
the length of the treatment. 
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4.3 Contraindications 
Aspirin protect 300 mg must not be used: 
- in cases of hypersensitivity to the active ingredient acetylsalicylic acid, other salicylates
or any of the other ingredients listed in section 6.1 
- by patients with asthma attacks in the history which were caused by salicylates or
substances with a similar action, especially nonsteroidal anti-inflammatory drugs;
- by patients with acute gastrointestinal ulcers;
- by patients with haemorrhagic diathesis;
- by patients with liver- or kidney failure; 
- by patients with severe heart failure for which they are not receiving adequate
treatment; 
- in combination with methotrexate at a weekly dosage of 15 mg or more (see section 
4.5); 
- in the last trimester of pregnancy at dosages above 150 mg acetylsalicylic acid/day (see 
section 4.6). 
4.4 Warnings and other precautionary measures
Particularly careful medical supervision is required:
- in cases of hypersensitivity to other analgesic/anti-inflammatory/antirheumatic drugs or
other allergenic substances (see section 4.3); 
- on concomitant ingestion of some non-steroidal anti-inflammatory drugs (NSAIDs), 
such as ibuprofen and naproxen. These may weaken the anti-platelet effect of
acetylsalicylic acid. Patients should be advised to talk to their physician if they are 
taking acetylsalicylic acid and are intending to take NSAIDs ( see section 4.5). 
- by patients with other allergies (e.g. with skin reactions, itching, nettle rash);
- by patients with bronchial asthma, hay fever, swelling of the nasal mucosa (nasal
polyps), chronic respiratory tract diseases; 
- in concomitant therapy with anticoagulant drugs;
- with a history of gastrointestinal ulcers or gastrointestinal bleeding;
- with impaired liver function;
- in patients with impaired renal function or patients with impaired cardiovascular
circulation (e.g. renal vascular disease, congestive heart failure, volume depletion, 
major surgery, sepsis or major hemorrhagic events), since acetylsalicylic acid may 
further increase the risk of renal impairment and acute renal failure; 
- by patients who are about to undergo surgery (including minor surgery such as dental
extractions): the bleeding tendency can be increased.
- in patients suffering from severe glucose-6-phosphate dehydrogenase (G6PD)
deficiency, acetylsalicylic acid may induce hemolysis or hemolytic anemia. Factors that
may increase the risk of hemolysis are e.g. high dosage, fever or acute infections;
Special instructions: 
At low doses acetylsalicylic acid reduces the excretion of uric acid. This may cause a gout
attack in predisposed patients.
Paediatric population 
Aspirin protect 300 mg should not be taken by children or adolescents with feverish
illnesses unless they have been instructed to do so by a doctor and other therapeutic
measures have failed. Prolonged vomiting in conjunction with such illnesses could be a 
sign of Reye’s syndrome, a very rare but life-threatening disease which requires immediate 
medical attention. 
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Drugs containing acetylsalicylic acid should not be taken for prolonged periods or at high
doses without consulting a doctor.
4.5 Interactions with other substances and other forms of interaction 
Enhanced effects ranging up to an increased risk of side effects:
- Anticoagulants / Thrombolytics: Acetylsalicylic acid can increase the risk of bleeding 
when taken before thrombolytic treatment. Attention should therefore be paid for signs 
of external or internal bleeding (e.g. bruising) in patients who are scheduled to undergo 
thrombolytic treatment.
- Antiplatelet drugs, e.g. ticlopidine, clopidogrel: the bleeding time can be prolonged.
- Other nonsteroidal anti-inflammatory drugs and antirheumatics in general: risk for 
gastrointestinal ulcers and haemorrhages is increased. 
- Systemic glucocorticoids (with the exception of hydrocortisone as replacement therapy 
for Addison’s disease): increased risk for gastrointestinal side effects.
- Alcohol: elevated risk of gastrointestinal ulcers and - bleeding.
- Digoxin: elevated plasma level
- Antidiabetics: the blood glucose level can be reduced. 
- Methotrexate: decrease in elimination and displacement from protein binding sites by
salicylates.
- Valproic acid: displacement from protein binding sites by salicylates.
- Selective-Serotonin-Re-uptake Inhibitors (SSRIs): elevated risk of gastrointestinal
bleeding due to synergistic effects.
Weakening of effects:
- Aldosterone antagonists (spironolactone and canrenoate).
- Loop diuretics (e.g. furosemide). 
- Antihypertensives (especially ACE inhibitors).
- Uricosuric agents (e.g. probenecid, sulphinpyrazone).
- NSAIDs: Concomitant use (on the same day) of some NSAIDs (except acetylsalicylic
acid), such as ibuprofen and naproxen, may weaken the irreversible anti-platelet effect
of acetylsalicylic acid. The clinical relevance of this interaction is not known. The 
treatment of patients who have an elevated cardiovascular risk with some NSAIDs, 
such as ibuprofen or naproxen, may limit the cardioprotective effect of acetylsalicylic
acid (see section 4.4).
Accordingly, patients should not take Aspirin protect 300 mg in conjunction with any of
the above-mentioned substances unless expressly instructed to do so by a doctor.
4.6 Pregnancy and breast-feeding 
Pregnancy 
Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the 
embryo/fœtal development. Data from epidemiological studies raise concern about an
increased risk of miscarriage and of malformations after the use of a prostaglandin 
synthesis inhibitor in early pregnancy. The risk is believed to increase with dose and 
duration of therapy.
Previous experience with administration of ASA at daily doses of 50 to 150 mg in the 
second and third trimesters of pregnancy has not produced any evidence of inhibition of
labour, an elevated tendency to bleed or premature closure of the ductus arteriosus. 
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No information is available for daily doses between 150 and 300 mg. In the last trimester
of pregnancy, administration of analgesic doses of ASA may, as a result of inhibited 
prostaglandin synthesis, cause prolonged gestation, inhibition of labour and, from the 28th-
30th week of pregnancy, premature closure of the ductus arteriosus. At these doses, there 
may also be an increased tendency to bleeding in both mother and child, as well as an
increased incidence of intracranial haemorrhage in preterm babies if ASA is administered 
shortly before birth. 
1st and 2nd trimester
During the first and second trimesters of pregnancy, Aspirin protect 300 mg should only be
prescribed at daily doses of up to 300 mg ASA if strictly indicated. 
3rd trimester
Administration of a daily dose of up to 150 mg ASA in the 3rd trimester should likewise 
only be prescribed if urgently indicated. In the last trimester of pregnancy, administration 
of Aspirin protect 300 mg at daily doses of 150 mg ASA and above is contraindicated (see 
section 4.3). 
Breast-feeding 
Small quantities of the active ingredient acetylsalicylic acid and their metabolites pass into
breast milk. Detrimental effects on the infant have not been reported to date, it is therefore 
not necessary to interrupt breast-feeding if the daily dose does not exceed 150 mg. The 
infant should be weaned if higher doses are taken (more than 150 mg daily).
4.7 Effects on the ability to drive and use machines
Acetylsalicylic acid has no influence on the ability to drive and to use machines. 
4.8. Undesirable effects
The following incidence rating is used to evaluate the frequency of side effects:
Very common:
Common:
Uncommon:
Rare:
Very rare:
Not known: Frequency cannot be estimated from the available data
Blood and lymphatic system disorders:
Rare to very rare serious bleedings, such as cerebral bleeding, especially in patients with
uncontrolled hypertension and/or concomitant treatment with anticoagulants, which in
isolated cases may be potentially life-threatening, have been reported. 
Hemolysis and hemolytic anemia in patients with severe forms of glucose-6-phosphate
dehydrogenase (G6PD) deficiency have been reported. 
Bleeding, e.g. nosebleeds, bleeding gums, cutaneous bleeding or urogenital bleedings, 
possibly with prolongation of the bleeding time (see section 4.4). This effect can persist for 
4 to 8 days after use.
Immune system disorders:
Rare:
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- Hypersensitivity reactions of the skin, respiratory tract, gastrointestinal tract and 
cardiovascular system, especially in asthmatics. Symptoms could be: hypotension, 
attacks of dyspnoea, rhinitis, nasal congestion, anaphylactic shock or angioneurotic
oedema. 
Metabolism and nutrition disorders:
Very rare:
- Hypoglycaemia, 
- Acetyl salicylic acid at low dosage reduces uric acid excretion. This may cause a gout
attack in predisposed patients.
Nervous system disorders:
Headaches, dizziness, impaired hearing ability, tinnitus and mental confusion may be signs 
of overdose (see section 4.9). 
Gastrointestinal disorders: 
Common:
- Gastrointestinal disorders such as heartburn, nausea, vomiting, abdominal pain and 
diarrhoea.
- Minor blood loss from the gastrointestinal tract (micro haemorrhaging)
Uncommon: 
- Gastrointestinal ulcers which in very rare cases can lead to perforation. 
- Gastrointestinal bleedings. 
Long-term use of Aspirin protect 300 mg may cause iron deficiency anaemia due to
occult blood loss from the gastrointestinal tract.
- Gastrointestinale Entzündungen. 
If you pass black stools (tarry stools) or vomit blood, both of which are a sign of serious
bleeding in the stomach, you must inform your doctor immediately.
Hepatobiliary disorders:
Very rare:
- Elevated liver values. 
Skin and subcutaneous tissue disorders: 
Uncommon: 
- Skin reactions (very rare cases ranging up to erythema exsudativum multiforme).
Renal and urinary disorders:
Very rare:
- Renal impairment and acute renal failure have been reported.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal 
product. Healthcare professionals are asked to report any suspected adverse reactions
via 
Bundesinstitut für Arzneimittel und Medizinprodukte 
Abt. Pharmakovigilanz
Kurt-Georg-Kiesinger Allee 3 
D-53175 Bonn
Website: http//www.bfarm.de
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4.9 Overdose 
A distinction is made between chronic acetylsalicylic acid over dosage with predominantly
central nervous manifestations such as drowsiness, dizziness, confusion or nausea 
("salicylism") and acute intoxication. 
The cardinal feature of acute intoxication with acetylsalicylic acid is severe disruption of
the acid-base balance. Even in the therapeutic dose range, respiratory alkalosis occurs as a 
consequence of increased respiration. This is compensated by increased renal excretion of
bicarbonate, which normalises the blood’s pH value. At toxic dosages, the level of
compensation is no longer sufficient and both the pH value and the bicarbonate
concentration in the blood drop. The plasma PCO2 value may be temporarily normal. The 
apparent clinical picture is that of metabolic acidosis. However, the actual condition is a 
combination of respiratory and metabolic acidosis. The causes are: Respiratory restriction 
caused by toxic doses, acid accumulation, partially due to decreased renal excretion 
(sulphuric acid, phosphoric acid, salicylic acid, lactic acid, acetoacetic acid etc.) caused by
impairment of carbohydrate metabolism. This is compounded by impairment of electrolyte
balance. Major potassium loss occurs.
Symptoms of acute intoxication 
Symptoms of milder acute intoxication (200 - 400 µg/ml): 
In addition to disruption of the acid-base balance and electrolyte balance (e.g. potassium
loss), hypoglycaemia, skin rashes and gastrointestinal haemorrhaging, hyperventilation, 
tinnitus, nausea, vomiting, disturbed vision and hearing, headache, dizziness and confusion 
have been observed. 
With severe intoxication (above 400 µg/ml), delirium, tremor, difficult breathing, sweating,
dehydration, hyperthermia and coma may occur.
In the event of intoxication with a fatal outcome, death usually occurs as a result of
respiratory failure. 
Treatment of intoxication 
The therapeutic measures for treatment of intoxication with acetylsalicylic acid depend 
upon the extent, stage and clinical symptoms of the intoxication. They comprise the 
standard measures for decreasing absorption of the active ingredient, monitoring of the 
water and electrolyte balances, impaired temperature regulation and respiration.
Treatment is focused on measures to accelerate excretion and normalise the acid-base
balance and the electrolyte balance. Infusion solutions of sodium hydrogen carbonate and 
potassium chloride and diuretics are administered. The urine reaction should be alkaline to
increase the degree of salicylate ionisation and decrease the rate of back-diffusion to the 
tubules. 
Monitoring of the blood values (pH, PCO2, hydrogen bicarbonate, potassium, etc.) is
strongly recommended. In severe cases, haemodialysis may be necessary. 
5. Pharmacological properties 
5.1 Pharmacodynamic properties 
Pharmacotherapeutic group: Antithrombotic agents, Platelet aggregation inhibitors, 
acetylsalicylic acid. 
ATC class: B01AC06 
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Acetylsalicylic acid has an irreversible platelet aggregation-inhibiting action. This
antiplatelet effect is achieved by acetylation of cyclooxygenase, irreversibly inhibiting the 
formation of thromboxane A2 (a prostaglandin with a platelet aggregation-promoting and 
vasoconstrictive action) in the platelets. The effect is long-term and usually persists for the 
entire eight-day lifespan of a platelet.
Paradoxically, acetylsalicylic acid also inhibits the formation of prostacyclin (a
prostaglandin with platelet aggregation-inhibiting but vasodilating effects) in the 
endothelial cells of the vascular walls. This effect is transient.
Once the acetylsalicylic acid has been washed out of the blood, the nucleated endothelial 
cells resume their production of prostacyclin. 
As a consequence, once daily administration of low- 300 mg / day) acetylsalicylic
acid causes inhibition of thromboxane A2 in the platelets without markedly impairing
prostacyclin formation. 
Acetylsalicylic acid also belongs to the class of acid-forming nonsteroidal anti-
inflammatory drugs with analgesic, antipyretic and anti-inflammatory properties. Its 
mechanism of action is based on irreversible inhibition of cyclooxygenase enzymes 
involved in prostaglandin synthesis.
Acetylsalicylic acid is used at higher oral doses to treat mild to moderate pain, elevated
temperature and acute and chronic inflammatory diseases (e.g. rheumatoid arthritis).
Experimental data suggest that ibuprofen may inhibit the effect of low dose acetylsalicylic
acid on platelet aggregation when they are dosed concomitantly. In one study, when a 
single dose of ibuprofen 400 mg was taken within 8 h before or within 30 min after 
immediate release aspirin dosing (81 mg), a decreased effect of ASA on the formation of
thromboxane or platelet aggregation occurred. However, the limitations of these data and 
the uncertainties regarding extrapolation of ex vivo data to clinical situation imply that no
firm conclusion can be made for regular ibuprofen use, and no clinically relevant effect is
considered to be likely for occasional ibuprofen use.
5.2 Pharmacokinetic properties 
Acetylsalicylic acid is converted before, during and after absorption into its main
metabolite salicylic acid. The metabolites are excreted primarily via the renal route.
In addition to salicylic acid, the main metabolites of acetylsalicylic acid are the glycine 
conjugate of salicylic acid (salicyluric acid), the ether and ester glucuronides of salicylic
acid (salicyl phenylglucuronide and salicyl acetylglucuronide) and gentisic acid, produced
by oxidation of salicylic acid, and its glycine conjugate.
Depending on the formulation, absorption of acetylsalicylic acid following oral
administration is rapid and complete. The residual acetyl portion of acetylsalicylic acid 
undergoes partial hydrolytic cleavage during its passage through the mucous membranes 
oft the gastrointestinal tract. 
Peak plasma concentrations are attained after 10-20 min (acetylsalicylic acid) and 0.3-2 h 
(total salicylate). 
The elimination kinetic of salicylic acid is dependent to a great extent on the dose, as the 
capacity for metabolisation of salicylic acid is limited (elimination half-life fluctuates
between 2 and 30 h). 
The elimination half-life of acetylsalicylic acid is only a few minutes; the elimination half-
life of salicylic acid is 2 h after consumption of a dose of 0.5 g acetylsalicylic acid and 4 h 
after administration of 1 g; following consumption of a single dose of 5 g, the elimination 
half-life is extended to 20 h. 
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Protein binding in human plasma is dependent on the concentration; values ranging from 
49 % to over 70 % (acetylsalicylic acid) and 66 % to 98 % (salicylic acid) have been 
reported. 
Salicylic acid has been detected in cerebrospinal fluid and synovial fluid after consumption 
of acetylsalicylic acid. 
Salicylic acid crosses the placental barrier and passes into breast milk. 
 
5.3 Preclinical safety data 
The preclinical safety profile of acetylsalicylic acid is well documented. In animal tests 
salicylates caused kidney damage and gastrointestinal ulcers. 
Acetylsalicylic acid has been appropriately tested for mutagenicity and carcinogenicity; no 
relevant evidence of a mutagenic or carcinogenic potential was found. 
Salicylates have shown teratogenic effects in a number of animal species. There have been 
implantation disturbance, embryotoxic and fetotoxic effects, and learning disorders in the 
young animals after prenatal exposure. 
 
 
6. Pharmaceutical data 
 
6.1 Other ingredients 
 Maize starch 
 Cellulose powder 
 Methacrylic acid – ethylacrylate copolymer 1:1 dispersion 30% 
 Polysorbat 80 
 Sodium Dodecylsulfate 
 Talc 
 Triethyl citrate 
 
6.2 Incompatibilities 
None 
 
6.3 Shelf-life 
5 years. 
 
6.4 Special storage instructions 
Do not store at temperatures above 25°C. 
 
6.5 Type and contents of container 
PP aluminium blisters: 
Packs of 42 and 98 enteric-coated tablets; 
Not all pack sizes may be marketed. 
 
6.6 Instructions for use 
None 
 
 
7. Product license holder 
Bayer Vital GmbH, 
51368 Leverkusen 
Germany 
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8. Registration number 
16854.00.01, 30828.00.01, 33171.01.00
9. Date of registration/extension of registration 
16854.00.01: 28.12.1993 / 12.09.2007
30828.00.01: 28.12.1993 / 25.07.2007
33171.01.00: 09.10.1995 / 18.11.2013
10. Date of preparation 
03.2017
11. Prescription/pharmacy status
Pharmacy only
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Appendix 3 Summary of protocol amendments
Amendment
reference; date Amendment details
Previous version
number and date
New version number
and date
Substantial amendments (SAs)
SA02;
8 August 2011
Changes to the protocol and PIL to ensure
wording is clearer for trial personnel and
participants
seAFOod trial protocol
version 1.1, dated
14 April 2011
seAFOod trial protocol
version 2.0, dated
8 August 2011
SA04;
30 November 2011
l Inclusion criteria: lower age limit reduced
to 73 years to reflect BCSP surveillance
guidelines
l Exclusion criteria updated to exclude patients
who are taking any non-aspirin antiplatelet
therapy
seAFOod trial protocol
version 2.0, dated
8 August 2011
seAFOod trial protocol
version 3.0, dated
28 November 2011
SA06;
25 May 2012
Change to exclusion criteria to include patients
who need a second repeat screening
endoscopy, allowing inclusion of participants
who have a second screening procedure
seAFOod trial protocol
version 3.0, dated
28 November 2011
seAFOod trial protocol,
version 4.0, dated
4 May 2012
SA10;
19 June 2013
Change to inclusion criteria to include patients
identified through the bowel scope FS screening
programme
seAFOod trial protocol
version 4.0, dated
4 May 2012
seAFOod trial protocol
version 5.0, dated
17 June 2013
SA14;
14 August 2014
Changes to the protocol in line with the
introduction of the replacement capsule IMP.
This includes additional information on the new
EPA-TG formulation
seAFOod trial protocol
version 5.0, dated
17 June 2013
seAFOod trial protocol
version 6.0, dated
11 August 2014
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Appendix 4 Additional tables, listings and figures
TABLE 40 Analyses of the primary outcome without adjustment for repeat colonoscopy
Estimate (95% CI) (%)
EPA vs. no EPA Aspirin vs. no aspirin
Primary analysis (risk difference) 0.7 (–6.8 to 8.3) –1.2 (–8.7 to 6.3)
Using per-protocol population (risk difference) 1.0 (–6.7 to 8.8) –1.0 (–8.7 to 6.7)
Multilevel model treating recruiting centre and site as random effects
(odds ratio)
1.03 (0.75 to 1.42) 0.95 (0.69 to 1.31)
Multiple imputation of missing data (risk difference) 0.1 (–7.3 to 7.6) –0.7 (–8.3 to 6.8)
Adjustment of baseline variables with imbalancea (risk difference) 1.1 (–6.4 to 8.6) –1.5 (–9.0 to 5.9)
Adjustment of oily fish intake during the trial (risk difference) –1.3 (–9.5 to 6.9) –2.7 (–10.9 to 5.5)
CACE analysis taking account of treatment adherence
Binary adherence (risk difference) 0.8 (–7.1 to 8.7) –1.2 (–8.9 to 6.4)
Continuous adherence (risk difference) 0.4 (–7.3 to 8.1) –1.3 (–8.6 to 6.4)
Adjustment of EPA formulation 0.8 (–6.7 to 8.3) –1.1 (–8.3 to 7.4)
Further adjustment for baseline RBC EPA (risk difference) –2.1 (–10.2 to 5.9) 1.7 (–6.3 to 9.8)
a Adjusted for sex, whether or not the participant had diabetes and smoking status.
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TABLE 41 Listing of ADRs
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA + placebo aspirin Heartburn GI disorders Dyspepsia No Mild 7 March 2013 15 March 2013 Trial medications
permanently
stopped
Recovered
EPA + aspirin Abdominal pain GI disorders Abdominal pain No Moderate 5 March 2013 14 March 2013 Trial medications
permanently
stopped
Recovered
EPA + aspirin Diarrhoea GI disorders Diarrhoea No Moderate 5 March 2013 14 March 2013 Trial medications
permanently
stopped
Recovered
EPA + placebo aspirin Vomiting GI disorders Vomiting No Mild 18 February 2014 20 February 2014 No action taken Recovered
Placebo + placebo Abdominal wind GI disorders Flatulence No Mild 2 July 2013 20 August 2013 No action taken Recovered
with sequelae
EPA + aspirin Dyspepsia GI disorders Dyspepsia No Mild 22 April 2014 2 May 2014 No action taken Recovered
Placebo + placebo Indigestion GI disorders Dyspepsia No Moderate 23 August 2015 30 August 2015 Trial medications
permanently
stopped
Condition
improving
Placebo EPA+ aspirin Abdominal pain GI disorders Abdominal pain No Mild 23 October 2012 15 November 2012 Trial medications
reduced
Recovered
EPA + aspirin Gastric irritation GI disorders Epigastric
discomfort
No Mild 15 November 2015 15 November 2015 No action taken Recovered
EPA + aspirin Dyspepsia GI disorders Dyspepsia No Mild 22 February 2016 22 February 2016 Trial medication
already
discontinued
Recovered
EPA + aspirin Diarrhoea GI disorders Diarrhoea No Mild 8 June 2013 9 June 2013 Unknown Recovered
EPA + placebo aspirin Halitosis GI disorders Breath odour No Mild 16 June 2013 23 June 2013 No action taken Recovered
Placebo + placebo Diarrhoea GI disorders Diarrhoea No Mild 24 November 2013 24 November 2013 No action taken Recovered
Placebo + placebo Indigestion GI disorders Dyspepsia No Mild 3 March 2014 10 March 2014 No action taken Recovered
Placebo + placebo Indigestion GI disorders Dyspepsia No Mild 20 April 2014 21 June 2014 No action taken Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
Placebo+ placebo Halitosis GI disorders Breath odour No Mild 3 March 2014 10 March 2014 No action taken Recovered
EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 1 November 2013 N/A No action taken Condition
present and
unchanged
Placebo EPA+ aspirin Indigestion GI disorders Dyspepsia No Mild 25 February 2014 15 April 2014 No action taken Recovered
Placebo EPA+ aspirin Indigestion GI disorders Dyspepsia No Mild 30 April 2014 27 October 2014 No action taken Recovered
EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 1 July 2015 4 March 2016 No action taken Condition
present and
unchanged
EPA+ placebo aspirin Nausea GI disorders Nausea No Mild 6 November 2015 23 December 2015 Trial medications
reduced
Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 5 April 2016 16 April 2016 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Dyspepsia GI disorders Dyspepsia No Mild 5 April 2016 16 April 2016 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Nausea GI disorders Nausea No Mild 5 April 2016 16 April 2016 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Dyspepsia GI disorders Dyspepsia No Mild 24 October 2015 1 January 2016 Trial medications
reduced
Recovered
Placebo EPA+ aspirin Abdominal pain GI disorders Abdominal pain No Mild 28 April 2012 4 May 2012 No action taken Recovered
Placebo EPA+ aspirin Constipation GI disorders Constipation No Mild 28 April 2012 4 May 2012 No action taken Recovered
Placebo+ placebo Halitosis GI disorders Breath odour No Mild 16 August 2012 N/A No action taken Condition
present and
unchanged
Placebo+ placebo Acid indigestion GI disorders Dyspepsia No Mild 2 August 2012 15 August 2012 No action taken Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA + placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 19 September 2012 15 May 2013 Unknown Recovered
Placebo + placebo Rash Skin and
subcutaneous tissue
disorders
Rash No Mild 16 November 2012 8 April 2013 Trial medications
reduced
Recovered
EPA + aspirin Diarrhoea GI disorders Diarrhoea No Mild 18 July 2013 20 July 2013 No action taken Recovered
EPA + placebo aspirin Gastritis GI disorders Gastritis Yes Mild 18 October 2013 1 November 2013 No action taken Recovered
EPA + placebo aspirin Epigastric pain GI disorders Abdominal pain
upper
No Mild 27 November 2013 28 November 2013 Trial medications
permanently
stopped
Recovered
EPA + placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 14 September 2013 N/A Trial medications
reduced
Condition
present and
unchanged
Placebo + placebo Abdominal discomfort GI disorders Abdominal
discomfort
No Mild 26 January 2014 31 March 2014 Trial medications
reduced
Recovered
Placebo + placebo Indigestion GI disorders Dyspepsia No Mild 26 January 2014 31 March 2014 Trial medications
reduced
Recovered
Placebo + placebo Abdominal pain GI disorders Abdominal pain No Mild 26 January 2014 31 March 2014 Trial medications
permanently
stopped
Recovered
Placebo + placebo Epigastric pain GI disorders Abdominal pain
upper
No Mild 26 January 2014 31 March 2014 Trial medications
permanently
stopped
Recovered
EPA + placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 11 May 2014 N/A Trial medications
reduced
Condition
present and
unchanged
Placebo EPA + aspirin Diarrhoea GI disorders Diarrhoea No Mild 21 May 2012 26 May 2012 No action taken Recovered
Placebo EPA + aspirin Oesophageal bleeding GI disorders Oesophageal
haemorrhage
Yes Severe 23 July 2012 30 July 2012 Trial medications
reduced
Recovered
A
PPEN
D
IX
4
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
124
TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
Placebo EPA+ aspirin Epistaxis Respiratory, thoracic
and mediastinal
disorders
Epistaxis No Mild 5 June 2012 5 June 2012 No action taken Recovered
EPA+ placebo aspirin Anal bleeding GI disorders Anal
haemorrhage
No Mild 15 November 2012 15 November 2012 No action taken Recovered
EPA+ placebo aspirin Dyspepsia GI disorders Dyspepsia No Mild 08 December 2012 6 January 2013 No action taken Condition
improving
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Moderate 27 June 2014 26 July 2014 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 25 June 2014 26 June 2014 No action taken Recovered
EPA+ aspirin Medication aftertaste General disorders and
administration site
conditions
Product taste
abnormal
No Mild 26 December 2014 29 April 2015 No action taken Recovered
EPA+ aspirin Diarrhoea GI disorders Diarrhoea No Mild 30 May 2015 31 May 2015 No action taken Recovered
EPA+ aspirin Head pressure Nervous system
disorders
Head
discomfort
No Mild 1 April 2015 N/A No action taken Condition
present and
unchanged
EPA+ aspirin Abdominal pain GI disorders Abdominal pain No Mild 2 June 2015 3 June 2015 No action taken Recovered
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Moderate 14 July 2012 14 July 2012 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 7 June 2012 15 July 2012 No action taken Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 7 June 2012 15 July 2012 No action taken Recovered
EPA+ aspirin Bruising Injury, poisoning
and procedural
complications
Contusion No Mild 1 September 2016 N/A No action taken Condition
present and
unchanged
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA+ aspirin Abdominal pain GI disorders Abdominal pain No Mild 7 October 2013 30 October 2013 Trial medications
delayed
Recovered
Placebo+ placebo Defaecation urgency GI disorders Defaecation
urgency
No Na 1 May 2016 N/A Trial medication
period
completed
Condition
present and
unchanged
EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 30 March 2016 25 August 2016 No action taken Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain Na Moderate 1 May 2016 6 June 2016 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Nausea GI disorders Nausea No Mild 29 June 2012 6 July 2012 Unknown Recovered
Placebo EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 29 June 2012 6 July 2012 Unknown Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 21 March 2013 31 March 2013 Trial medications
reduced
Recovered
with sequelae
EPA+ aspirin Negative thoughts Psychiatric disorders Negative
thoughts
No Mild 19 April 2013 19 June 2013 Trial medications
reduced
Recovered
with sequelae
Placebo EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 22 May 2015 10 July 2015 No action taken Recovered
Placebo EPA+ aspirin Bruising Injury, poisoning
and procedural
complications
Contusion No Mild 26 May 2015 11 May 2016 No action taken Recovered
Placebo EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 2 February 2016 1 March 2016 No action taken Recovered
Placebo EPA+ aspirin Halitosis GI disorders Breath odour No Mild 15 December 2015 30 January 2016 No action taken Recovered
Placebo EPA+ aspirin Abdominal pain GI disorders Abdominal pain No Moderate 26 May 2015 N/A No action taken Condition
improving
Placebo EPA+ aspirin Headache Nervous system
disorders
Headache No Moderate 20 May 2015 22 July 2015 No action taken Recovered
Placebo EPA+ aspirin Urinary frequency Renal and urinary
disorders
Pollakiuria No Mild 20 May 2015 N/A No action taken Condition
present and
unchanged
A
PPEN
D
IX
4
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
126
TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA+ placebo aspirin Abdominal discomfort GI disorders Abdominal
discomfort
No Mild 17 January 2013 N/A No action taken Condition
present and
unchanged
EPA+ placebo aspirin Nausea GI disorders Nausea No Moderate 10 January 2013 17 January 2013 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Nausea GI disorders Nausea No Moderate 7 May 2013 16 August 2013 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 10 September 2014 N/A No action taken Condition
improving
Placebo+ placebo Halitosis GI disorders Breath odour No Mild 28 March 2013 1 June 2013 Trial medications
reduced
Recovered
EPA+ aspirin Nausea GI disorders Nausea No Mild 1 August 2013 14 August 2013 Trial medications
permanently
stopped
Recovered
Placebo+ placebo Nausea GI disorders Nausea No Moderate 3 July 2015 18 September 2015 Trial medications
permanently
stopped
Condition
present and
unchanged
Placebo+ placebo Nausea GI disorders Nausea No Moderate 19 May 2015 2 June 2015 Trial medications
permanently
stopped
Recovered
with sequelae
Placebo+ placebo Nausea GI disorders Nausea No Mild 6 June 2015 26 June 2015 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Moderate 22 June 2015 29 June 2015 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Moderate 20 May 2015 22 June 2015 Trial medications
reduced
Condition
deteriorated
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
Placebo EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 9 April 2015 20 May 2015 No action taken Condition
deteriorated
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 16 April 2012 25 May 2012 Trial medications
reduced
Recovered
Placebo EPA+ aspirin Acid reflux
(oesophageal)
GI disorders Gastro-
oesophageal
reflux disease
No Mild 15 February 2015 14 May 2015 No action taken Recovered
Placebo EPA+ aspirin Acid reflux
(oesophageal)
GI disorders Gastro-
oesophageal
reflux disease
No Moderate 30 January 2015 10 February 2015 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Acid reflux
(oesophageal)
GI disorders Gastro-
oesophageal
reflux disease
No Mild 25 December 2014 30 January 2015 Trial medications
reduced
Condition
deteriorated
Placebo EPA+ aspirin Excessive flatulence GI disorders Flatulence No Mild 10 May 2015 5 June 2015 Trial medications
reduced
Recovered
Placebo EPA+ aspirin Loose motions GI disorders Diarrhoea No Mild 10 May 2015 12 May 2015 Trial medications
reduced
Recovered
Placebo EPA+ aspirin Acid reflux
(oesophageal)
GI disorders Gastro-
oesophageal
reflux disease
No Mild 10 May 2015 2 June 2015 Trial medications
reduced
Recovered
EPA+ aspirin Acid reflux
(oesophageal)
GI disorders Gastro-
oesophageal
reflux disease
No Mild 18 May 2015 30 May 2015 No action taken Recovered
EPA+ aspirin Burping GI disorders Eructation No Mild 6 August 2015 9 August 2015 No action taken Recovered
EPA+ aspirin Burping GI disorders Eructation No Mild 5 August 2015 31 July 2016 No action taken Recovered
EPA+ placebo aspirin Exacerbation of
asthma
Respiratory, thoracic
and mediastinal
disorders
Asthma No Moderate 24 July 2016 N/A No action taken Condition
present and
unchanged
EPA+ placebo aspirin Flatulence GI disorders Flatulence No Mild 28 February 2016 N/A No action taken Condition
improving
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA+ placebo aspirin Flatulence GI disorders Flatulence No Mild 27 October 2015 11 January 2016 No action taken Recovered
EPA+ placebo aspirin Loose stools GI disorders Diarrhoea No Moderate 27 October 2016 N/A No action taken Condition
present and
unchanged
Placebo+ placebo Wind GI disorders Flatulence No Mild 19 November 2015 7 December 2015 No action taken Recovered
Placebo+ placebo Acid reflux
(oesophageal)
GI disorders Gastro-
oesophageal
reflux disease
No Mild 1 July 2016 27 October 2016 No action taken Recovered
EPA+ placebo aspirin Bloating GI disorders Abdominal
distension
No Mild 1 June 2016 4 July 2016 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 5 July 2012 3 August 2012 Trial medications
reduced
Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 5 July 2012 3 August 2012 Trial medications
reduced
Recovered
Placebo EPA+ aspirin Loose stools GI disorders Diarrhoea No Mild 16 April 2013 30 July 2013 No action taken Recovered
Placebo EPA+ aspirin Excessive flatulence GI disorders Flatulence No Mild 16 April 2013 30 July 2013 No action taken Recovered
Placebo+ placebo Oesophageal reflux GI disorders Gastro-
oesophageal
reflux disease
No Na 20 February 2013 N/A Unknown Na
EPA+ placebo aspirin Defaecation urgency GI disorders Defaecation
urgency
No Mild 7 October 2012 15 June 2013 No action taken Recovered
EPA+ placebo aspirin Hyperhidrosis Skin and
subcutaneous tissue
disorders
Hyperhidrosis No Mild 14 March 2013 15 June 2013 No action taken Recovered
EPA+ placebo aspirin Loose stools GI disorders Diarrhoea No Mild 7 October 2012 15 June 2013 No action taken Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 5 November 2012 10 December 2012 No action taken Recovered
EPA+ placebo aspirin Halitosis GI disorders Breath odour No Mild 7 October 2012 15 June 2013 No action taken Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA+ placebo aspirin Dizziness Nervous system
disorders
Dizziness No Mild 14 March 2013 15 June 2013 No action taken Recovered
Placebo EPA+ aspirin Blood in stool GI disorders Haematochezia No Mild 20 May 2013 21 May 2013 No action taken Recovered
Placebo EPA+ aspirin Blood in stool GI disorders Haematochezia No Mild 3 February 2013 4 February 2013 No action taken Recovered
Placebo EPA+ aspirin Blood in stool GI disorders Haematochezia No Mild 17 June 2013 18 June 2013 No action taken Recovered
Placebo+ placebo Diarrhoea GI disorders Diarrhoea No Mild 15 July 2013 N/A No action taken Condition
present and
unchanged
Placebo EPA+ aspirin Duodenitis GI disorders Duodenitis Yes Moderate 7 September 2013 13 September 2013 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Diarrhoea GI disorders Diarrhoea No Mild 1 October 2013 20 January 2014 No action taken Recovered
Placebo EPA+ aspirin Blood in stool GI disorders Haematochezia No Mild 5 November 2013 8 November 2013 No action taken Recovered
Placebo EPA+ aspirin Stool discolored GI disorders Faeces
discoloured
Yes Severe 30 August 2013 13 September 2013 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Reflux oesophagitis GI disorders Gastro-
oesophageal
reflux disease
Yes Moderate 7 September 2013 13 September 2013 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Dyspepsia GI disorders Dyspepsia No Mild 12 May 2014 9 September 2014 No action taken Recovered
EPA+ placebo aspirin Blood in stool GI disorders Haematochezia No Mild 21 December 2014 28 December 2014 No action taken Recovered
EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 13 January 2014 N/A No action taken Condition
improving
EPA+ aspirin Diarrhoea GI disorders Diarrhoea No Mild 10 September 2014 27 November 2014 No action taken Recovered
EPA+ aspirin Borborygmi GI disorders Gastrointestinal
sounds
abnormal
No Mild 7 April 2014 N/A No action taken Condition
present and
unchanged
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA + aspirin Halitosis GI disorders Breath odour No Mild 7 April 2014 N/A No action taken Condition
present and
unchanged
Placebo + placebo Dyspepsia GI disorders Dyspepsia No Mild 8 June 2014 N/A No action taken Condition
improving
EPA + placebo aspirin Gastric bleeding GI disorders Gastric
haemorrhage
No Mild 19 September 2014 N/A Trial medications
permanently
stopped
Condition
present and
unchanged
EPA + placebo aspirin Defaecation urgency GI disorders Defaecation
urgency
No Mild 31 March 2014 12 December 2014 No action taken Recovered
EPA + placebo aspirin Oesophagitis GI disorders Oesophagitis No Mild 19 September 2014 N/A Trial medications
permanently
stopped
Condition
present and
unchanged
EPA + placebo aspirin Flatulence GI disorders Flatulence No Mild 31 March 2014 N/A No action taken Condition
present and
unchanged
EPA + placebo aspirin Gastritis GI disorders Gastritis No Mild 19 September 2014 N/A Trial medications
permanently
stopped
Condition
present and
unchanged
EPA + placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 26 August 2014 N/A Trial medications
reduced
Condition
present and
unchanged
Placebo + placebo Stomach ache GI disorders Abdominal pain
upper
No Mild 11 August 2014 13 August 2014 No action taken Recovered
EPA + aspirin Bruising of leg Injury, poisoning
and procedural
complications
Contusion No Mild 12 February 2015 28 February 2015 No action taken Recovered
EPA + aspirin Bruising of leg Injury, poisoning
and procedural
complications
Contusion No Mild 10 September 2014 1 October 2014 No action taken Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
Placebo+ placebo Diarrhoea GI disorders Diarrhoea No Mild 1 October 2015 31 December 2015 No action taken Recovered
EPA+ placebo aspirin Dizzy Nervous system
disorders
Dizziness No Mild 1 July 2016 31 July 2016 Trial medications
reduced
Recovered
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 1 July 2016 31 July 2016 Trial medications
reduced
Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 1 July 2016 31 July 2016 Trial medications
reduced
Recovered
EPA+ placebo aspirin Burping GI disorders Eructation No Mild 1 September 2012 1 December 2012 No action taken Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 1 September 2012 1 December 2012 No action taken Recovered
EPA+ placebo aspirin Constipation GI disorders Constipation No Mild 7 August 2012 12 August 2012 No action taken Recovered
EPA+ placebo aspirin Indigestion GI disorders Dyspepsia No Mild 7 August 2012 12 August 2012 No action taken Recovered
Placebo+ placebo Stool discoloured GI disorders Faeces
discoloured
No Mild 1 March 2013 1 April 2013 No action taken Recovered
EPA+ placebo aspirin Bruising of hand Injury, poisoning
and procedural
complications
Contusion No Mild 20 July 2013 27 July 2013 No action taken Recovered
Placebo+ placebo Loose stools GI disorders Diarrhoea No Mild 1 September 2014 N/A No action taken Condition
present and
unchanged
EPA+ placebo aspirin Dyspepsia GI disorders Dyspepsia No Mild 11 April 2015 N/A No action taken Condition
present and
unchanged
EPA+ placebo aspirin Loose stools GI disorders Diarrhoea No Mild 23 April 2015 N/A No action taken Condition
present and
unchanged
Placebo EPA + aspirin Gastritis GI disorders Gastritis No Mild 27 June 2016 1 July 2016 Trial medications
permanently
stopped
Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
Placebo EPA+ aspirin Hiatus hernia GI disorders Hiatus hernia No Mild 27 June 2016 1 July 2016 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Moderate 5 March 2016 1 July 2016 Trial medications
reduced
Recovered
Placebo EPA+ aspirin Change of bowel
habit
GI disorders Change of
bowel habit
No Mild 11 November 2015 N/A No action taken Condition
present and
unchanged
EPA+ placebo aspirin Epigastric pain GI disorders Abdominal pain
upper
No Mild 14 January 2012 28 May 2012 No action taken Recovered
EPA+ placebo aspirin Belching GI disorders Eructation No Mild 14 January 2012 28 May 2012 No action taken Recovered
Placebo EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 1 February 2015 30 September
2015
No action taken Recovered
Placebo EPA+ aspirin Diarrhoea GI disorders Diarrhoea No Mild 1 September 2015 30 September
2015
No action taken Recovered
EPA+ aspirin Constipation GI disorders Constipation No Mild 9 April 2013 13 April 2013 No action taken Recovered
EPA+ aspirin Constipation GI disorders Constipation No Mild 14 February 2013 18 February 2013 No action taken Recovered
EPA+ aspirin Diarrhoea GI disorders Diarrhoea No Moderate 25 December 2012 27 December 2012 No action taken Recovered
EPA+ aspirin Diarrhoea GI disorders Diarrhoea No Moderate 4 January 2013 6 January 2013 No action taken Recovered
EPA+ placebo aspirin Constipation GI disorders Constipation No Mild 17 March 2013 28 March 2013 Trial medications
reduced
Recovered
Placebo EPA+ aspirin Change of bowel
habit
GI disorders Change of
bowel habit
No Moderate 1 August 2013 23 August 2013 Trial medications
permanently
stopped
Recovered
EPA+ aspirin Nauseous GI disorders Nausea No Moderate 3 July 2015 3 July 2015 Trial medications
permanently
stopped
Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA+ aspirin Retching GI disorders Retching No Moderate 24 April 2015 12 May 2015 Trial medications
reduced
Recovered
EPA+ placebo aspirin Loose stools GI disorders Diarrhoea No Moderate 16 March 2016 22 March 2016 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Faeces discoloured GI disorders Faeces
discoloured
No Moderate 16 March 2016 22 March 2016 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Abdominal cramps GI disorders Abdominal pain No Moderate 16 March 2016 22 March 2016 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Gout Metabolism and
nutrition disorders
Gout No Mild 8 May 2017 18 May 2017 Study med.
Period
completed
Recovered
Placebo EPA+ aspirin Headache Nervous system
disorders
Headache No Moderate 9 August 2012 28 August 2012 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Anal mucositis GI disorders Anal
inflammation
No Moderate 12 October 2015 30 July 2016 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 19 December 2015 19 December 2015 No action taken Recovered
EPA+ placebo aspirin Angioedema Skin and
subcutaneous tissue
disorders
Angioedema No Moderate 22 December 2015 23 December 2015 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 28 November 2011 5 March 2012 No action taken Recovered
Placebo+ placebo Dyspepsia GI disorders Dyspepsia No Moderate 20 March 2012 29 March 2012 Trial medications
reduced
Recovered
EPA+ aspirin Indigestion GI disorders Dyspepsia No Mild 27 February 2012 9 May 2012 No action taken Recovered
Placebo EPA+ aspirin Diarrhoea GI disorders Diarrhoea No Moderate 23 January 2016 22 March 2016 Trial medications
reduced
Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Moderate 21 August 2015 23 August 2015 Trial medications
reduced
Recovered
EPA+ placebo aspirin Gout Metabolism and
nutrition disorders
Gout No Mild 14 June 2013 27 June 2013 Trial medications
delayed
Recovered
with sequelae
Placebo+ placebo Frequent bowel
movements
GI disorders Frequent bowel
movements
No Moderate 18 December 2012 19 December 2012 Trial medications
reduced
Recovered
Placebo+ placebo Excessive flatulence GI disorders Flatulence No Moderate 18 December 2012 19 December 2012 Trial medications
reduced
Recovered
Placebo+ placebo Excessive flatulence GI disorders Flatulence No Mild 1 December 2012 19 December 2012 Trial medications
permanently
stopped
Condition
improving
Placebo+ placebo Heartburn GI disorders Dyspepsia No Moderate 21 March 2014 12 April 2014 Trial medications
permanently
stopped
Recovered
Placebo EPA + aspirin Diarrhoea GI disorders Diarrhoea No Mild 24 May 2012 16 June 2012 Trial medications
reduced
Recovered
with sequelae
Placebo+ placebo Medication aftertaste General disorders and
administration site
conditions
Product taste
abnormal
No Mild 26 March 2013 26 March 2014 No action taken Condition
present and
unchanged
Placebo+ placebo Abdominal distension GI disorders Abdominal
distension
No Mild 26 March 2013 26 March 2014 No action taken Condition
present and
unchanged
EPA+ placebo aspirin Dyspepsia GI disorders Dyspepsia No Mild 2 March 2015 10 March 2015 Trial medications
reduced
Recovered
EPA+ placebo aspirin Vomiting GI disorders Vomiting No Severe 2 March 2015 5 March 2015 Trial medications
reduced
Recovered
EPA+ aspirin Indigestion GI disorders Dyspepsia No Moderate 16 July 2015 20 July 2015 Trial medications
permanently
stopped
Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
Placebo + placebo Belching GI disorders Eructation No Mild 15 November 2012 21 November 2012 Trial medications
reduced
Recovered
Placebo + placebo Constipation GI disorders Constipation No Mild 15 November 2012 21 November 2012 Trial medications
reduced
Recovered
EPA + placebo aspirin Vomiting GI disorders Vomiting No Mild 16 May 2013 20 July 2013 Trial medications
permanently
stopped
Recovered
EPA + placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 16 May 2013 20 July 2013 Trial medications
permanently
stopped
Recovered
EPA + placebo aspirin Halitosis GI disorders Breath odour No Mild 16 May 2013 1 July 2013 Trial medications
permanently
stopped
Recovered
EPA + placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 16 April 2013 16 May 2013 Trial medications
permanently
stopped
Recovered
EPA + placebo aspirin Taste abnormality Nervous system
disorders
Dysgeusia No Mild 16 May 2013 1 July 2013 Trial medications
permanently
stopped
Recovered
EPA + placebo aspirin Nausea GI disorders Nausea No Mild 16 May 2013 20 July 2013 Trial medications
permanently
stopped
Recovered
Placebo + placebo Dyspepsia GI disorders Dyspepsia No Mild 12 November 2013 13 November 2013 No action taken Recovered
Placebo + placebo Stomach pain GI disorders Abdominal pain
upper
No Mild 3 September 2014 4 September 2014 No action taken Recovered
Placebo + placebo Perianal bleeding GI disorders Anal
haemorrhage
No Mild 24 December 2013 24 December 2013 No action taken Recovered
Placebo + placebo Knee pain Musculoskeletal and
connective tissue
disorders
Arthralgia No Mild 13 January 2014 24 February 2014 Trial medications
permanently
stopped
Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
Placebo EPA+ aspirin Bleeding
postoperatively
Injury, poisoning
and procedural
complications
Post procedural
haemorrhage
No Mild 20 December 2012 3 January 2013 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Haematuria Renal and urinary
disorders
Haematuria No Mild 13 August 2014 19 August 2014 No action taken Recovered
Placebo EPA+ aspirin Haematuria Renal and urinary
disorders
Haematuria No Mild 24 December 2013 26 December 2013 Trial medications
reduced
Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 17 January 2015 19 January 2015 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 2 February 2015 N/A Trial medications
permanently
stopped
Na
EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 14 November 2014 16 November 2014 No action taken Recovered
Placebo EPA+ aspirin Bleeding PR
(excluding gut
haemorrhage and
piles)
GI disorders Rectal
haemorrhage
No Mild 20 December 2015 22 December 2015 No action taken Recovered
Placebo EPA+ aspirin Bleeding PR
(excluding gut
haemorrhage and
piles)
GI disorders Rectal
haemorrhage
No Mild 25 June 2015 24 July 2015 No action taken Recovered
EPA+ aspirin Pustule Infections and
infestations
Rash pustular No Mild 12 December 2013 8 January 2014 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Loose motions GI disorders Diarrhoea No Mild 1 July 2013 N/A No action taken Condition
present and
unchanged
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 1 July 2013 N/A No action taken Condition
present and
unchanged
Placebo EPA+ aspirin Generalised itching Skin and
subcutaneous tissue
disorders
Pruritus
generalised
No Mild 24 January 2014 25 July 2014 Trial medications
delayed
Recovered
EPA+ placebo aspirin Acid reflux
(oesophageal)
GI disorders Gastro-
oesophageal
reflux disease
No Moderate 28 April 2014 12 May 2014 Trial medications
delayed
Recovered
EPA+ placebo aspirin Constipation GI disorders Constipation No Mild 28 November 2012 29 November 2012 Trial medications
reduced
Recovered
EPA+ placebo aspirin Stomach pain GI disorders Abdominal pain
upper
No Mild 28 November 2012 29 November 2012 Trial medications
reduced
Recovered
EPA+ placebo aspirin Stomach pain GI disorders Abdominal pain
upper
No Mild 17 November 2012 28 November 2012 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Constipation GI disorders Constipation No Mild 2 November 2012 28 November 2012 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Constipation GI disorders Constipation No Mild 2 November 2012 N/A No action taken Condition
present and
unchanged
Placebo+ placebo Lower abdominal pain GI disorders Abdominal pain
lower
No Moderate 8 January 2013 10 January 2013 Trial medications
delayed
Recovered
Placebo+ placebo Indigestion GI disorders Dyspepsia No Moderate 13 January 2013 22 January 2013 Trial medications
delayed
Recovered
Placebo+ placebo Indigestion GI disorders Dyspepsia No Moderate 25 January 2013 10 February 2013 Trial medications
permanently
stopped
Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
Placebo + placebo Abdominal pain GI disorders Abdominal pain No Moderate 13 January 2013 22 January 2013 Trial medications
delayed
Recovered
Placebo + placebo Constipation GI disorders Constipation No Moderate 8 January 2013 10 January 2013 Trial medications
delayed
Recovered
Placebo + placebo Abdominal pain GI disorders Abdominal pain No Moderate 25 January 2013 10 February 2013 Trial medications
permanently
stopped
Recovered
EPA + aspirin Dizziness Nervous system
disorders
Dizziness No Mild 30 April 2013 27 January 2014 No action taken Recovered
EPA + aspirin Dizziness Nervous system
disorders
Dizziness No Mild 1 April 2013 14 April 2013 No action taken Recovered
EPA + placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 25 September 2013 N/A No action taken Recovered
EPA + placebo aspirin Flatulence GI disorders Flatulence No Mild 25 September 2013 N/A No action taken Recovered
EPA + aspirin Constipation GI disorders Constipation No Moderate 16 March 2014 18 March 2014 Trial medications
permanently
stopped
Condition
present and
unchanged
EPA + aspirin Constipation GI disorders Constipation No Moderate 25 January 2014 28 January 2014 Trial medications
delayed
Recovered
Placebo EPA + aspirin Constipation GI disorders Constipation No Severe 1 May 2014 1 July 2014 Trial medications
permanently
stopped
Recovered
Placebo EPA + aspirin Stomach pain GI disorders Abdominal pain
upper
No Moderate 1 May 2014 1 July 2014 Trial medications
permanently
stopped
Recovered
EPA + placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 31 July 2014 14 August 2014 No action taken Recovered
Placebo EPA + aspirin Abdominal pain GI disorders Abdominal pain No Mild 24 March 2014 3 April 2014 Trial medications
permanently
stopped
Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
Placebo EPA+ aspirin Abdominal discomfort GI disorders Abdominal
discomfort
No Moderate 3 May 2015 N/A Trial medications
delayed
Condition
improving
Placebo+ placebo Dyspepsia GI disorders Dyspepsia No Mild 15 May 2013 15 May 2013 No action taken Recovered
Placebo+ placebo Lower abdominal pain GI disorders Abdominal pain
lower
No Mild 13 October 2013 15 October 2013 No action taken Recovered
Placebo EPA+ aspirin Blood in stool GI disorders Haematochezia No Mild 7 September 2015 11 September 2015 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Stomach discomfort GI disorders Abdominal
discomfort
No Mild 8 August 2015 11 September 2015 Trial medications
permanently
stopped
Recovered
EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 1 August 2015 30 May 2016 No action taken Recovered
EPA+ aspirin Bruising Injury, poisoning
and procedural
complications
Contusion No Mild 1 December 2015 N/A No action taken Condition
improving
EPA+ aspirin Burping GI disorders Eructation No Mild 7 July 2015 29 May 2016 No action taken Recovered
Placebo+ placebo Acid reflux
(oesophageal)
GI disorders Gastro-
oesophageal
reflux disease
No Moderate 20 April 2016 2 May 2016 Trial medications
permanently
stopped
Recovered
EPA+ aspirin Medication aftertaste General disorders and
administration site
conditions
Product taste
abnormal
No Mild 7 February 2016 N/A No action taken Condition
present and
unchanged
EPA+ aspirin Flatulence GI disorders Flatulence No Mild 10 February 2013 N/A No action taken Condition
present and
unchanged
EPA+ placebo aspirin Lower abdominal pain GI disorders Abdominal pain
lower
No Mild 1 July 2013 1 September 2013 No action taken Recovered
EPA+ placebo aspirin Lower abdominal pain GI disorders Abdominal pain
lower
No Mild 24 June 2013 27 June 2013 No action taken Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA + placebo aspirin Tongue eruption GI disorders Tongue eruption No Mild 24 June 2013 30 August 2013 No action taken Recovered
EPA + aspirin Macroscopic
haematuria
Renal and urinary
disorders
Haematuria No Moderate 1 February 2014 20 May 2014 No action taken Recovered
Placebo EPA+ aspirin Vomiting GI disorders Vomiting No Moderate 4 December 2013 16 December 2013 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Nausea GI disorders Nausea No Moderate 4 December 2013 16 December 2013 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Heartburn GI disorders Dyspepsia No Mild 21 November 2013 23 November 2013 Trial medications
reduced
Recovered
with sequelae
Placebo EPA+ aspirin Abdominal pain GI disorders Abdominal pain No Mild 21 November 2013 23 November 2013 Trial medications
reduced
Recovered
with sequelae
Placebo + placebo Black stools GI disorders Faeces
discoloured
No Moderate 12 June 2013 12 July 2013 Trial medications
permanently
stopped
Recovered
Placebo + placebo Acid reflux
(oesophageal)
GI disorders Gastro-
oesophageal
reflux disease
No Mild 1 May 2013 12 June 2013 Trial medications
permanently
stopped
Recovered
EPA + placebo aspirin Dyspepsia GI disorders Dyspepsia No Mild 20 April 2013 02 May 2013 Trial medications
reduced
Recovered
EPA + placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 20 April 2013 20 June 2013 Trial medications
reduced
Recovered
EPA + placebo aspirin Nausea GI disorders Nausea No Mild 20 April 2013 20 June 2013 Trial medications
reduced
Recovered
EPA + aspirin Acid reflux
(oesophageal)
GI disorders Gastro-
oesophageal
reflux disease
No Mild 29 May 2015 N/A Trial medications
permanently
stopped
Condition
improving
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA+ aspirin Acid reflux
(oesophageal)
GI disorders Gastro-
oesophageal
reflux disease
No Moderate 15 July 2015 N/A Trial medications
permanently
stopped
Condition
deteriorated
EPA+ placebo aspirin Nausea GI disorders Nausea No Mild 16 September
2015
N/A No action taken Condition
present and
unchanged
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Moderate 7 March 2016 16 March 2016 Trial medications
reduced
Recovered
Placebo EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 3 July 2015 11 August 2015 No action taken Condition
deteriorated
Placebo EPA+ aspirin Melaena GI disorders Melaena No Moderate 3 August 2015 11 August 2015 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Nausea GI disorders Nausea No Mild 31 May 2016 N/A No action taken Condition
present and
unchanged
EPA+ placebo aspirin Nausea GI disorders Nausea No Mild 27 May 2016 31 May 2016 No action taken Recovered
EPA+ placebo aspirin Abdominal discomfort GI disorders Abdominal
discomfort
No Mild 1 February 2013 25 March 2013 Trial medications
reduced
Recovered
Placebo+ placebo Frequent bowel
movements
GI disorders Frequent bowel
movements
No Mild 1 April 2013 18 April 2013 No action taken Recovered
Placebo+ placebo Frequent bowel
movements
GI disorders Frequent bowel
movements
No Mild 1 July 2013 30 July 2013 Trial medications
reduced
Recovered
Placebo EPA+ aspirin Abdominal pain GI disorders Abdominal pain No Mild 16 December 2013 22 December 2013 No action taken Recovered
Placebo EPA+ aspirin Diarrhoea GI disorders Diarrhoea No Mild 28 August 2013 2 September 2013 Trial medications
permanently
stopped
Recovered
Placebo+ placebo Abdominal discomfort GI disorders Abdominal
discomfort
No Mild 31 May 2014 4 June 2014 No action taken Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA+ placebo aspirin Increased frequency
of bowel movements
GI disorders Frequent bowel
movements
No Mild 20 January 2013 N/A No action taken Condition
improving
EPA+ aspirin Increased frequency
of bowel movements
GI disorders Frequent bowel
movements
No Mild 6 February 2013 2 April 2013 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Indigestion GI disorders Dyspepsia No Mild 3 April 2014 N/A No action taken Condition
present and
unchanged
Placebo+ placebo Dry skin Skin and
subcutaneous tissue
disorders
Dry skin No Mild 13 January 2014 N/A No action taken Condition
improving
EPA+ aspirin Constipation GI disorders Constipation No Moderate 21 August 2014 29 August 2014 No action taken Recovered
Placebo+ placebo Itchy skin Skin and
subcutaneous tissue
disorders
Pruritus No Moderate 1 July 2015 13 October 2015 No action taken Recovered
EPA+ placebo aspirin Nose bleed Respiratory, thoracic
and mediastinal
disorders
Epistaxis No Mild 8 January 2016 11 April 2016 No action taken Recovered
EPA+ aspirin Weight loss Investigations Weight
decreased
No Mild 9 July 2013 N/A Trial medications
reduced
Condition
present and
unchanged
EPA+ aspirin Nausea GI disorders Nausea No Mild 9 July 2013 N/A Trial medications
reduced
Condition
present and
unchanged
EPA+ aspirin Stomach cramps GI disorders Abdominal pain
upper
No Mild 9 July 2013 N/A Trial medications
reduced
Condition
present and
unchanged
EPA+ aspirin Nausea GI disorders Nausea No Mild 14 August 2013 1 May 2014 Trial medications
reduced
Condition
improving
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
Placebo+ placebo Loose stools GI disorders Diarrhoea No Mild 7 January 2015 2 April 2015 Trial medications
delayed
Recovered
Placebo+ placebo Abdominal pain GI disorders Abdominal pain No Mild 7 January 2015 2 April 2015 Trial medications
delayed
Recovered
Placebo+ placebo Constipation GI disorders Constipation No Mild 7 January 2015 2 April 2015 Trial medications
delayed
Recovered
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 6 January 2015 24 February 2015 No action taken Recovered
Placebo EPA + aspirin Diarrhoea GI disorders Diarrhoea No Mild 23 January 2015 30 January 2015 No action taken Recovered
Placebo EPA + aspirin Diarrhoea GI disorders Diarrhoea No Mild 2 December 2015 3 January 2016 Trial medication
period completed
Recovered
Placebo EPA + aspirin Constipation GI disorders Constipation No Mild 2 December 2015 3 January 2016 Trial medication
period completed
Recovered
Placebo EPA + aspirin Diarrhoea GI disorders Diarrhoea No Mild 21 April 2015 28 April 2015 Trial medications
reduced
Recovered
Placebo EPA + aspirin Diarrhoea GI disorders Diarrhoea No Mild 8 February 2015 17 February 2015 No action taken Recovered
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Moderate 1 September 2015 8 October 2015 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Moderate 1 September 2015 8 October 2015 Trial medications
permanently
stopped
Recovered
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Moderate 22 August 2015 29 August 2015 No action taken Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 26 February 2015 N/A Trial medications
permanently
stopped
Condition
present and
unchanged
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Moderate 22 August 2015 29 August 2015 No action taken Recovered
Placebo EPA + aspirin Constipation GI disorders Constipation No Mild 16 October 2015 N/A No action taken Condition
improving
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
Placebo EPA+ aspirin Bruising Injury, poisoning
and procedural
complications
Contusion No Mild 16 October 2015 N/A No action taken Condition
improving
EPA+ aspirin Bloating GI disorders Abdominal
distension
No Mild 1 December 2015 7 December 2015 Trial medication
already
discontinued
Recovered
EPA+ aspirin Feeling unwell General disorders and
administration site
conditions
Malaise No Mild 1 December 2015 7 December 2015 Trial medication
already
discontinued
Recovered
Placebo EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 5 June 2013 9 June 2013 No action taken Recovered
EPA+ aspirin Stomach pain GI disorders Abdominal pain
upper
No Mild 14 March 2015 18 March 2015 Trial medications
permanently
stopped
Recovered
Placebo EPA+ aspirin Taste abnormality Nervous system
disorders
Dysgeusia No Mild 22 January 2013 5 February 2013 No action taken Recovered
Placebo EPA+ aspirin Epistaxis Respiratory, thoracic
and mediastinal
disorders
Epistaxis No Moderate 6 January 2014 7 January 2014 Trial medications
reduced
Recovered
Placebo EPA+ aspirin Abdominal pain GI disorders Abdominal pain No Moderate 10 October 2013 25 November 2013 No action taken Recovered
with sequelae
Placebo EPA+ aspirin Taste abnormality Nervous system
disorders
Dysgeusia No Mild 14 March 2013 20 March 2013 Trial medications
reduced
Recovered
Placebo+ placebo Dyspepsia GI disorders Dyspepsia No Mild 25 August 2016 27 August 2016 Trial medications
permanently
stopped
Recovered
Placebo+ placebo Dyspepsia GI disorders Dyspepsia No Mild 28 August 2016 30 August 2016 Trial medications
permanently
stopped
Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Moderate 1 June 2016 6 June 2016 Trial medications
reduced
Condition
improving
EPA+ placebo aspirin Abdominal discomfort GI disorders Abdominal
discomfort
No Mild 1 November 2016 N/A No action taken Condition
present and
unchanged
EPA+ placebo aspirin Nausea GI disorders Nausea No Mild 3 March 2015 N/A Trial medications
reduced
Condition
improving
EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 15 July 2015 30 September 2015 No action taken Recovered
with sequelae
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Moderate 7 July 2015 8 June 2016 Trial medications
reduced
Recovered
EPA+ placebo aspirin Loose stools GI disorders Diarrhoea No Mild 7 February 2013 10 February 2013 Trial medications
permanently
stopped
Recovered
EPA+ aspirin Macroscopic
haematuria
Renal and urinary
disorders
Haematuria No Mild 12 September 2015 15 September 2015 Trial medications
permanently
stopped
Recovered
Placebo EPA + aspirin Bleeding mouth GI disorders Mouth
haemorrhage
No Mild 21 August 2013 21 August 2013 No action taken Recovered
EPA+ aspirin Dyspepsia GI disorders Dyspepsia No Mild 23 August 2013 25 August 2013 No action taken Recovered
EPA+ placebo aspirin Diarrhoea GI disorders Diarrhoea No Moderate 19 November 2013 22 November 2013 Trial medications
permanently
stopped
Recovered
with sequelae
EPA+ placebo aspirin Nausea GI disorders Nausea No Moderate 19 November 2013 22 November 2013 Trial medications
permanently
stopped
Recovered
with sequelae
EPA+ placebo aspirin Defaecation urgency GI disorders Defaecation
urgency
No Mild 19 September 2013 22 September 2013 No action taken Recovered
EPA+ placebo aspirin Abdominal pain GI disorders Abdominal pain No Mild 19 September 2013 22 September 2013 No action taken Recovered
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TABLE 41 Listing of ADRs (continued )
Treatment group Description
System organ
class name
Preferred
term name SAE Severity Start date End date Action taken Outcome
Placebo + placebo Abdominal pain GI disorders Abdominal pain No Moderate 30 January 2014 10 March 2014 Trial medications
permanently
stopped
Recovered
EPA + aspirin Chest pain General disorders and
administration site
conditions
Chest pain Yes Moderate 29 July 2013 31 July 2013 No action taken Recovered
Placebo EPA + aspirin Diarrhoea GI disorders Diarrhoea No Mild 12 October 2012 14 October 2012 No action taken Recovered
EPA + placebo aspirin Diarrhoea GI disorders Diarrhoea No Mild 22 November 2012 26 November 2012 No action taken Condition
improving
Placebo + placebo Halitosis GI disorders Breath odour No Mild 22 February 2013 22 August 2013 No action taken Recovered
EPA + aspirin Epistaxis Respiratory, thoracic
and mediastinal
disorders
Epistaxis No Mild 4 June 2014 12 June 2014 No action taken Recovered
N/A, not available; PR, per sectum.
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TABLE 42 Listing of SAEs
Treatment group System organ class name Preferred term name
Placebo+ placebo Neoplasms: benign, malignant and unspecified (including
cysts and polyps)
Renal cancer
EPA+ placebo aspirin GI disorders Gastritis
Placebo+ placebo Neoplasms: benign, malignant and unspecified (including
cysts and polyps)
Lung neoplasm malignant
Placebo EPA+ aspirin GI disorders Oesophageal haemorrhage
Placebo EPA+ aspirin Vascular disorders Thrombosis
Placebo EPA+ aspirin Vascular disorders Thrombosis
Placebo EPA+ aspirin Infections and infestations Lower respiratory tract infection
EPA+ aspirin Infections and infestations Pharyngeal abscess
Placebo EPA+ aspirin Investigations Blood glucose increased
Placebo+ placebo Neoplasms: benign, malignant and unspecified (including
cysts and polyps)
Lung neoplasm malignant
Placebo+ placebo GI disorders Abdominal pain
EPA+ placebo aspirin GI disorders Small intestinal perforation
EPA+ aspirin Vascular disorders Deep-vein thrombosis
Placebo EPA+ aspirin Vascular disorders Deep-vein thrombosis
EPA+ placebo aspirin Infections and infestations Lung infection
EPA+ placebo aspirin Neoplasms: benign, malignant and unspecified (including
cysts and polyps)
Oesophageal carcinoma
Placebo+ placebo Infections and infestations Labyrinthitis
Placebo EPA+ aspirin GI disorders Gastro-oesophageal reflux disease
Placebo EPA+ aspirin GI disorders Duodenitis
Placebo EPA+ aspirin GI disorders Hiatus hernia
Placebo EPA+ aspirin GI disorders Faeces discoloured
Placebo+ placebo Vascular disorders Femoral artery occlusion
EPA+ placebo aspirin Respiratory, thoracic and mediastinal disorders Pulmonary embolism
Placebo EPA+ aspirin Infections and infestations Post procedural infection
EPA+ placebo aspirin Hepatobiliary disorders Liver disorder
EPA+ placebo aspirin Neoplasms: benign, malignant and unspecified (including
cysts and polyps)
Lung neoplasm malignant
Placebo+ placebo Vascular disorders Deep-vein thrombosis
Placebo+ placebo General disorders and administration site conditions Chest pain
Placebo EPA+ aspirin Nervous system disorders Syncope
Placebo EPA+ aspirin Respiratory, thoracic and mediastinal disorders Respiratory failure
EPA+ placebo aspirin Cardiac disorders AF
EPA+ placebo aspirin Cardiac disorders AF
EPA+ placebo aspirin Cardiac disorders AF
EPA+ placebo aspirin Cardiac disorders AF
Placebo EPA+ aspirin Nervous system disorders Transient ischaemic attack
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TABLE 42 Listing of SAEs (continued )
Treatment group System organ class name Preferred term name
Placebo+ placebo Infections and infestations Colonic abscess
EPA+ placebo aspirin Cardiac disorders Acute myocardial infarction
Placebo+ placebo Cardiac disorders Acute myocardial infarction
Placebo+ placebo Infections and infestations Lower respiratory tract infection
EPA+ aspirin Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary
disease
EPA+ placebo aspirin Cardiac disorders Atrial fibrillation
EPA+ placebo aspirin Infections and infestations Cellulitis
EPA+ aspirin Neoplasms: benign, malignant and unspecified (including
cysts and polyps)
Prostate cancer
EPA+ aspirin Neoplasms: benign, malignant and unspecified (including
cysts and polyps)
Metastases to bone
EPA+ placebo aspirin General disorders and administration site conditions Chest pain
Placebo EPA+ aspirin Injury, poisoning and procedural complications Laceration
Placebo EPA+ aspirin Cardiac disorders Myocardial infarction
Placebo+ placebo Psychiatric disorders Confusional state
Placebo+ placebo Neoplasms: benign, malignant and unspecified (including
cysts and polyps)
Bladder squamous cell carcinoma
stage unspecified
EPA+ placebo aspirin Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary
disease
Placebo+ placebo Psychiatric disorders Alcohol withdrawal syndrome
Placebo+ placebo Nervous system disorders Encephalopathy
Placebo+ placebo GI disorders Faeces discoloured
EPA+ aspirin General disorders and administration site conditions Chest pain
Placebo EPA+ aspirin Cardiac disorders Arrhythmia
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TABLE 43 Summary of GI ADRs by preferred term name and by severity
Preferred term name Severity
Trial group (n)
EPA+ aspirin
EPA+ placebo
aspirin
Placebo
EPA+ aspirin Placebo+ placebo
Abdominal discomfort Mild 0 3 1 2
Moderate 0 0 1 0
Abdominal distension Mild 1 1 0 1
Abdominal pain Mild 2 16 5 2
Moderate 1 5 2 3
Abdominal pain lower Mild 0 2 0 1
Moderate 0 0 0 1
Abdominal pain upper Mild 2 4 0 3
Moderate 0 0 1 0
Anal haemorrhage Mild 0 1 0 1
Anal inflammation Moderate 0 0 1 0
Breath odour Mild 1 3 1 4
Change of bowel habit Mild 0 0 1 0
Moderate 0 0 1 0
Constipation Mild 2 5 3 2
Moderate 3 0 0 1
Severe 0 0 1 0
Defaecation urgency Mild 0 3 0 0
Diarrhoea Mild 4 18 12 5
Moderate 3 10 1 0
Duodenitis Moderate 0 0 1 0
Dyspepsia Mild 11 10 11 9
Moderate 1 0 3 5
Epigastric discomfort Mild 1 0 0 0
Eructation Mild 3 2 0 1
Faeces discoloured Mild 0 0 0 1
Moderate 0 1 0 1
Severe 0 0 1 0
Flatulence Mild 1 4 2 3
Moderate 0 0 0 1
Frequent bowel movements Mild 1 1 0 2
Moderate 0 0 0 1
Gastric haemorrhage Mild 0 1 0 0
Gastritis Mild 0 2 1 0
GI sounds abnormal Mild 1 0 0 0
Gastro-oesophageal reflux disease Mild 2 0 3 2
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TABLE 43 Summary of GI ADRs by preferred term name and by severity (continued )
Preferred term name Severity
Trial group (n)
EPA+ aspirin
EPA+ placebo
aspirin
Placebo
EPA+ aspirin Placebo+ placebo
Moderate 1 1 2 1
Haematochezia Mild 0 1 5 0
Hiatus hernia Mild 0 0 1 0
Melaena Moderate 0 0 1 0
Mouth haemorrhage Mild 0 0 1 0
Nausea Mild 3 8 1 1
Moderate 1 3 1 2
Oesophageal haemorrhage Severe 0 0 1 0
Oesophagitis Mild 0 1 0 0
Rectal haemorrhage Mild 0 0 2 0
Retching Moderate 1 0 0 0
Tongue eruption Mild 0 1 0 0
Vomiting Mild 0 2 0 0
Moderate 0 0 1 0
Severe 0 1 0 0
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Appendix 5 Summary of gastrointestinal adverse
events according to the categories defined by the
chief investigator
GI AE
Trial group
EPA+ aspirin
EPA+ placebo
aspirin
Placebo
EPA+ aspirin Placebo+ placebo
FFA TG FFA TG FFA TG FFA TG
Number in safety population 99 71 107 70 99 75 109 167
Participants reporting at least one
GI AE, n (%)
25 (25) 22 (31) 43 (40) 24 (34) 24 (24) 20 (27) 38 (35) 13 (19)
Diarrhoeaa (n) 9 2 27 15 11 9 9 7
Upper GI symptoms (n) 11 18 21 15 11 15 19 9
Lower abdominal symptoms (n) 4 5 20 17 7 3 18 3
Eructation/halitosis (n) 1 3 5 0 0 1 5 0
Other (n) 12 3 19 7 15 14 11 4
a Data are at event level.
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